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Therapeutic aerosols have been widely used for the treatment of a variety 
of lung diseases for several decades. Using the pulmonary route, it is possible 
to achieve high topical concentrations of medications such as bronchodilators, 
corticosteroids and antimicobials within the respiratory tract without unwanted 
high systemic concentrations and resultant side effects. Aerosolised beta-
agonist bronchodilators have been used as first-line treatment of asthma in 
adults and older children for many years.^ ^ Inhaled corticosteroids have also 
replaced their systemic counterparts in the maintenance treatment of chronic 
asthmatics. 
Inhaled bronchodilators and corticosteroids may have a particular role in 
the treatment of infants suffering from bronchopulmonary dysplasia (BPD), ” 
BPD is a complication of newborn infants that develops usually after prolonged 
positive pressure ventilation and oxygen therapy. The condition is characterised 
by mucosal inflammation, edema, constriction and fibrosis of the airways, and 
hypertrophy of the bronchial smooth muscle/^'^^ It is one of the commonest and 
most serious complications of survivors of neonatal intensive care. For these 
infants, systemic bronchodilators can bring about temporary relief of the 
bronchiolar constriction,^ ® "'® and systemic corticosteroids can shorten the length 
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of mechanical ventilation.^" '^^  It is possible that when given directly to the lungs 
in aerosol form, both medications can produce faster and more significant 
improvement, and with fewer systemic side effects such as tachycardia, 
hypertension, hyperglycaemia, impairment of bone growth, and suppression of 
the hypothalamic-pitultary-adrenal axis. 
In addition to bronchodilators and corticosteroid, there is recently 
considerable interest in the use of exogenous surfactant in the aerosol form. 
Studies on animal models of lung injury showed that even a small amount of 
surfactant aerosol reaching the lower respiratory tract couid produce clinical 
effects comparable or superior to that of instilled surfactant."^® It appears that 
the medication has a potential in the treatment of infants with either neonatal or 
adult type of respiratory distress syndrome. 
Despite their popularity among adults and older children, the use of 
therapeutic aerosols has not been well established in newborns and infants. 
This is at least partly related to the uncertainties of the amount of medications 
that can reach the lungs through the inhaled route in this population of patients. 
Currently jet nebuliers are the most commonly used device for aerosol delivery 
to both spontaneously breathing and ventilated infants. Previous studies have 
consistently shown that only a small fraction of aerosol generated by a jet 
nebuliser could reach the lungs of intubated and mechanically ventilated young 
infants or small lung models (0.1 -2% of aerosol released into the ventilator 
circmt)2®"33 Only very few studies have evaluated aerosol deposition in non-
ventilated infants or infant models, and the data available were similar to those 
observed in the ventilated ones.^^® 
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1.2 Factors limiting aerosol delivery to small infants 
Several factors might limit the penetration of aerosol through the upper 
and conducting airways to deposit at the lower respiratory tract of small infants. 
These include the small size of their airways, their respiratory pattern, and the 
design of neonatal ventilators: 
a. Small size of the conducting airway: When aerosol particles travel 
down the airway, a proportion of the particles is deposited in different parts 
of the respiratory tract mainly by one of three mechanisms: Inertial impaction, 
gravitational sedimentation, and d i f f u s i o n , 龙 37 //,erf/a/ impaction occurs 
when the airstream bringing along the particles is deflected due to changing 
direction of the airway, but inertial force continues to bring the particles along 
their original path until they reach the wall of the airway and become 
deposited. Sedimentation is the deposition of aerosol particles in the 
respiratory tract due to gravity. Diffusion is the phenomenon where aerosol 
particles are constantly being bounced about due to the constant random 
collisions with gas molecules. During these bouncing movements, particles 
become deposited when they come in contact with the wall of the airway. 
The probability of a particle depositing by inertial impaction is directly 
proportional to the mass median aerodynamic diameter (MMAD) of the 
particle, the velocity of the particle travelling down the airway, and inversely 
proportional to the dimension of the airway (Appendix 1). It is the most 
important mechanism by which aerosol particles deposit at the upper 
respiratory tract (nose, mouth, pharynx, and larynx) and large conducting 
airways where air flow is at high velocity^ and constantly changing direction. 
In adults, the majority of the drug dose (80% or more) delivered by a metered 
dose inhaler impacts in the oropharynx, and only 10% is delivered to the 
In small infants, the small size of the upper and conducting 
airways further favour aerosol deposition by impaction, resulting in 
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significantly reduced deposition at the lower airways which are the principal 
site of action of most therapeutic aerosols. In ventilated infants, impaction 
on the wall of the ventilator circuit and endotracheal tube may significantly 
reduce the amount of aerosol available to the infants. 
b. Respiratory pattern of newborns and small infants: Deposition 
of aerosol increases with increasing tidal volume and inspiratory time.加 
Furthermore, the greater the tidal volume, the more peripherally the particles 
will be distributed in the lungs.^ ® '" In the small airways, the most important 
mechanism for aerosol deposition is gravitational sedimentation, which 
increases with the length of time the particles stay in the airway # (Appendix 
1). At the bronchiolar level, the sudden increase in cross-sectional area 
of the airways gives rise to low flow, allowing enough time for the particles to 
deposit by sedimentation. When the inspiratory time is too short, some of 
these particles may not have time to become deposited and will be exhaled. 
Compared to adults, small infants have relatively small tidal volume and 
breathe at a much faster rate with a shorter inspiratory time. Both factors 
may significantly reduce aerosol deposition i门 the lower respiratory tract. 
c. Design of neonatal ventilators: Most neonatal ventilators are time-
cycled, pressure-limited, continuous flow ventilators. The continuous gas 
flow through the ventilator circuit rapidly removes the aerosol through the 
exhalation tubing, making it unavailable to the patient. 
Humidification of the ventilator circuit significantly Increases particle 
size. It has been shown by Cinkotai that at 95% humidity, the diameter of 
NaCi particles tripled and at 100% humidity, the size of the particles can 
increase without bound.箱 Similar observations have been made on dry 
atmospheric aerosols.斗？ This phenomenon could have significant effect on 
aerosol delivery through a fully humidified ventilator circuit.'^ ® 
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Thus aerosol therapy in young infants is limited by both intrinsic and 
extrinsic factors, and ways to improve aerosol deposition in this group of patients 
are necessary. One obvious approach is to identify the most efficient delivery 
device among the currently available methods. 
1.3 Devices for the generation of therapeutic aerosols 
Clinical aerosols can be generated by a nebuliser, a metered dose inhaler 
(MDI), or a dry powder inhaler. As dry powder inhalers are breath actuated and 
their operation requires a relatively high inspiratory flow rate, they cannot be 
used on small infants and will not be discussed here. The jet nebuliser is 
currently the most commonly used device. From previous experience in both 
adults and infants, both the MDI^ ®"^ ^ and ultrasonic nebuliser^ are potentially 
more efficient alternatives. The three types of devices have however never been 
compared on newborns or young infants. A summary on the design of these 
devices are given below. 
a. Jet Nebunser:36 55*57 Nebulisation involves the atomization of a solution 
followed by condensation from the gas phase to form particles. In a jet 
nebuliser, the energy required for the atomization is generated by 
compressed gas. When the gas stream passes through the nebuliser nozzle 
at high speed, it entrains liquid placed In the nebuliser reservoir through a 
capillary tube by the Venturi effect, and the entrained liquid is atomized by 
the blast of gas into aerosol droplets. Large particles impact on the baffle 
and the wails of the nebuliser, and reflux back to the reservoir for re-
nebulisation. About 1 ml of the liquid remains permanently in the reservoir 
and constitutes a "dead volume" which cannot be utiiized.^ 
The particle size of aerosol produced is governed by the design of the 
baffles and also the flow rate of compressed gas through the device. The 
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droplet size can be reduced by increasing the compressed gas flow rate or 
driving pressure. The overall aerosol output increases with flow rate. The 
optimum operating flow rate appears to be 6-8 l/min. which can generate 
particles within the respirable range (1-5|jm) at a high output rate. Higher 
flows (10-12 l/min) may be needed to nebulise some viscous solutions 
efficiently. 
Evaporation of water from the refluxing liquid in the nebuliser 
increases the concentration of the solution and also results in rapid cooling 
of the nebuliser and its contents, resulting in an initial temperature drop of 
about 10 to 12 deg C.^ ^ This leads to reduction in aerosol output^^® and 
could conceivably cause bronchoconstriction in susceptible individuals. 
b. Ultrasonic nebuliser:^ The atomising energy of ultrasonic 
nebuiisers is generated by a piezoelectric crystal that transforms high-
frequency (1-2 Mhz) electric oscillations into mechanical oscillations. The 
vibrations are transmitted through the coupling fluid and a thin-walled cup to 
the nebuliser solution, and produce a fountain of liquid droplets. The latter 
are carried out of the generator by an air stream. 
Both the rate of aerosol production and droplet size are related 
directly to the intensity of the ultrasonic vibrations. Aerosol production rate 
is also inversely proportional to the viscosity of the liquid. During ultrasonic 
nebulisation, aqueous solution of viscous medications may become 
sufficiently concentrated that the increased viscosity progressively slows the 
rate of nebulisation until the formation of aerosol ceases.®^ 
The standard medication reservoirs of the currently available 
ultrasonic nebuiisers have a round bottom and a relatively large "dead 
volume". Some ultrasonic nebuiisers (e.g. Siemens Electronic Inc., Sweden) 
can be used together with a small medication cup with a tapered bottom. 
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The cup is placed inside the standard reservoir after filling the latter with an 
appropriate amount of coupling solution (usually water) for the transmission 
of vibration energy. The small cup has the theoretical advantage of allowing 
more complete nebulisation and greater aerosol output. Its use has however 
not been evaluated in small infants. 
Both the jet and ultrasonic nebulisers have their advantages and 
disadvantages. The operating flow rate of the jet nebullser can be easily 
adjusted to produce a wide range of respirable particles while the oscillation 
frequency of the ultrasonic nebuliser is not amenable to changes. However 
the jet nebuliser is a noisy device and its use causes cooling of the ventilator 
gas. It requires an external gas flow and, when used in patients on 
mechanical ventilation, requires adjustment of the ventilator flow rate to 
ensure a constant ventilator pressure. In contrast the ultrasonic nebuliser 
is silent and warm, and, as it is not driven by an external gas source, no 
adjustment of ventilator flow is required. 
b. Metered dose inhaler:^®^^ ®^  ®^  Introduced in 1956, The metered dose 
inhaler is currently the most popular aerosol device among adults and older 
children. The drug is either dissolved in solution or suspended as fine drug 
crystals in a liquid propellant mixture of chlorofluorocarbons (CFC) in a 
sealed canister. The low boiling point and high vapour pressure of CFC 
(about 400 kPa; >3 atmospheres) keeps the mixture in liquid phase within 
the canister. Actuation of the MDI opens the metering valve which supplies 
a fixed volume (25-100^1) of solution to a small metering chamber The 
propellants evaporate rapidly on meeting atmospheric pressure, and the 
contents of the metering chamber are released with rapid, initial vaporisation 
of propellants. This breaks up the liquid stream into droplets, providing the 
aerosol. 
On leaving the MDI canister, the aerosol particles are of large size 
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(MMAD typically >35ijm) and travel at high speed (about 112 km per hour or 
31m/sec).62 Both factors tend to increase aerosol impaction at the 
oropharynx and reduce its penetration into the lungs,"*。As particle size and 
velocity both decrease with increasing distance from the actuator orifice, 
lung deposition in a non-ventilated patient can be 丨mfDroved by firing the MDI 
3 to 5 cm from the mouth during a slow, steady inhalation, followed by a 
period of 10 seconds' breath holding/^ ® ^ Slow inhalation reduces upper 
airway impaction, and breath holding allows those particles which reach the. 
lung periphery to settle under gravity. 
The use of MDI thus requires considerable skill from the patients and 
therefore are not practicable for young children and infants. For these 
patients, aerosol delivery can be optimised by placing a spacer device 
between the MDI and the patient's lip, or, in the case of ventilated infants, 
between the MDI and the endotracheal tube. The spacer allows the aerosol 
particles to reduce their velocity and decrease in size through evaporation 
before they enter the patient's airway. Large and fast-moving particles will 
impact on the wails of the spacer. The advantages of using a spacer 
together with the MDI can be summarised as follows: 
[1] improving lung deposition by reducing particle size and velocity; 
[2] minimising oropharyngeal deposition due to inertial impaction, 
thus reducing systemic absorption; 
[3] reducing the need for patient cooperation in synchronizing firing 
and inhaling, thus improving lung delivery in patient who fail to 
master the technique? 
In adults, the use of the spacer has been associated with reduction in 
oropharyngeal impaction by 15% to 75%,®®*^ ^ and improvement of the 
therapeutic effects of medications delivered by the MDI.^ ^^^ When used for 
the delivery of corticosteroid, the spacer is able to prevent the occurrence of 
20 
oropharyngeal candidiasis and dysphonia 74 
1.4 Conc lus ion : The need for further studies 
All the delivery devices discussed above have been used on newborns 
and young infants, but formal comparison of their efficiencies under identical 
experimental conditions have not been performed. As a result, there is no 
uniformity among neonatal units in their protocols on the use of therapeutic 
aerosols. This has prompted me to carry out the series of studies presented 
later in this thesis.丨 firstly studied the delivery of salbutamol which is the most 
commonly used bronchodilator in the infant population. This was followed by a 
study on the delivery of surfactant aerosol which at the time has aroused a great 
deal of interest because of its potential benefit on patients with adult respiratory 
distress syndrome. 
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•Sgcf謂 / Back^ound 
The main objectives of the original studies described in this thesis were 
(1) to evaluate the hypothesis that the commercially available delivery devices 
could effectively deliver therapeutic aerosols to the lower respiratory tract of 
small infants; and (2) to identify the most efficient aerosol delivery method for 
infants who might benefit from the treatment. The devices under evaluation 
were the metered dose Inhaler and spacer, the jet nebuliser, and the ultrasonic 
nebuUser with and without a small medication cup. The aerosols studied were 
salbutamol, a beta-agonist bronchodilator. and a synthetic and natural 
surfactant. Parameters assessed included: 
[1] the particle size of the aerosols; 
[2] the quantity of aerosols that could be deposited in the lungs; 
[3] the distribution of aerosols in the lung and airway： 
[4] for the jet and ultrasonic nebuiisers, the pattern of aerosol accumulation in 
the lungs during nebulisation; and 
[5] the clinical effects of the aerosol on the subjects studied. 
In connection to the main studies, two additional studies were carried out 
to investigate the effect of (1) induced paralysis, and (2) the presence of a non-
rebreathing valve in the MDf-spacer, on aerosol delivery to ventilated and non-
ventilated subjects respectively. 
A total of seven Inter-related studies were carried out in three stages 
according to plan. In stage 1. I used the radiotracer technique to study the 
deposition of radioiabelled aerosols (salbutamol and surfactant) on a ventilated 
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rabbit model, and, using the data obtained, the suitability of using gamma 
scintigraphy to estimate aerosol deposition in small lungs was evaluated. In 
stage 2’ I used gamma scintigraphy to estimate aerosol deposition in the lungs 
of newborns and Infants. This was followed by an infant study to evaluate the 
clinical effects of salbutamol aerosol (stage 3). The objectives of the seven 
individual studies are summarised as follows: 
[1] an animal study to compare pulmonary deposition and distribution of 
salbutamol aerosol delivered by MDI and spacer, jet nebuiiser, and ultrasonic 
nebuliser (with and without a small medication cup) in a ventilated rabbit 
model; 
[2] an animal study to evaluate the effect of induced paralysis on aerosol 
delivery to ventilated rabbits; 
[3] an animal study to evaluate the suitability of using gamma scintigraphy in the 
estimation of aerosol deposition in small lungs (this study was carried out in 
preparation for the subsequent infant study)： 
[4] a study on both ventilated and non-ventilated infants with bronchopulmonary 
dysplasia to evaluate the pulmonary deposition and distribution of salbutamol 
aerosol delivered by the MDI plus spacer and jet nebuliser; 
[5] a study on both ventilated and non-ventilated infants with bronchopulmonary 
dysplasia to evaluate the clinical effects of salbutamol aerosol delivered by 
the MDI plus spacer, jet nebuliser, and ultrasonic nebuliser with a small 
medication cup; 
[6] a study on non-ventilated infants with bronchopulmonary dysplasia to 
compare the clinical effects of salbutamol delivered by MDI through a spacer 
device with and without a non-rebreathing valve; 
[7] a study to evaluate the pulmonary deposition and distribution, and clinical 
effects of nebulised synthetic (Exosurf) and bovine (Survanta) surfactant on 
a ventilated rabbit model of respiratory distress syndrome. 
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Section 2: Part 1 Literature reviews 
Chai^m 
wM m 
3.1 The early fallacy: bronchodiiators have no role in young infants 
For a long time, bronchodiiators were considered to be of no therapeutic 
value in newborns and young infants. This opinion stemmed from a study by 
Engel et al which showed that in infants under the age of 12 months, 
bronchiolar smooth muscle was thin and poorly developed, and probably could 
not narrow the lumen of the airway by contraction." This was supported by a 
number of clinical studies on young infants with acute bronchiolar obstruction. 
In these studies, administration of beta-agonist aerosols failed to decrease the 
airway resistance of infants aged 4 weeks to 18 months/®*®. Two studies even 
demonstrated paradoxical bronchial constriction in wheezy infants after receiving 
nebulised salbutamol.®^®^ 
While these clinical studies were consistent with Engel's findings, the lack 
of therapeutic effects of the bronchodiiators could have resulted from failure to 
deliver the medications to the respiratory tract of young infants. Furthermore, the 
methods used for lung function measurement (forced oscillatory technique or 
inductive plethysmorgraphy) used in these studies had been criticised for being 
insensitive in detecting changes in bronchiolar resistance as they were readily 
affected by changes in the upper or large central airway resistance." The two 
studies showing paradoxical bronchial constriction®^ ® d^id not refute the presence 
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of bronchial beta-receptors in the infants. The phenomenon was postulated to 
be caused by increase in osmolality of the nebuliser solution in one study.®^ In 
the other study, the investigators hypothesised that the main cause of airway 
obstruction might be inflammation and edema of the mucosa, and decrease In 
airway smooth muscle tone after bronchodilator treatment might further increase 
the airway obstruction.®^ 
3.2 Evidence of bronchia丨 responsiveness to bronchodilators m young 
infants 
Since the late 1970s, there have been accumulating evidence on the 
beneficial effects of bronchodilators in even very young infants. Following a 
report by Reid describing the presence of smooth muscles in the small airways 
as far peripheral as the alveolar ducts even in newborns’枯 a number of clinical 
studies provided convincing evidence that young infants did respond to 
bronchodilators. In a double blind randomised controlled trial on 32 infants aged 
one to twelve months with bronchiolitis, Tal et al demonstrated that treatment 
with intramuscular dexamethasone plus inhaled and oral salbutamol resulted in 
clinical improvement.肪 Conner et al also showed that salbutamol delivered by 
an MDl aided with a spacer device was effective in alleviating the "asthmatic" 
symptoms of infants as young as 6 months of age.®^ By performing a bronchial 
provocation test using histamine on 45 infants, Clarke et al confirmed that 
bronchial reactivity was present in most infants at 6 months of age.®® This was 
further substantiated by Henderson et a I®® who demonstrated that following 
histamine induced bronchoconstriction in 40 infants aged 3 weeks to 12 months, 
treatment with inhaled salbutamol resulted in significantly faster rate of recovery 
than inhaled saline placebo. More recently, Clarke et al followed a cohort of full 
term, healthy infants on whom histamine provocation test had been performed 
at one month of age, and showed that early bronchial responsiveness in the 
neonatal period is a risk factor for wheezing in infancy.的 
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Bronchial reactivity might be particularly important in the pathogenesis of 
BPD as hypertrophy of the bronchial smooth muscle has been shown in infants 
with this c o n d i t i o n . Several studies demonstrated improvement in the 
lung mechanics or clinical state of these infants following systemic 
bronchodilators. In 1979, Rooklin etal reported an observational study on 11 
infants aged 25 to 145 days with BPD who were given intravenous aminophyliine 
and oral theophylline/® Infants less than 30 days of age all responded 
favourably with a reduction in airway resistance and successful weaning from 
mechanical ventilation within 72 hours; some infants older than 30 days did not 
respond presumably due to extensive fibrosis and irreversible airway obstruction. 
In another observational study by Sosulski et al, 8 infants with BPD at postnatal 
age 13±3.2 weeks showed significant improvement in both lung compliance 
(38%) and resistance (-23%) as well as PaOjand PaCOj after a subcutaneous 
dose (5^jg/kg) of terbutaline.'® In 24 infants aged 2 to 22 months who had 
bronchopulmonary disease (including 3 ventilated preterm infants at high risk of 
developing BPD), Kraemer et al demonstrated that administration of salbutamol 
through a gastric tube was followed by a reduction in airway resistance.®^ 
3.3 Bronchodilator aerosols I'n young infants with BPD 
Because of their high topical concentration in the airways and minimal 
systemic effects, aerosoiised bronchodilators have generated a great deal of 
interest among neonatologists. Several studies had been carried out to 
investigate their role in the management of infants with BPD. A review of these 
studies is given below. 
In a randomised cross-over study on 10 non-ventilated infants with 
established BPD, Kao et al” demonstrated that administration of nebulised 
0.1 % Isoproterenol but not saline placebo was followed by a significant decrease 
in airway resistance (-28±5%) and a significant increase in specific airway 
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conductance (53*15。/。）for 30 minutes. There was however no significant 
change in thoracic gas volume or dynamic compliance. 
Similar observation was made by Cabal et af® on 8 very low birth weight 
(VLBW) preterm infants with BPD. Fifteen minutes after a dose of 
metaproterenol, ail infants showed significant improvement in respiratory system 
compliance and transcutaneous POj, and significant reduction in airway 
resistance andjtranscutaneous PCOj. 
Wflkie et a f reported a non-randomised study showing the beneficial 
effects of bronchodilator on even very young ventilated infants with BPD. In 
these infants, both salbutamol and ipratropium bromide but not saline placebo 
delivered by a submicronic jet nebuliser were associated with improvement in 
respiratory system compliance and airway resistance 1 hour after delivery. 
Improvement in airway resistance was not related to postnatal age, and even the 
most immature infants responded to the bronchodllators. 
Motoyama et al provided further evidence that bronchial reactivity is 
present in very young and immature infants with developing BPD.®^ Thirty-two 
ventilator-dependent preterm infants who later fulfilled the diagnostic criteria of 
BPD were studied serially to investigate their airway responsiveness to nebulised 
1% isoetharine. All infants tested beyond 3 weeks of age responded to the 
bronchodilator by a significant decrease in airway resistance. The youngest 
infant who responded was only 12 days old, and the most immature infant who 
responded was 26 weeks postconceptlon. 
In a randomised cross-over study on 20 ventilated VLBW infants with 
developing BPD, Rotschild et al® observed that nebulised salbutamol aerosol 
but not saline placebo could bring about improvement in lung compliance and 
transcutaneous PCOg. There was however no significant change in airway 
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resistance following either safbutamol or placebo. 
In 1990, Yuksel et al^  reported a study on 10 previously premature 
infants who did not have classical BPD but had chronic cough or wheeze at age 
8-26 months. Each infant received a placebo for 2 weeks, followed by 2 weeks 
of treatment with terbutaline aerosol delivered by MDI through a spacer made 
of coffee cup. Treatment with terbutaline but not placebo was followed by 
improvement in both symptom scores and functional residual capacity. 
More recently, Lee et al®^  demonstrated beneficial effects of 
bronchodilator aerosols in very young preterm infants at risk of BPD. In 10 
extremely low birth weight infants receiving mechanical ventilation for respiratory 
distress syndrome, treatment with saibutamol or ipratropium bromides delivered 
by the MDI and spacer at 1 week of age both resulted in improvement in PaOj, 
PaCOs, and ventilation efficiency index. 
A dose-related response to bronchodilator aerosols has been 
demonstrated in VLBW infants. In a non-randomised study by Brundage et a I®® 
a jet nebuliser was used to deliver sequentially a nominal dose of 75|jg, 125|jg. 
and 175[jg of Ipratropium bromide to 10 ventilated preterm infants with 
established or developing BPD. Improvement in respiratory system compliance 
and resistance was observed only following the highest dose of the medication. 
The improvement was further enhanced when the infants were given a 
combination treatment of ipratropium bromide (175pg) and saibutamol (0.04mg) 
delivered by the same nebuliser. 
A similar dose-related response to saibutamol was also demonstrated by 
Denjean et al^ on 10 oxygen-dependent premature infants at risk of developing 
BPD . At intervals of 10 minutes, each infant was given a placebo, followed by 
increasing doses of saibutamol aerosol (100pg, 200pg and 400pg) delivered by 
the MDI through a spacer. Lung mechanics measured 10 minutes after each 
delivery showed a dose-related Improvement in respiratory system compliance 
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and resistance. Drug effect lasted for 3 hours, which was similar to that reported 
for older infants and adults/ ” 
In the evaluation of a new spacer device (Babyhaler, Glaxo, UK), 
Kraemer et observed an improvement in thoracic gas volume and airway 
conductance following a dose of salbutamol aerosol in 14 infants aged 10.1±5.4 
months suffering from obstructive airway diseases, including 3 infants with BPD. 
Finally, comparison has been made on the therapeutic effects of a 
bronchodilator given systemically or by the inhaled route by Pfenninger and 
Aebi.s In a randomised cross-over study on 8 premature, ventilator dependent 
infants with BPD, the investigators showed that salbutamol given intravenously 
(10|jg/kg) or from MDI (200pg) aided with a spacer resulted in a significant and 
similar improvement in lung compliance and airway resistance. 
A summary of the above studies were given in Table 3.1. 
30 
Table 3.1: Summary of studies on the therapeutic effects of bronchodilator 





Patient demography & diagnosis Drug Delivery 
device 
Outcome 






GA 30±1 wk： BW 1590±200g; 
Post^conceptiona 丨 age 41±3wk; 





jet neb Decreased Rrs 




GA 25-28wk： BW 650-1600(?)g; 
Postnatal age 29-41 d; 




jet neb Increased Crs & 
TcPOj： 









GA 25-29wk; BW 560-1Q50g; 
Postnatal age 19-103d; 
Current wt 680-1900g; 
BPD： Ventilated 
Salbutamol 
(n 二 17): 
ipratropium 
(n 二 5) 
jet neb Increased Crs; 
Decreased Rrs 
Moloyama 





GA 24-32wk; BW 630-21 OOg; 
Post-conceptiona丨 age 26-38wk; 
At risk of BPD： Ventilated 
1% isoeth-
ari门e 










GA 24-29wk： BW 710-1330g： 
Postnatal age 5-31 d; 
Current wt 670-1320g; 
BPD/at risk of BPD: Ventilated 
Salbutamol jet neb Improved Crs 
and TcPOj； 








GA 25-36wk; BW 550-2440g; 
Postnatal age 8-26m; 
Not dassicaf BPD but with 
chronic cough or wheeze; Non-
ventilated 











GA 26-34wk： BW 620-1760g： 
Postnatal age 5-l2d; 

















GA 24-28wk; BW 750-1300g 
Postnatal age 16-34d; 





jet neb Dose-dependent 
Improvement in 










GA 28.5±1.8wk： BW 790-1340g 
Postnatal age 13.3±4.9d 
Current wt 820-1250g 
At risk of BPD; Ventilated 












GA 28-36wK; BW 810-2510g 
Postnatal age 28-70d 















Postnatal age 10.1 ±5.4m 
wheezy bronchitis (n=8); cystic 
fibrosis (n:=3)： BPD (n=3). 
Non-ventilated 






volume & Rrs 
3.4 CONCLUSIONS 
The following conclusions can be drawn from this literature review: [1] 
bronchial reactivity is present in preterm infants shortly after birth, especially 
those developing BPD; [2] bronchodilator aerosols can be delivered by the MDI 
or jet nebuliser to the lower respiratory tract of both ventilated and non-ventilated 
infants with BPD; [3] bronchodilator aerosols have beneficial therapeutic effects 
on these infants. It must be recognised that some of the studies were 
weakened by the lack of a proper control group; being either observational or 
non-randomised studies. Only very few were double-blind, and the unblinded 
studies were subjected to observer bias. Nonetheless the studies demonstrated 
a close temporal relationship between treatment and improvement, suggesting 
that the improvement was a drug effect rather than the result of spontaneous 
resolution of BPD. Some of the studies also demonstrated a dose-dependent 
effect of the medications. 
A reduction in respiratory system resistance (Rrs) was shown in most of 
the studies measuring lung mechanics. Since 40% of total airway resistance 
was contributed by the endotracheal tube (intubated infants) or the upper and 
conducting airway (non-intubated infants)®® which was not affected by the 
bronchodilators, the actual improvement in resistance of the lower respiratory 
tract should in fact be substantially more than that estimated. Unlike Rrs, 
improvement in respiratory system compliance (Crs) or oxygenation was not 
consistently demonstrated. In infants who showed an improved Crs, it is likely 
that dilation of the peripheral airways resulted in recruitment of collapsed alveoli 
and increase in lung volume. Oxygenation, on the other hand, improved with 
better distribution of ventilation to better perfused areas. It appears that all these 
changes after bronchodilator treatment are less predictable than that in airway 
resistance. 
None of the studies provided any comparative data on the efficiency of 
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the delivery devices. Information on the quantity of aerosol delivered 
lungs was also not available. The latter will be addressed in the literature 




Section 2: Part 1 Literature review 
The therapeutic effects of clinical aerosols are likely determined by their 
ability to penetrate the upper and conducting airways to deposit in the lower 
respiratory tract. Quantitative data on aerosol deposition in the lungs are 
therefore important information to respiratory clinicians and therapists. There are 
however only very scanty studies that directly estimate aerosol deposition in 
young infants, and most of the deposition studies relevant to this population 
have been carried out on either filter or animal models. 
4.1 Review of deposition studies 
4.1.1 Delivery through neonatal ventilator circuit and endotracheal tube 
a. Jet nebulisers: 
At present, therapeutic aerosols are administered to small Infants 
most commonly with a jet nebuliser. As discussed in Chapter 1, this form of 
nebulisation is relatively inefficient. In adults, pulmonary deposition from this 
device was only 1.2% - 2.9% of the nebuliser dose.®^^ ®^  Deposition is even 
lower in ventilated newborns: current data suggest that only 0.1% - 2% of the 
aerosol released into a neonatal ventilator circuit reach the lungs.^ ®'^ ^ 
Jet nebulisers were evaluated by Flavin et al^ using the radiotracer 
technique. Two conventional jet nebulisers, and a jet nebuliser that 
generated submicronic particles at two different flow rates (6L/min. and 




in isotonic saline) aerosol to 27 ventilated rabbits. After 10 minutes of 
nebulisation, pulmonary deposition as estimated by gamma scintigraphy 
ranged from 0.19±0.1% to 1.96+1.19% (mean±sd) of the initial nebuiiser 
dose. Highest deposition was obtained from the submicronic nebuiiser 
operating at a flow rate of 8L/min. which produced a much greater aerosol 
output than a flow rate of 6L/min. This suggests that aerosol deposition can 
be Increased by either increasing the output from the nebuiiser or by 
decreasing the particle size. With all three nebulisers evaluated, deposition 
in the endotracheal tube was significantly greater than that in the lungs, 
ranging from 2.53% to 6.25% of the initial nebuiiser dose. The validity of 
these data has however been questioned because sulphur colloid aerosol 
tends to stick to the plastic wall of the nebuiiser, and has resulted in 
underestimation of aerosol production by a ratio of 3:1.^ ® It is however not 
known whether this property of sulphur colloid had affected the comparison 
between the conventional and submicronic nebuiiser. 
The submicronic nebuiiser was again found to be superior to the 
conventional nebuiiser in a subsequent study by Ahrens et a I®®. In this 
study, an aerosol of isotonic saline mixed with a tracer (0.1% uranine) was 
delivered by a conventional jet nebuiiser or a submicronic nebuiiser into a 
collection bag through an endotracheal tube and a plexigias model of trachea 
and main stem bronchi. The use of the submicronic nebuiiser was 
associated with a significantly reduced deposition at the endotracheal tube 
and large airway, and increased aerosol penetration beyond the main stem 
bronchi by up to 9 fold. 
Contrary to the above findings, the superiority of the submicronic 
nebuiiser was not demonstrable in a study by Cameron et al.^ ^ In this study, 
four jet nebulisers, including a submicronic nebuiiser, were used to nebulise 
a solution of aminophylline to filter lung models through a neonatal ventilator 
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circuit. After 5 minutes of nebulisation, deposition ranged from 0.15% to 
1.52% of the amount nebulised. Deposition by the submicronic nebuliser 
was only 0.22%. 
The submicronic nebuliser appeared to be particularly inefficient in 
delivering corticosteroid aerosol. Cameron et a P compared two 
conventional and one submicronic nebullsers in delivering a suspension of 
budesonide to a filter model. Deposition from the conventional nebullsers 
was 1.08% and 2.72% of the nebulised amount, but only 0.06% from the 
submicronic nebuliser. Similar observations were made by Am on et al^ ® on 
a filter model. After 5 minutes of nebulisation, deposition of budesonide from 
a conventional nebuliser (0.68±0.06% of the initial nebuliser dose) was 
significantly greater than that from a submicronic nebuliser (0.02+0.01%). 
The reason for the low efficiency of the submicronic nebuliser was not clear. 
The size of budesonide particles in the suspension was considerably larger 
than that generated by the submicronic nebuliser. It is possible that during 
nebulisation, only the suspending fluid but not the particles was 
aerosolised.32 
It has been shown in adult lung models that aerosol deposition is 
enhanced by increasing the tidal volume or inspiratory The effects 
of ventilator settings on aerosol deposition in a small lung model have been 
investigated in a study reported by Cameron et aP。In this study. 
Technetium-99m pertechnetate aerosol was delivered by a jet nebuliser to 
20 freshly killed rabbits intubated and ventilated with a neonatal ventilator. 
At "standard" ventilator and nebuliser settings (Table 4.1), pulmonary 
deposition after 3 min. of nebulisation was 0.09±0.02% (meantsd) of the 
initial nebuliser dose per kg body weight, . Reducing inspiratory time (Ti). 
tidal volume (by reducing peak inspiratory pressure [PIP]), and nebuliser flow 
rate decreased deposition to 60%, 56%, and 75% respectively. In contrast, 
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increasing ventilation rate had no effect on deposition. In all the animals, 
gamma Imaging showed good peripheral distribution of activities. 
The effects of nebuliser position and volume of nebuliser fill on lung 
deposition have been investigated by Watterberg et al.^ ^ In a human 
study, sodium cromoglycate aerosol was delivered in 43 occasions to 9 
infants ventilated for BPD using a conventional and a submicronic jet 
nebuliser. With both nebulisers, lung deposition estimated from urinary 
excretion of the drug was less than 1% of the test dose for both nebulisers. 
Contrary to previous findings on adult lung models,increasing the initial 
volume fill from 2 ml to 5 ml did not improve deposition. Placing the 
nebulisers at the endotracheal tube adaptor or 60cm proximal to the 
endotracheal tube also had no effect on pulmonary deposition. 
These findings were however contradictory to those of an in-vitro 
experiment conducted by the same group of workers.^^ In this experiment, 
when the nebulisers were placed at the endotracheal tube level, aerosol 
output from the submicronic nebuliser was twice that from the conventional 
one( 40% vs 20.5% of initial nebuliser dose). Placing the nebulisers 60cm 
from the endotracheal tube significantly reduced deposition by the 
conventional nebuliser but not the submicronic nebuliser. 
In the same study, the investigators demonstrated that heating and 
humidifying the ventilator gas significantly reduced aerosol delivery, 
especially when the nebuliser was connected directly to the endotracheal 
tube. In this position, most of the aerosol generated was condensed on the 
wall of the endotracheal tube. 
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b. Ultrasonic Nebuliser 
Ultrasonic nebuiisers have been evaluated extensively on adults and 
adult lung models, but there is relatively little information on its use 
in neonates and small infants. Using sodium cromoglycate aerosol, Grigg 
et studied the delivery efficiency of a Pentasonic ultrasonic nebuliser on 
7 infants receiving ventilation for the treatment of a variety of medical and 
surgical conditions (3 respiratory distress syndrome, 1 apnoea, 2 myopathy, 
and 1 persistent fetal circulation). Using a volume fill of 4 ml, lung deposition 
after 5 minutes of nebulisation was 1.3% of the initial 20mg nebuliser fill. 
This amount of lung deposition was comparable to that from the MDI 
evaluated in the same study (1.7% of the actuated dose). 
In a study comparing 3 different types of jet nebuiisers and an 
ultrasonic nebuliser (Pulmosonic), Cameron et aP^ reported that after 5 
minutes of nebulisation, only 0.6% of the aerosol output from the ultrasonic 
nebuliser could be deposited on a filter model of ventilated newborns. This 
was comparable to that deposited by the conventional jet nebuiisers tested 
in the same study. 
A summary of the above deposition studies is given in Table 4.1. 
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Table 4.1 ： Deposition of Aerosol delivered by Jet and Ultrasonic Nebulisers 
ventilated lung models: 
Authors Drug Ventilator hTT ID Lung Device (flow MMAD Deposition 
(year) (Nebulisa settings (mm) model rate) 
t-ion time) 
Flavin*" Sulphur Tidal vol 7ml/kg, 3 Rabbit [1]Misty Neb [112.52 (130.19±0.1% of initial 
coUoid rate 30 bpm) nebuliser dose 
1986 (10min) [2]Wee Neb [212.20 [2]0.73±0.37% 
(Volume cycled 




[4] 1.85 I4]1.96±1.19% 
Ah- Isotonic Lung model 3 Plexi- [IJconvent- [1]3.95 I1]8.5%(nebuliser flow 
rens" saline connected glas ional jet (Fan 7.5L/mm)-30% (flow 
with 1% directly to the airway jet) 22.5L/min) of aerosol 
1986 uranine nebuliser, but attach- penetrated the 
(till not to a ed to a [2)0.54 "airway" 
collection ventilator collec 
bag 90% t-fon [2]submicroni [2]78-85% 
full) bag c jet 
(Ultravent) 
Camer- Aminoph- PIP 20cm HjO 3.5 Filter [lJUItravent [1]94%- [1]0.22% of amount 
on « yliine PEEP 2cm HjO aerosolised 
(Smin.) Rate 30 bpm [2]Acom {2]93%* 
1990 Ti 1 sec [210.88% 




Budeson- [5]Ultravent (• % < 





Cam- WMJC "Standard- Not Freshl Ultravent 1.3|jm Standard settings; 
ero门“ pertech- settings: known y killed (8L/min) 0.09±0.02% initial 
1990? netate PIP 30cm HjO; rabbits nebuliser dose 
(3min.) PEEP 2cm HjO; 
Rate: 30bpm; Ti 0.5sec:reduced to 
Ti 1.0 sec. 60% 
Reducing PIP by half 
56% 
Rate 60 bpm: no 
AFFORD eneci 
Nebuliser flow rate 
6L/min; 75% 
Amon ^ Budeson- PIP 20cmH20 3.5 Filter [1]Ultravent not [1]0.02(sem 0.01)% 
1992 ide PEEP 2cmH20 ment- initial nebuliser dose; 
(5min.) Rate 30 bpm ioned 



























[1]< 1% initial 
nebuliser dose 




















PEEP 2cm H20 
Rate 30 bpm 
Ti 1 sec 
Vt 15ml 
3.5mm Filter Pulmosonic 2.9pm 0.6% of aerosol 
delivered into circuit 
c. Metered Dose Inhaler (MD\) (Table 4.2): 
In recent years, there has been an increasing interest in the use of 
MDI for the delivery of therapeutic aerosols to small infants. Compared to 
nebulisers, MDI is more convenient to use and does not require any 
additional gas source or electrical power; and its use does not cause cooling 
of the inspired gas. It may be particularly suitable for steroid delivery as 
nebullsation of this medication is difficult and the steroid nebuliser solutions 
are expensive. In both ventilated and spontaneously breathing adults, lung 
deposition from MDI used together with a spacer device has been shown to 
be greater than that from jet nebulisers.^''"" The following is a review of 
studies on the use of MDI on in-vitro and in-vivo infant lung models. 
In a study on the deposition of sodium cromoglycate on intubated filter 
lung models, Grigg et al^ ® firstly actuated a dose of MDI aerosol into a 
spacer device (Aerochamber), and then manually ventilated the lung model 
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with a resuscitation bag connected to the spacer. Deposition in the lungs 
and endotracheal tube was 1.62% and 7.8% of the actuated dose 
respectively. In the second part of the study, similar amount of lung 
deposition (1.7±0.18%) was detected in 7 intubated and ventilated infants 
who were given the aerosol in a similar manner. Pulmonary deposition in 
these infants was estimated from the 24-hour urinary excretion of sodium 
cromoglycate, assuming that 38% of a lung dose is excreted in the urine. 
A simple device for the improvement of delivery of MDI aerosol has 
been described by Rozycki et al?助 The device consisted of a 250-m丨 self: 
inflating resuscitation bag connected to a Tygon 16-cm plastic spacer 
through a one way valve assembly which was attached to a MDI actuator 
adaptor. After actuation of the MDI, ventilation was provided manually by 
the resuscitation bag, and aerosol inside the spacer was carried down the 
airway by the manual breaths. Using this device, the investigators were able 
to deposit 3.14+0.81% of an MDI dose of beclomethasone dipropionate on 
a filter lung model. The same study also showed that reducing the length 
of the spacer to 7.5cm significantly reduced deposition to 1.88±0.45% of the 
MDI dose. 
Everard et al^ ^ evaluated the effects of a number of factors on aerosol 
delivery by MDI on a ventilated neonatal filter lung model: timing of actuation 
of the MDI in relation to the respiratory cycle, length of inspiratory time, tidal 
volume, position of the spacer along the ventilator circuit, and the 
characteristics of the tubing (smooth or corrugated) between the spacer and 
the endotracheal tube. At standard ventilator settings (Table 4.2), and with 
the spacer being placed just before the endotracheal tube, actuating the MDI 
immediately before inspiration resulted tn deposition of 1.54(sd 0.05)% of the 
actuated dose. Deposition was significantly reduced when the MDI was 
actuated after the inspiratory cycle, when the inspiratory time was reduced 
to 0.5 sec., or when a 10-cm tubing was inserted between the spacer and the 
endotracheal tube, especially when the tubing was corrugated. In contrast, 
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increasing the tidal volume (by increasing PIP ) to 16m! and 22ml increased 
deposition to 1.87(0.06)% and 2.01(0.09)% respectively. 
Using the radiotracer technique on 4 ventilated rabbits, the same 
group of workers observed that the aerosol was evenly distributed in the 
lungs.42 As the animals were kept in a supine position during aerosol 
delivery, this observation suggested that aerosol distribution is relatively free 
from gravitational effect. 
In 1991, O'Caliaghan etal^ estimated the deposition and distribution 
of radiolabeled corticosteroid delivered by MDi in the lungs of rabbits either 
ventilated or breathing spontaneously through tracheostomy. Technetium-
99m labelled beclomethasone propionate was first delivered to 4 intubated 
and anaesthetized rabbits by actuating the MDI into a collapsible spacer (a 
modified resuscitation bag) which was then used to provide manual breaths 
for 30 sec. at a rate of 40 per min. Total lung deposition was 1.2 (sd 0.4)% 
of the actuated dose. 
The aerosol was then delivered through a spacer device (Nebuhaler) 
to 4 rabbits breathing spontaneously through a tracheostomy. The spacer 
was fitted with a face mask which was applied tightly over the tracheostomy. 
Total lung deposition was 1.9(sd 0.9)% (range 0.7-2.6%). 
In both groups of animals, deposition was greatest in the anterior 
lobes of both lungs. Deposition at the peripheral parts of the lungs was 
substantial, amounting to over 40% of total lung deposition. Deposition in the 
trachea and main bronchi was twice that in the lungs, being 2.9(sd 0.4)% of 
the initial dose among the ventilated rabbits, and 4.4(sd 2.1)% among those 
breathing spontaneously. 
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In 1992 Arnon et aP compared a rigid spacer (MV15 Aerochamber, 
Truded, Canada) and a collapsible spacer (Aerovent, Monaghan Corp., USA) 
for their effects on the delivery of budesonide aerosol by a MDI to a 
ventilated neonatal filter lung model. With the spacer devices connected 
directly to the endotracheal tube, mean deposition in the lung mode! was 
14.2±0.87% of the nominal dose delivered through the MV15 Aerochamber 
and 3.6±0.46% through the Aerovent. Both were significantly greater than 
the deposition achieved by jet nebulisers (0.02±0.01% to 0.68±0.06% of the 
initial nebuliser dose) evaluated in the same study. 
A summary of the above studies on MDI is given in Table 4.2. 
Table 4.2: Deposition of Aerosol delivered by MDI and spacer device 
Authors 
(year) 


















































PIP 30cm HjO; 
PEEP 2cm HjO; 
Rate: 30/min.; 
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4.1.2 Delivery to non-ventilated newborns and infants 
In adults, pulmonary deposition of aerosol is significantly greater in the 
non-intubated, spontaneously breathing subjects than in those receiving 
mechanical ventilation.^^ There is however only very scanty information on 
aerosol deposition in non-ventilated newborns and infants. In a group of 
relatively old (age 9 to 36 months) infants with wheezy symptoms, Salmon et 
have demonstrated that pulmonary deposition of aerosol delivered by MDI 
and a jet nebuliser was small and variable, being 0.3-1.5% of the delivered dose. 
In this study, the aerosol used was sodium cromoglycate and lung deposition 
was estimated from urinary excretion of the medication. 
The amount of nebulised aerosol that could reach the mouth of small 
subjects has been measured by Lodrup Carlsen et al.^ The investigators 
delivered budesonide aerosol with a jet nebuliser to 6 infants aged 4 to 30 
months through a T-piece and face mask. An inhalation filter was inserted 
between the T-piece and the face mask to collect the aerosol that could reach 
the patient. After nebulisation, budesonide eluted from the filter was about 14% 
of the initial nebuliser dose, increasing from 9 to 19% with increasing age. In 
the same study, the investigators were able to show that following a lung dose 
of nebulised budesonide, a significant proportion of the aerosol (up to 1/3 of that 
reached the patients' mouth) was exhaled. K is likely that the exhaled particles 
were those that failed to settle in the lungs by sedimentation because of their 
small size. 
In a freely breathing filter lung model, Everard et aP® studied the effects 
of a number of factors on the delivery of MDI aerosol through a spacer and face 
mask. Factors being investigated included the size of the spacer device, tidal 
volume, drug concentration inside the spacer, and the dead space inside the 
face mask. Four spacer devices were tested. In order of decreasing size, they 
were the Nebuhaler, the Aerochamber (Infant and neonatal versions, the latter 
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having a lighter valve), and a coffee cup. At a tidal volume of 25ml, mean 
deposition was 2.7%(coffee cup), 2.9% (Nebuha(er), 3.3% (infant Aerochamber), 
and 5.3% (neonatal Aerochamber) of the actuated dose. Deposition increased 
with increasing tidal volumes for ail the spacers, especially with larger devices. 
Increasing the dead space inside the face mask by about 50ml resulted in a 
reduction in deposition by over 50%. Increasing the dose concentration from 
1mg per puff to 5mg per puff increased deposition by only 3 fold. Similarly, 
when multiple 1mg doses were introduced into the spacer, increase in deposition 
was parallel to the increasing dose only for the first two doses but further 
actuations produced very little additional drug delivery. The investigators 
postulated that using the larger dose had increased drug loss from impaction. 
Likewise, multiple actuations into the spacer also Increased Impaction due to 
turbulence. 
4.2 Discussion: limitations of earlier studies 
The above studies provide useful data on the pulmonary deposition of 
aerosols delivered by various devices. However, a number of factors might have 
affected the accuracy of their estimations. These include the limitations of the 
lung models used, and the ventilation strategies employed in the studies on 
ventilated models. 
4.2.1 The Lung Models and their limitations 
In the above studies, estimation of aerosol deposition had been made 
directly on filter and animal lung models, and also indirectly on human subjects 
from the urinary excretion of sodium cromoglycate. All these methods might 
result in overestimation of deposition due to their inherent limitations: 
a. In-vitro Filter lung model: Filter lung models provide a convenient 
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means for studying deposition which can be quantified by measuring its 
radioactivity (when radiolabeled aerosol is used) or by assaying the drug 
eluted from the filter The (imitations of this model are due to its lack of 
branching airway and mucous epithelium, and its different geometry from the 
lungs. In a ventilated model, deposition in the filter reflects any amount of 
aerosol that penetrates through the endotracheal tube. In a spontaneously 
breathing model, deposition in the filter represents any amount that comes 
out of the delivery system and reaches the mouth of the patient. In either 
cases, the estimated amount of lung deposition includes aerosol deposited 
in the trachea, main bronchi, and upper airway (spontaneously breathing 
model). In addition, overestimation may result from contamination by large 
aerosol particles that condense in the tubings, and also from retention by the 
filter of very small particles which are normally exhaled by the lungs.躲 This 
might be of particular importance when aerosols are generated by the 
submicronic nebullsers. 
b. In-vivo studies - Animal lung models: Animal lung models are 
commonly used for the study of aerosol deposition and distribution using the 
radiotracer technique. Total and regional deposition in the lungs can be 
estimated by either gamma scintigraphy or counting the radioactivity in the 
excised lungs. However, aerosol deposition is affected by the anatomy and 
geometry of the conducting airway, the branching pattern of the bronchi and 
bronchioles, and the presence of lung pathology. As the anatomy of the 
respiratory tract is different from species to species, deposition in animal 
lungs may not truly represent that in human subjects. Furthermore, the 
lungs of the animals being studied are usually healthy; deposition and 
distribution of aerosol in these healthy lungs may be different from that in 
human subjects with pulmonary pathologies. Another source of error in using 
animal models is the absorption and clearance from the lungs of the 
deposited drug. For this reason freshly killed animals have been proposed 
as a better alternative to living animals for aerosol studies.% 
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c. human subjects: lung deposition estimated from urinary excretion 
of sodium cromoglycate Pulmonary deposition of an aerosolised drug 
can be estimated indirectly by determining the amount of urinary excretion 
of the drug if its metabolism and urinary clearance are known. Sodium 
cromoglycate has been used extensively for this purpose. In adult human 
subjects, sodium cromoglycate is well absorbed in the lungs after inhalation, 
and excreted unchanged in the urine with an apparent terminal half-life of 
120-200 minutes. The drug first appears in the plasma 30 sec. after delivery, 
followed by a second, slower phase of absorption. Its bioavailability after 
direct instillation in the airways via bronchoscope is approximately 70。/o.畑 
Approximately 50% is excreted in urine and 50% in the Urinary 
excretion correlates closely with plasma data in the estimation of lung 
deposition.i。7 Conventionally, 24-hour urine sample is used for drug assay. 
In small infants from whom urine collection is difficult, the duration may be 
shortened to 4 hours as it has been shown on children 9m to 36m of age that 
after a dose of sodium cromoglycate aerosol, 90% of the drug found in 24-
hour urine was excreted in the first 4 hours. 
This method however has serious limitations when used In newborns 
and young infants. The metabolism and pharmacokinetics of sodium 
cromoglycate are not known in this population, and urinary excretion of the 
drug may be very variable in small infants. In a study carried out by Grigg 
et al,49 a known intra-pulmonary dose of the drug was given to four infants 
by instillation through a catheter wedged in the right main bronchus. Urinary 
excretion of the drug over the subsequent 24 hours was very variable, 
ranging from 22.3% to 59.7% of the lung dose. Estimation of pulmonary 
deposition using sodium cromoglycate aerosol is therefore only approximate. 
Furthermore, as shown by previous workers^^-^ and also in our studies 
presented below, a significant proportion of aerosol is deposited in the 
trachea. Absorption of the medication at this site will likely lead to 
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overestimation of the effective lung dose. 
4.2.2 Ventilation strategies 
Aerosol deposition in the lungs of ventilated subjects is to a large extent 
affected by the ventilator parameters. In the ventilated filter and animal studies 
described above, an excessively high inspiratory pressure (20-30 cmHjO) and 
long inspiratory time (1 sec.) were used, both being known enhancing factors of 
aerosol deposition.? The lack of humldification in the ventilator circuit might 
further promote deposition by allowing more small particles to reach the 
airways."*®47 Many of the MDI studies had used a collapsible spacer or 
resuscitation bag to "bag" the aerosol down the airway. As there were no control 
data, ft is not known whether this manoeuvre can actually improve lung 
deposition. However, it is likely that hand ventilation had enhanced aerosol 
deposition by providing a larger tidal volume. 
4.3 Conclusions 
From the above studies, it appears that nebulisers (jet and ultrasonic) 
and MDI are both able to deliver 0.5-2% of a nominal dose of aerosol to the 
lungs of small infants or small lung models. This might already be an 
overestimation due to reasons discussed above. One MDI study showed a 
pulmonary deposition of as much as 14.2% of the actuated dose.^ This high 
value is very different from those of aii other studies, and exceeds that reported 
for adults and older c h i l d r e n . T h e reason for this discrepancy is not 
known. 
Very little comparative data on the different modalities of aerosol delivery 
were available from the above studies. Only one study compared the jet 
nebuliser with the ultrasonic nebuliser and reported similar amount of 
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deposition.32 Another study compared the MDI with an ultrasonic nebuliser, also 
showing no difference in their efficiencies.明 None of the studies had compared 
all three devices, and lack of uniformity in experimental conditions also made 
between-study comparison impossible. This, together with the limitations of the 
earlier studies as discussed above, led me to carry out a series of studies in 
animals and infants described in this thesis. In these studies, I would evaluate 
the performance of the various aerosol delivery devices. A uniform mode! 
(ventilated rabbit) would be used in all the animal studies, and in each study i^e 
animals would be ventilated with the same ventilator setting so as to avoid the 
confounding effects of different settings on aerosol deposition, (n the infants, 
the efficiency of the devices would be evaluated both by the amount of aerosol 
that could be delivered to the infants' lungs, and by their clinical and lung 
function response to a bronchodllator aerosol. In both deposition and functional 
studies, the confounding effects due to factors such as body weight and tidal 
volume, ventilator settings, and severity of lung disease would be avoided by 
using a randomised cross-over design. The operation of the devices would also 
be uniform for all the studies, and would be identical to that used clinically. In 
the deposition studies, aerosol delivery would be estimated directly using the 
radiotracer technique which should be more accurate than the indirect method 
such as that using sodium cromoglycate. 
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5.1 INTRODUCTION 
From the above literature review, it is evident that bronchodilator aerosols 
are useful in relieving bronchiolar obstruction in infants with BPD. To achieve 
maximum therapeutic effect, the aerosol should be administered using the most 
efficient delivery device. The MDI, jet nebuliser, and ultrasonic nebuliser have 
ail been evaluated in deposition studies conducted on either small infants or 
infant lung models, but studies directly comparing all three devices are not 
available. The following study was carried out to provide such comparative data 
by estimating the pulmonary deposition of radiolabelled salbutamol aerosol 
delivered by each of the devices to a ventilated rabbit model. The use of a small 
medication cup, which might enhance aerosol delivery by the ultrasonic 
nebuliser, was also evaluated. The radiotracer technique provided a convenient 
means for the study of the distribution pattern of aerosol in the lungs, 
endotracheal tube, trachea, and different sites of the ventilator circuit. The 
technique also allowed measurement of the rate of aerosol accumulation in the 
lungs during nebullsation. Throughout the study the animals were ventilated with 
identical ventilator parameters so that the results truly reflected the relative 
efficiencies of the delivery devices. 
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5.2 Subjects and methods 
5.2.1 The animal model 
This study was approved by the Animal Ethics Committee of the 
McMaster University Medical Centre. A total of 31 adult white New Zealand 
rabbits weighing 2.7 to 3.1 kg were studied. Each animal was anaesthetized 
with intramuscular ketamine (40mg/kg) and xylazine (5mg/kg). A tracheostomy 
was performed and an endotracheal tube with internal diameter 3.5mm was 
inserted into the trachea through the tracheostomy for a distance of 2.5cm. The 
trachea was tied tightly around the endotracheal tube to prevent leak of either 
air or the aerosol. The animal was then established on mechanical ventilation 
with either a Siemens Servo 300 (Siemens Electronic Inc., Sweden) or Bournes 
BP200 (Bear Cub, USA) ventilator. Both are time-cycled, pressure-nmrted. 
continuous flow, neonatal ventilators. The inspired gas was warmed and 
humidified with the gas temperature maintained at 35°C at the level of the 
endotracheal tube. After institution of mechanical ventilation, the animal was 
paralysed with Pancuronium 100mcg/kg. The following ventilator settings were 
used in all the animals and maintained unchanged throughout the experiment: 
Flow rate SL/minute, 
PIP12cm H2〇， 
PEEP 2cm H20, 
rate 30/minute, 
Ti 0.5 second, and 
Fi02 1.0. 
These ventilator settings had been shown in our preliminary study on 
rabbits of similar size to provide appropriate ventilation resulting in an arterial 
PaCOj of 35 to 40mmHg and a tidal volume of 7-10ml/kg. The latter was 
measured using a Neonatal Volume Monitor (Bear Cub, USA). 
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5.2.2 Delivery of aerosol (Figure 5.1): 
The animals were divided into 4 groups. Group 1 was given salbutamol 
aerosol from the MDI, group 2 from a jet nebuliser, and group 3 and 4 from an 
ultrasonic nebuliser. 
Group 1 fn=7): MDI 
Radiolabelled salbutamol was delivered by the MDI (Ventolin® MDI, 
Glaxo. U.K.) through an aerosol holding chamber (MV15 Aerochamber, 
Trudell Inc., Canada) which had an internal volume of 145 ml. The MV15 
Aerochamber does not have an one-way valve. There is instead a baffle at 
its outlet that allows gas movement in both directions without causing 
obstruction to either the inspiratory or expiratory flow. The holding chamber 
was inserted between the T-piece of the ventilator circuit and the 
endotracheal tube imnnediately prior to the administration of the medication. 
The MDI was vigorously shaken for at least 10 sec. before each acutation at 
end-expiration into the holding chamber. A total of 5 puffs (salbutamol 100^9 
per puff) were given at intervals of 1 minute. The holding chamber was 
removed from the circuit 2 minutes after completion of the aerosol delivery. 
Group 2 (n=”)： jet nebuliser 
The jet nebuliser (Flo Thru®, Hudson RCI, USA) was connected to the 
inspiraotry limb of the ventilator circuit 20cm away from the endotracheal 
tube, and operated at a flow rate of 6L/min. as recommended by the 
manufacturer. During nebulisation, the gas flow rate from the ventilator was 
reduced accordingly so as to maintain the same total flow rate and ventilation 
pressures. At each delivery, the reservoir was filled with 0.1 ml/kg of 
salbutamol respirator solution (Ventolin®, Glaxo, UK, 100pg/kg of salbutamol) 
diluted to 3ml with ®®"Tc labelled (approximately 1mCi/ml) human serum 
albumin. Each animal received the nebulised medication for 20 minutes. 
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Group 3 (=6) and 4 (n=7): ultrasonic nebuliser 
The ultrasonic nebuliser ussd in the study (Siemens Electronic Inc., 
Sweden) is available as an accessory of the Siemens Servo 300 Ventilator. 
Its function is however Independent of the ventilator except for the power 
supply. The nebuliser was connected with a T-piece to the Inspiratory limb 
of the ventilator circuit 20cm away from the endotracheal tube. As no 
additional gas flow was involved, there was no need to adjust ventilator flow 
rate during nebulisation. Two different nebuliser reservoirs were available: 
[1] the standard reservoir with a round-bottom and a volume of 20 ml; and [2] 
a small medication cup (volume 10ml) with a tapered bottom which could be 
put inside the standard reservoir to which 10ml of isotonic saline had been 
added as a coupling fluid. The standard reservoir was used on the group 3 
animals while animals in group 4 received the aerosol from the small cup. 
The drug dose (0.1ml [lOOpg] /kg of salbutamol respirator solution diluted to 
3 ml with 的"Tc-labelled human serum albumin), volume fill, and duration of 
nebulusation were similar to those for the jet nebuliser. 
The connection of the devices to the ventilator circuit are illustrated in 
Figure 5.1. A paper filter (Pall Biomedical, M.Y., USA) was connected to the 
expiratory limb of the ventilator circuit to prevent contamination of the ventilator 
and the atmosphere by the radioisotope. All the containers containing the 
radiolabelled drug (MDI and spacer, nebuliser reservoir), ventilator tubings, and 
exhalation filter were shielded with lead sheets throughout the experiments. 
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Figure 5.1: Connection of (A)MV15 Aerochamber, (B) jet nebuliser 












5.2.3 Radiolabelling and calibration of saibutamol formulations: 
a. Metered dose inhaler: 
Labelling of saibutamol MDI was performed using a variation of the 
technique described by Summers et Briefly, technetium pertechnetate 
的mTc04 was extracted from saline using methyl ethyl ketone (MEK). The 
solution was then placed in an empty metal canister (Glaxo, CA) and the 
MEK evaporated under a stream of liquid nitrogen. A previously frozen (-70 
deg. C) canister of Ventolin (Glaxo, CA) was cut open and the contents 
immediately poured into the metal canister containing the radioisotope. This 
canister was then sealed with a Neotechnic 63pl metering valve (Glaxo, CA) 
using a Socage Aerosol Crimper, Model 721.11 (BLM, USA), and then 
placed in an ultrasonic bath for five minutes to ensure thorough mixing. The 
labelled MDI was allowed to reach room temperature prior to calibration and 
use. 
The emitted dose from each canister was measured by assaying the 
radioactivity released from 5 individual puffs, each actuated into a cotton 
wool bali. Only canisters that produced consistent doses with less than 15% 
variation in radioactive counts were accepted for use. The mean dose in pCi 
released per actuation calculated from the 5 actuations was subsequently 
used to express the deposition in the lung as a percentage of administered 
dose. All the measurements were corrected for the natural decay of isotope 
(half-life 6 hours) between manufacture of the laeiled MDI and lung imaging 
(Appendix 3). The total weight of each canister was also obtained to ensure 
that no leakage of propellant had occured. 
b. Nebuliser solution: 
Instead of directly labelling the saibutamol, each dose of saibutamol 
respirator solution was mixed with approximately 4 millicuries of 
labelled human serum albumin (HSA) in saline. The total volume of the 
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mixture was 3 ml. ®®"Tc-HSA is a non-absorbab(e tracer which, when 
nebulised as a mixture with salbutamol, is released from the nebuliser with 
a 1:1 ratio between drug and radioactivity. 
5.2.4 Estimation of aerosol deposition: 
Pulmonary deposition of aerosol was estimated by counting the 
radioactivity of the excised lungs. After completion of aerosol delivery, the 
animals were sacrificed with IV pentobarbitone and the lungs excised. Each 
lung lobe was dissected out from the lobar bronchus and divided into peripheral 
(subpleural) and central (hilar) portions. Each lung piece was weighed with an 
electronic weighing scale. The trachea was divided from the main bronchi just 
above the carina. The radioactivity in the endotracheal tube, the trachea, the 
carina region which consisted of the malnstem and lobar bronchi, and each lung 
piece was measured by a gamma counter (Minaxi auto-gamma 5000, Canada) 
with corrections made to allow for decay between manufacture of the tracer and 
counting (Appendix 3). This allowed us to calculate the amount of salbutamol 
in each specimen. The amount of radioactivity in different parts of the ventilator 
circuit, as well as the residual radioactivity in the nebuliser at the end of 
nebulisation, was determined with a dose calibrator (Capintec Inc.. Pittsburg, 
PA). The activity in the expiratory ventiator tubing and the filter, which were too 
large to be put into the dose calibrator, was measured by the gamma camera. 
Both lung deposition and deposition in the airways and ventilator circuit 
were expressed as the percentage of the amount of medication released into the 
ventilator circuit. For the jet and ultrasonic nebulisers, the latter was equivalent 
to differences in radioactivity in the nebuliser reservoir before and after 
nebulisation. For aerosol delivered by the MDI, the latter equalled the amount 
of radiolabeiled salbutamol actuated into the Aerochamber. 
Lung deposition was in addition expressed as percentage of the initial 
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nominal dose which was equivalent to the actuated dose for the MDI, and for the 
nebulisers, the total dose placed in the nebuliser reservoir. To demonstrate the 
distribution of salbutamol in the various lung regions, deposition in each region 
was calculated from radioactivity detected in each gram of lung tissue expressed 
as a percentage of total lung radioactivity. 
5.2.5 Pattern of aerosol accumulation: dynamic gamma scintigraphy 
In order to study the pattern of accumulation of the nebulised aerosol in 
the lungs, dynamic gamma scintigraphy was obtained throughout the 20 minutes 
of nebulisation. The accumulation of 的"Tc in the lungs was monitored with a 
Large field of View gamma camera (Model 410 LFOV, Ohio Nuclear, USA) 
interfaced to a Digital PDP 11-23 computer. Consecutive 30-second frames 
were recorded for a total of 40 frames. The pattern of accumulation was 
expressed by plotting radioactivity accumulated in the lungs (as percentage of 
maximum acccumulation) against time. 
5.2.6 Particle size estimation 
The particle size distribution of the aerosol was estimated using an 8-
stage Non-Viable Anderson Cascade Impactor, operated at 28.32 丨pm. Six 
repeat sizings were performed for each delivery system with the aerosol sampled 
at the exit of each of the systems and also at the exit of a 3.5-mm endotracheal 
tube connected to the system. Five doses of salbutamol from the MDI and 
Aerochamber were actuated into the impactor, one dose every 30 sec. Aerosol 
from the nebulisers was sampled for 30 sec. to avoid excessive wetting of the 
impactor stages. The aerosol from the ventilator circuit was sized with and 
without passing an endotracheal tube. In both occasions, the impactor inlet 
(throat) was not used. The endotracheal tube or the inspiratory line exit was 
held slightly above the impactor, and the ventilator flow together with the 
surrounding air was sampled into the impactor at a total flow rate of 28.3 Lpm. 
Since the supplementary flow of ambient air was greater than the ventilator flow, 
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all aerosol delivered at the endotracheal tube or circuit exit was collected in the 
impactor for sizing. 
The stages of the impactor were assayed for salbutamol using UV spectroscopy 
at 276nm (Hitachi Spectrophotometer, Model 100-60, Trudell Inc., Canada). The 
results were plotted on log-probability paper to obtain a mass accumulative 
distribution curve. The mass median aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) were determined from the plots. 
5.3 Results 
Demography: 
The four groups of animals were of similar body weight (group 1: 
2861±83g, group 2: 2966±81g, group 3: 2765±81g, group 4: 2803±39g). 
Nebuiiser output: 
After 20 minutes of nebulisation, the amount of medication nebulised into 
the ventilator circuit, expressed as the percentage of the total initial reservoir 
dose, was 42.72 ± 2.63o/o in group 2. 35.42±7.60o/o in group 3, and 56.89±1.82% 
in group 4. The amount nebulised in group 4 was significantly greater than that 
in the other two groups (p=0.007) 
Particle size 
The droplet size distributions of the aerosols are given in Table 5.1. 
Aerosols generated by all the delivery systems contained fine particles that were 
well within the resptrable range (MMAD 1-5[jm). Among the systems, the 
ultrasonic nebuiiser produced the largest particles, while particles generated by 
the jet nebuiiser had the smallest MMAD. Particle size was reduced for all 
systems at the exit of the endotracheal tube. 
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Table 5.1: Particle size characteristics (MMAO and GSD) 
neonatal delivery systems: mean(sem) 
System MMAD(um) 
Ventolin MDI + MV15 Aerochamber 1.98(0.04) 
Ventolin MDi + MV15 Aerochamber + endotracheal tube i .84(0.03) 
Hudson jet nebuliser 1.07(0.04) 
Hudson jet nebuliser + endotracheal tube 0.67(0.07) 
Ultrasonic (standard reservoir) 2.26(0.12) 
Ultrasonic (standard reservoir) + endotracheal tube 1.06(0.01) 
Ultrasonic (small cup) 2.63(0.07) 
Ultrasonic (small cup) + endotracheal tube 1.19(0.01) 











Table 5.2 shows the amount of radioactivity deposited In the lungs 
beyond the level of the lobar bronchi. When expressed as the percentage of the 
amount released into the ventilator circuit, deposition was significantly different 
among the groups and pairwise multiple comparison showed a progressive 
increase from group 1 through group 4 (group 1 < group 2 < group 3 < group 4). 
However, when expressed as the percentage of the total initial dose, only the 
pulmonary deposition of group 4 was significantly greater than that in the other 
groups whereas the differences among groups 1, 2, and 3 did not reach 
statistical significance. 
Pulmonary deposition of salbutamol aerosol delivered by MDI. jet nebuliser (Jet), 
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One way ANOVA (followed by Student-Newman-Keul test for multiple pairwise comparison): 
• p < 0.001 (group 1 < group 2 « group 3 < group 4. p<0.05) 
** p <0.001 (group 4 > all other groups: p<0.05) 
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posterior lobe 
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Distribution of the aerosol in the lungs: 
The distribution of aerosol in various regions of the lungs was determined 
by calculating the amount of radioactivity deposited In each gram of lung tissue, 
which was then expressed as the percentage of total radioactivity in both lungs. 
There was no significant difference in deposition between the right and left lungs 
for all 4 groups as shown in Figure 2. Distribution among the lobes was uniform 
in both groups 1 and 2 with no significant difference noted in the amount of lobar 
deposition. In groups 3 and 4, deposition in the anterior azygous lobe was 
significantly greater than that in the right anterior, posterior azygous, and the 
right posterior lobes in both groups of animals (group 3: 16.3[3.1]%/g vs 
7.5[0.9]%/g vs 5.8[0.9]%/g vs 7.3[1.6]%/g, one way repeated measures ANOVA: 
p = 0.004; group 4: 15.6[2.8]%/g vs 7.8[1.2]%/g vs 5.9[0.8]%/g vs 5.2[1.2]%/g, 
one way repeated measures AN OVA: p=0.002, Student-Newman-Keul test: 
p<0.05 for both groups). 
Figure 5.2: Distribution of "H'c-labelled salbutamol in the 2 lungs and lung lobes: Y-axis 
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Figure 5.3 shows the distribution of salbutamol in the peripheral and 
central parts of each lung and each lobe of the lungs. There was a tendency for 
the aerosol to deposit in greater amount at the central parts of both lungs. 
However, the difference was of statistical significance only in the left posterior 
lobe of animals in group 4 (central vs peripheral [median]: 11.4%/g vs 7.8%/g, 
p=0.031, Wilcoxon signed rank test). 
Figure 5.3: Distribution of '*^c-labelled salbutamol in peripheral and central lung 
regions: Y-axis represents deposition per gram lung tissue expressed as 
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Deposition in the airways and ventilator circuit: 
Table 5.3 shows the distribution of salbutamol in drfferent parts of the 
airway and ventilator circuit. In group 1, almost 80% of the aerosol stayed in the 
holding chamber In the other three groups, a similar amount was deposited on 
the exhalation tubings and filters (over 70%). There was also considerable 
deposition (8-20%) in the 20-cm inspiratory tubing connecting the nebuliser and 
the endotracheal tube Y-connector. Deposition in the Y- connector, the 
endotracheal tube connector, and the carina region of the trachea did not differ 
significantly among the groups. Group 3 and 4 however had significantly greater 
deposition in the trachea than the other two groups. 
Table 5.3: Deposition of saibutamol aerosol in the ventilator circuit and airway: as 














































•One way ANOVA: p<0.00l; group 2 and 3 > group I or 2 (p<0.05，Student-Newman-Keul test) 
Note: Total deposition in each group did not add up to 100% since the filter and exhalation tubing . 
being too large to be put into either the gamma counter or the dose calibrator, had to be measured as 
one piece by gamma camera. It was not possible to calibrate the camera for this purpose because 
of the variable and irregular shape and geometry of the specimen, and the amount of deposition 
estimated could only be approximate. 
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Dynamic gamma scintigraphy study: 
The accumulation of radioactivity in the lungs of the groups 2, 3 and 4 
animals during nebulisation is illustrated in Figure 5.4. in the figure, the Y-axis 
represents the activity in the lungs, expressed as the percentage of the final total 
pulmonary radioactivity deposited in each animal after 20 minutes of 
nebulisation. In groups 2 and 3, accumulation of radioactivity in the lungs had 
a biphasic pattern, with an initial period of rapid accumulation for about 10 
minutes, after which the rate of accumulation slowed. The curves suggest that 
80% of the total lung dose of the radiolabelled aerosol delivered by both jet 
nebuiiser and ultrasonic nebuliser with the standard reservoir was deposited in 
the first 10 minutes, and only minimal deposition took place during the latter half 
of nebulisation. In contrast, the accumulation curve of Group 4 animals appears 
to be more linear, indicating that the ultrasonic nebuliser with a small cup 
continued to deposit aerosol at a constant rate almost till the end of nebulisation. 
After approximately 10 minutes, only about 60% of the total final lung dose was 
deposited. The rate of accumulation in the lungs began to decrease only after 
17 minutes, and aerosol deposition continued up to the end of the experiment. 
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Figure 5.4: Mean (sem) pf radioactivity in the lungs (expressed as 
percentage of maximum radioactivity) plotted against time 
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5.4 Discussion 
Particle sizing: 
The Anderson Cascade Impactor used for particle size measurements 
has a sampling flow rate of 28.3 Lpm.丨 and my coworkers responsible for 
particle sizing recognize that this impactor flow rate did not match the ventilator 
flows for neonates. However, since we were examining the aerosol particles that 
were collected in the impactor, we believe that the effect of flow rate on the 
classification of particles that had past the inlet and first stage of the impactor, 
while not to be discounted, should not be a major problem. The particle size 
might be underestimated due to increased evaporation caused by the larger air 
flow, and this could certainly be a source of error. One could reduce the 
sampling flow rate on the impactor (say 14.1 Lpm) and recalculate the cut-off 
diameters. The impactor is however not calibrated at flows other than stated, ie 
28.3 Lpm, and this manoeuvre would introduce another error which we felt might 
be more problematic. 
Pulmonary Deposition: 
Using uniform experimental conditions that were similar to the real clinical 
settings, this study demonstrated that of the delivery devices tested, the 
ultrasonic nebuliser. when used together with the small medication cup, was able 
to deliver the greatest amount of aerosol to the lungs of ventilated rabbits. Our 
findings on the jet nebuliser concurred with those of previous workers that the 
device was relatively inefficient, delivering only 0.48% of the initial reservoir dose 
(1.13% of nebulised amount) to the lungs of the animals. This was similar to that 
observed by Banks et al In piglets (0.28±0.1% of reservoir dose) which were 
ventilated with ventilator settings similar to those used clinically."^ 
Aerosol deposition from the MDl was significantly smaller in our study 
than that previously reported. There are several possible reasons for this 
discrepancy: 
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[1] Lung deposition reported by previous studies, especially those performed 
on filter lung models, were usually calculated as any deposition beyond 
the tip of the endotracheal tube. In view of the substantial amount of 
deposition in the trachea as shown by previous workers圾®° and also in 
this present study, deposition at the bronchiolar and alveolar level in 
these studies should be much lower. 
[2] In most previous studies, the lung models were ventilated with relatively 
high inflation pressure (30cm HjO) and long inspiratory time (1 sec). 
Some investigators had tried to enhance aerosol delivery by ventilating 
the lung model manually through the spacer to try to "bag" the aerosol 
down the a i r w a y I n contrast, animals in the present study were 
ventilated with relatively low pressure and short inspiratory time which 
produced a physiological tidal volume and PaCOa. 
[3] Unlike most previous studies, animals in the present study were ventilated 
with fully humidified gas. Absorption of moisture by the aerosol would 
result in growth in particle size, increased impaction in the ventilator 
tubings and upper airway, and diminished deposition in the lower 
airways.妨 奶 
[4] In our experiment, each animal was given five actuations of aerosol from 
the MDI. It has been shown that multiple actuations into the spacer 
device significantly reduces the proportion of aerosol available for 
i n h a l a t i o n . ' ® 
Unlike the MDI and the jet nebuliser. there is very little information on the 
use of ultrasonic nebuliser in newborns. Two earlier studies reported lung 
deposition of 0.6%and 1.3% of the initial nebuliser dose.^^ The nebuiisers 
used in these studies were not incorporated with a small medication cup. In our 
study, similar amount of lung deposition was obtained when aerosol was 
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generated directly from the standard reservoir (0.9% of reservoir dose). In 
contrast, the use of the small medication cup was associated with a significant 
improvement in aerosol output, and a 3-4 fold increase tn pulmonary deposition 
(3.05% of reservoir dose). 
Possible mechanism for the superiority of the ultrasonic nebuliser with 
small cup: 
Dynamic gamma scintigraphy showed that the small cup continued to 
deposit aerosol in the animal lungs for a significantly longer time than the jet 
nebuliser or ultrasonic nebuliser with the standard reservoir. The tapered bottom 
of the small cup might have ensured more complete aerosolisation of the 
medication resulting in a smaller "dead" volume, it also allowed a good interface 
between the drug solution and the coupling fluid, resulting in better transmission 
of ultrasonic vibration and a higher aerosol output In a recent evaluation of 
ultrasonic nebulisers, Thomas et ai studied the effect of three different volume 
fills (3ml, 12ml, and 18ml) on aerosol release. The larger volume fills resulted 
in aerosol output several times greater than that from the small volume fills in all 
the nebulisers tested It is possible that the ultrasonic nebuliser cannot 
release aerosol properly when the solution in the reservoir is too shallow. The 
tapered bottom of the small medication cup thus enables nebulisation to 
continue for a longer time than when the solution is placed in the round 
bottomed large reservoir. 
Distribution of aerosol in the lungs: 
Very few studies have investigated the distribution of aerosol in the lungs. 
The present study showed that the aerosol reaching the lungs was fairly evenly 
distributed among the lobes. Using gamma scintigraphy, previous workers have 
shown that both jet nebuiser ^ and MDI ^^  could deposit a significant proportion 
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of a lung dose of aerosol to the peripheral lung regions. In our animals, though 
there was a tendency in all groups for the aerosol to deposit more at the central 
lung regions, peripheral deposition was substantial. 
Deposition in airway and ventilator circuit: 
Our data on fractional deposition showed that about 80% of the aerosol 
delivered by the MDI was retained in the holding chamber. In the nebuliser 
groups, a similar proportion of the aerosol escaped into the expiratory limb of the 
ventilator curcuit. Hence only a relatively small proportion of the aerosol 
generated is available for lung deposition irrespective of the method of delivery. 
There was considerable deposition in the trachea beyond the tip of the 
endotracheal tube, being 35 - 87% of pulmonary deposition in the nebuliser 
groups, and up to 227% in the MDI group. Excessive tracheal deposition of 
aerosol delivered by the MDI to intubated rabbits has also been observed by 
O'Callaghan et al.^ These findings suggest that studies using filter lung models 
may tend to overestimate pulmonary deposition. Similarly, when sodium 
cromoglycate is used to study aerosol delivery, similar error might be introduced 
by the systemic absorption of the medication deposited in the trachea. 
5.5 Conclusions 
In this study, the MDI (plus neonatal Aerochamber), a jet nebuliser, and 
an ultrasonic nebuliser were compared on their abilities to deliver salbutamol 
aerosol to ventilated rabbits. Among these devices, the ultrasonic nebuliser 
used together with a small medication cup was able to deposit the greatest 
amount of aerosol in the lungs of the animals. Irrespective of the device used, 
however, only a small fraction of the aerosol generated was available for lung 
deposition, the rest being lost to the delivery device (Aerochamber) or the 
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ventilator circuit (nebulisers), the endotracheal tube, and the trachea. With all 
the devices, a substantial proportion of the lung dose could reach the peripheral 
lung regions. This last observation, however, needs to be Interpreted cautiously 
since aerosol penetration of the airways is affected by the presence and type of 
lung pathology, and our findings on healthy animal lungs might not be 
extrapolated to human Infants with lung diseases. 
By using ventilator settings appropriate for the size and lung condition of 
the animals, our data should be more relevant to the real clinical situations than 
those from deposition studies that have used excessively high ventilation 
pressure or long inspiratory time. The general application of the findings is 
however limited by the limitations of animal models (please see Chapter 2， 
Discussion), and also by the fact that only one model of each type of delivery 
devices has been tested. Despite these limitations, the superiority of the 
ultrasonic nebuliser used in combination with the small medication cup is 
encouraging and deserves further evaluation. 
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Section 2: Part 2 Original studies: animal models 
6.1 Introduction 
In most previous deposition studies on ventilated lung models, ventilation 
was provided entirely by either the ventilator or hand ventilation. In the real 
clinical situation, many infants requiring bronchodilator therapy (such as those 
with BPD) are on slow intermittent mandatory ventilation (IMV), with a significant 
proportion of their ventilation being provided by the infants' own spontaneous 
respiratory efforts. Data on aerosol delivery relevant to this group of infants are 
however not available. After completion of the previous study, I proceeded to 
study a separate group of rabbits who were ventilated with slow IMV at a rate of 
10 breaths per min. These rabbits were given light anaesthesia without 
pancuronium so that they continued to breathe spontaneously. Pulmonary 
deposition in this group was compared with that in the paralysed rabbits who 
received the aerosol from the MDI in the previous study (Chapter 5). 
6.2 Subjects and methods 
Six adult White New Zealand rabbits were prepared and ventilated in a 
similar manner as those in Chapter 5 except for a slower ventilation rate of 10 
per min. The animals were however not paralysed with pancuronium so that 
spontaneous respiration continued at a rate of 40 to 50 per min. Blood gas 
analysis in this group showed a satisfactory PaCOj of around 35 mmHg. 
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Similar to the group 1 (MDI) animals in Chapter 5, each rabbit was given 
5 puffs (100ug of salbutamol per puff) of ®^c-labelled salbutamo! from the MDI 
through the MV15 Aerochamber at 1-minute intervals. Each puff was actuated 
immediately before the onset of a ventilator generated breath. Deposition and 
distribution of radioactivity in the lungs, airways, and ventilator circuit were 
estimated as described above and compared with those in the group 1 animals 
(paralysed) in the previous study (Chapter 5). 
6.3 Results 
Demography: 
The body weight of the non-paralysed animals (2743±75g) were similar 
to that of the paralysed group 1 animals in Chapter 5 (2861 士 83g; p=0.32). 
Pulmonary deposition: 
Aerosol deposition, as estimated from the radioactivity of the autopsy 
specimens, was calculated as a percentage of the total radioactivity actuated by 
the MDI (Table 6.1). There was no significant difference between the two groups 
of animals in deposition distal to the tip of the endotracheal tube. However, when 
only deposition in the lung tissues beyond the carina was counted, the non-
paralysed animals had significantly greater deposition than the paralysed ones. 
Deposition at the trachea and the carina region did not differ significantly 
between the two groups. 
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Table 6.1: Deposition of Salbutamol in the lungs and airway of 
paralysed and non-paralysed rabbits: mean (sem) 
Deposition (as % of total amount actuated by the MDI) 
Group Bevond ETT Lungs Trachea Carina & main bronchi 
Paralysed 0.80(0.23) 0.23(0.05)* 0.50(0.19) 0.07(0.05) 
Non-paralysed 1.10(0.21) 0.51(0.08)* 0.44(0.16) 0.15(0.02) 
“p=0.0094 (unpaired t test) 
Ditribution of aerosol in the lungs, airway, and ventilator circuit: 
The two groups were similar in lobar distribution of the aerosol (Figure 
6.1), as well as distribution between the central and peripheral lung regions 
(Figure 6.2). In both groups, lobar distribution was fairly uniform, and there was 
no significant difference in deposition between the right and left lungs. Both 
groups showed a tendency for the medication to deposit in greater amount at the 
central parts of both lungs. The differences between central and peripheral 
deposition were however small and not statistically significant. 
Deposition at the delivery system, the endotracheal tube, and the airway 
is given in Table 6.2. There was no significant difference in the percentage 
deposition at any of the sites between the two groups. In both groups, most of 
the medication (>70%) stayed in the aerosol holding chamber. 
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Lung Region 
a: anterior azygous lobe, b:R anterior lobe, c: R posterior lobe, d: posterior azygous lobe, e: L anterior lobe, 
f: L posterior lobe, g: right lung, h: left lung, t: both lungs; 1 = peripheral. 2 = central 
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Figure 6.1: Distribution of**Tc-labelled salbutamol in the 2 lungs and lung lobes: Y-axis 
represents deposition per gram iung tissue expressed as percentage of total 
lung deposition 
R lung: right lung; L lung: left lung; Ant. azy.: anterior azygous lobe; R ant.: right anterior lobe; R 
post.: right posterior lobe: Post, azy: posterior azygous lobe. L ant.; left anterior lobe; L post.: left 
posterior lobe 
Figure 6.2: Distribution of•*n'c-Iabelied salbutamol in peripheral and central iung regions: 
Y-axis represents deposition per gram lung tissue expressed as percentage 




Table 6.2: Deposition of salbutamol in the airway and the ventilator 
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Studies on rabbit neonatal lung models have shown that aerosol 
deposition is greater in non-intubated, spontaneously breathing animals than in 
those who are completely ventilator dependent.®® Similar observations have 
been made on both adult patients and filter adult lung " 
However, aerosol deposition through the a ventilator circuit in subjects breathing 
spontaneously on slow IMV has not been evaluated in either the infant or adult 
population. Using identical delivery systems (MDI plus MV15 Aerochamber). this 
study demonstrated that rabbits on slow IMV had significantly greater lung 
deposition than those who were fully ventilator dependent. The ventilator-
generated breaths in both groups were of identical tidal volume and inspiratory 
time, and therefore should not be responsible for the discrepancy in deposition. 
It is possible that in the non-paralysed animals, the ventilator breaths had been 
augmented by the animals' own inspiratory effort, resulting in a larger tidal 
volume and hence increased lung deposition. Similar to that in fully ventilated 
rabbits, the aerosol was fairly evenly distributed among the iung lobes, and a 




This study demonstrates for the first time the difference in pulmonary 
deposition of aerosol between paralysed and non-paralysed animals. This 
finding is of clinical significance since a uniform dose of salbutamol aerosol may 
not achieve the same clinical effect in infants ventilated with or without induced 
paralysis. Although only MDI aerosol was tested in this study, it is likely that the 
same is also true for aerosol delivery by the nebulisers. This however requires 
confirmatioR by repeating the experiment using the appropriate devices. 
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Section 2： Part 3 Original 他di然 infants with BPD 
7.1 Introduction 
The radiotracer technique has been used to estimate the deposition of 
aerosol in filter ^ and animal lung models 认錢”7 的 的 in human 
adults.sm®® In animals the lungs can be excised for the direct measurement of 
radioactivity using a well gamma counter. In human studies, gamma 
scintigraphy provides the only method for the direct measurement of aerosol 
deposition. When properly conducted, gamma scintigraphy is convenient and 
involves only minimal irradiation.”® However the accuracy of the method has not 
been evaluated either in adults or in infants. As a preparation for the infant 
deposition study described in Chapter 8, I have examined the validity of using 
gamma scintigraphy in the estimation of aerosol deposition in small animal 
lungs. In a series of radiotracer studies on rabbits, pulmonary deposition of 
labelled aerosol was first mesured by gamma scintigraphy before the 
animals were sacrificed. The accuracy of the method was determined by 
comparing the scintigraphy counts with the radioactivty measured direcly on the 
lung specimens using the gamma well counter. 
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7.2 Methods 
7.2.1 Data collection 
The data for this analysis were collected fom a total of 58 White New 
Zealand rabbits during the evaluation of different methods of delivery of 
aerosoloised salbutamol (Chapter 5 and 6) and exogenous surfactants (Chapter 
11) to ventilated neonatal animal models. The animal model was prepared as 
described in the respective chapters.抽"Tc-labelled salbutamol was delivered 
by means ofaMDI (n=13), a jet nebuliser (Flo Thru®. Hudson RCI, USA) (ti=13). 
or an ultrasonic nebuliser (Siemens Electronics Inc., Sweden) (n=13). 
Radiolabelied surfactant (Exosurf, Burro ugh Wellcome Laboratory, Canada; or 
Survanta, Abbott Laboratory, USA) was delivered by a jet nebuliser (Up-Mist 
Medication Nebuliser, Hospitek, USA) (n=9) or an ultrasonic nebuliser (Siemens 
Electronics Inc., Sweden) (n=10). The actutated dose of radioactivity from the 
MDI was approxiamtely SOOjjCi，and the initial nebuliser dose was about 
4000^iCi. Details of aerosol delivery were given in the relevant chapters. 
7.2.2 Gamma scintigraphy count 
Immediately after delivery of the radiolabelied drugs, the amount of 的"Tc 
in each lung was measured by static gamma scintigraphy for 2 minutes with the 
animal lying supine on a Large Field of View gamma camera (Model 410 LFOV, 
Ohio Nuclear) interfaced to a Digital PDP 11-23 computer. Using a manual 
cursor, an area of interest was drawn around each lung excluding the tracheal 
region on the computer screen. The total number of counts recorded over the 
2-minute period was read from the computer file. 
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7.2.3 Calibration of gamma camera 
The gamma camera was firstly calibrated by taking supine images of the 
lungs of 2 rabbits following an intravenous dose of labelled 
macroaggregate (MAA) of human serum albumen with known rad ioact iv i ty . ”® 
As all the MAA were trapped within the pulmonary capillary bed, the lung 
scintigraphy count should represent the MAA activity. A conversion factor 
(counts in 2 min./pCi) was thus calculated by dividing the 2-minute scintigraphy 
lung counts by the MAA activity to quantitate the amount of radiolabeiied aerosol 
deposited in each lung of the animals studied subsequently. The ratio of counts 
in each lung to the whole lung was calculated and applied to the total activity to 
obtain the specific factor for each lung. 
7.2.4 Tissue count 
As previously described, aerosol deposition in the lungs was estimated 
from the amount of radioactivity in each lung measured by a gamma counter 
(Minaxi autogamma 5000, Canada). Both the gamma camera counts and the 
tissue counts were corrected to allow for decay between manufacture of the 
tracer and counting (Appendix 3). 
7.2.5 Comparison 
The amount of ®®"Tc in each of the right and left lung determined by static 
gamma scintigraphy was compared with that measured by the gamma counter 
on the lung specimens using the Pearson Product Moment Correlation test and 
linear regression. In addition, the method yielding "limits of agreement" 
proposed by Bland and Altman was used to assess the extent of agreement 
between the camera and tissue c o u n t s . j p this method, the differences 
between the two measurements were plotted against their mean. Their limits of 




Calibration of gamma camera: 
From the calibration studies using intravenous ®®"Tc labelled MAA of 
human serum albumen, the distribution of radioactivity to the right and left lungs 
was: 586 counts per 2 min/|jCi for the right lungs and 572 counts per 2 min/jjCi 
for the left lungs. 
Correlation between camera and tissue counts: 
The 58 study rabbits gave a total of 116 pairs (one from each lung) of 
gamma camera/gamma counter readings. Radioactivity estimated by static 
scintigraphy showed a linear relationship with that measured in the lung 
specimens with the gamma counter. The correlation coefficient was 0.990 
(p<0.001) for the right lung and 0.994 (p<0.001) for the left lung. When data 
from both lungs were considered together, the correlation coefficient was 0.997 
(p<0.001). The prediction of radioactivity in the tissue from that estimated by 
scintigraphy is given by the linear regression equation: 
Tissue count = 0.048 + 1.015 x scintigraphy count. 
The regression line and the 95% confidence intervals were given in Figure 7.1. 
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Figure 7. :Gamma scintigraphy counts vs Tissue: regression line 
and 95th % confidence limits 
>0 100 
Tissue count (pCi) 
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Limits of agreement between camera and tissue counts: 
Figure 7.2 plots the differences between camera and tissue counts 
against their means and the limits of agreement drawn at the points equivalent 
to the mean differences of the 2 measurements 土 2SD. Figure 7.2A includes 
all the data pairs and Figure 7.2B and 7.2C were magnified views to include 
data pairs falling within a range of average counts 0 to 5 pCi and 0 to 10|jCi 
respectively. The mean differences (SD) betwen tissue and camera counts were 
-0.17(1.90) pCi in Figure 7.2A, -0.006(0.31) in Figure 7.2B, and -0.10(0.56) pCi 
in Figure 7.2C. 
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Average of tissue and camera counts (yCi) 
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7.4 Discussion 
Gamma scintigraphy provides the only method for the direct 
measurement of aerosol deposition in the human lungs. In human adult 
studies, the gamma camera was usually calibrated by the lung phantom method 
and the scintigraphy counts were corrected for attenuation from the chest 
51.97.121 Another method of calibration is to use radiolabeled MAA of human 
serum albumin which is trapped entirely in the pulmonary capillary bed following 
intravenous injection. Macey and Marcha!! has shown good correspondence 
between the radioactivity of an intravenous dose of labelled MAA of 
human serum albumin and gamma scintigraphy counts in human adults.”® This 
method has subsequently been used to determine aerosol deposition in the 
lungs of a ventilated neonatal animal model? However it is not known whether 
calibration of the gamma camera using MAA activity, which stays in the blood 
stream, is appropriate for estimating the amount of activity in the airspaces. No 
previous studies have been performed to assess the magnitude of errors 
introduced by this method of calibration. 
The present study shows that lung radioactivities estimated by gamma 
scintigraphy correlate well with the direct tissue assays obtained by gamma 
counter with a narrow 95% confidence interval. However, good correlation only 
means that there is a linear relationship between the two measurements, and 
does not necessarily mean that the two methods agree:扣 I therefore used the 
method of "limits of agreement" proposed by Bland and Altman^^ to evaluate the 
extent of agreement between the tissue and camera counts. By plotting the 
differences between the two measurements against the average counts from 
the two methods, and constructing the limits of agreement at a point equivalent 
to the mean±2SD of the differences. 95.8% of the differences will lie within the 
limits of agreement. If the limits of agreement are narrow enough to indicate that 
the differences between the two measurements are of no clinical significance, 
then it can be accepted that the tissue counts are in agreement with the camera 
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counts. In Figure 7.2A, when all the data are considered together, the limits of 
agreement are -3.97 to 3.63 pCi. This would be clinically acceptable if the actual 
counts being measured are high. As an example, if the counts being measured 
are of the order of 50 to lOOpCi, the differences between the tissue and camera 
counts would not exceed 4 to 8% of the actual counts. However, if the counts 
being measured are low, the differences between the two measurements will be 
clinically significant. I therefore reviewed the distribution of the differences at the 
lower count ranges of 0 to 10pCi (Figure 7.2B) and 0 to 5\iC\ (Figure 7.2C). At 
a count range o f 0 to10 pCi, the mean differences (SD) a re -0 .10(0 .56) pCi, 
hence the limits of agreement are -1.22 and 1.02 pCi. When the count range 
is 0 to 5 jjCi’ mean (SD) of the differences become -0.006(0.31), and the limits 
of agreement -0.63 and 0.61 |jCi. The limits of agreement In both count ranges 
are narrow enough to indicate that the tissue counts agree witht the camera 
counts. 
This study also confirms that gamma scintigraphy calibrated by the MAA 
method can be reliably used to estimate pulmonary deposition of radiolabelled 
aerosol. The findings also show that there is no need to carry out calibration on 
every animal provided the study animals are of similar size. To minimise errors 
in estimation due to the thickness of the lungs, previous workers carried out 
gamma imaging from both the front (anterior projection) and back (posterior 
projection) of the lungs and calculated their geometric mean.®? ”® In this study, 
scintigraphy counts obtained from the anterior projection of the study animals 
were significantly attenuated by the heart. It appears that in small animals, 
reliable estimation of lung counts can be obtained from the posterior projection 
alone presumably because of the small size of the lungs 
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7.5 Conclusions 
This study confirms the validity of using gamma scintigraphy to estimate 
aerosol deposition in small lungs. The information allowed me to proceed with 
the deposition study on BPD infants (Chapter 8). 
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Section 2: Part 3 Original studies： infants with BPD 
8.1 Introduction 
Pulmonary deposition of aerosol in human infants has been estimated 
indirectly in a few studies from the urinary excretion of an inhaled dose of sodium 
cromoglycate.31 明 Direct quantification, which could only be performed using 
the radiotracer technique, has never been reported on infants or children. In 
view of the increasing evidence on the beneficial effects of bronchodilator 
aerosols on infants with BPD, ” accurate data on aerosol deposition in this 
population of infants should be made available. The following study was carried 
out In an attempt to provide such data, and also to compare directly the 
efficiencies of the various delivery devices under identical experimental 
conditions. 
Among the currently available delivery devices, the jet nebuliser and MDI 
are the most commonly used methods both in adults and infants. In ventilated 
rabbits, the ultrasonic nebuliser incorporated with a small medication cup was 
able to deposit the largest amount of aerosol in the lungs (Chapter 5). I had 
originally intended to compare all three devices on human infants. However, 
owing to ethical and practical considerations (please see paragraphs 8.2 and 
8,3), only the jet nebuliser and the MDI were evaluated in the following 
experiment. Comparison with the ultrasonic nebuliser has to be performed in a 





8.2 Ethical considerations 
The study was approved by the Ethics Committee of the McMaster 
University Medical Centre where the study was conducted. To my knowledge, 
this is the first study that directly estimates aerosol deposition in infants using the 
radiotracer technique. The use of radiolabelled markers in the paediatric age 
group has been limited by the concerns surrounding the administration of even 
relatively low radiation doses to small children and infants. A previous study 
however showed that the total absorbed dose of radiation from 10pCi 
administered to infants is approxiamtely equivalent to one chest x - ray . ”® This 
comprises 30mR to the lung parenchyma and 1mR to the gonads. Based on 
this small dose of radioactivity”® the context of numerous clinically indicated 
chest radiographs in infants with BPD, it became evident that direct measures 
were indeed ethical and in keeping with the need to provide more accurate 
estimates of the actual pulmonary dose and distribution of medication aerosols 
in these infants. The need to protect the thyroid gland from exposure to the 
radioisotope was considered. However, had all the radiolabelled salbutamoi 
deposited in the lungs following delivery been absorbed into the vascular 
compartment, the maximum radioactive dose to the thyroid would be only 
30mR. Blocking the thyroid uptake of radioactivity with iodine was therefore not 
attempted, surmising that problems of hypothyroidism associated with giving 
large doses of iodine to infants far outweighed the risk from any potential small 
radiation to the thyroid. (Review of the gamma scintigraphy scans after 
completion of the study failed to detect any radioactivity in the kidney or the 
thyroid. This suggests that little or no radioactive label had been systemically 
absorbed.) 
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8.3 Study design 
The experiment was a randomised cross-over study comparing the MDI 
and jet nebuliser in their delivery of aerosolised salbutamoi to the lungs of 
infants with BPD. I had intended to include the ultrasonic nebuliser in the 
comparison. However, with a cross-over design, each infant would be exposed 
to three doses of radioisotope in order to compare all three modalities. This was 
considered to be excessive by most of my medical and nursing colleagues whom 
I consulted during the planning stage of the study. An alternative option was to 
perform a randomised study with three different arms. However, unlike animal 
studies, aerosol deposition in the infants would be affected by a large number 
of confounding factors especially the gestation, body weight, severity of lung 
disease, and ventilator settings. For such a study to be of sufficient power, an 
unrealistically large sample size would be required. After careful consideration, 
I opted to evaluate only the two most commonly used devices, namely jet 
nebuliser and MDI, in a randomised cross-over fashion. 
8.4 Enrolment of infants 
Thirteen spontaneously breathing non-ventilated infants and ten ventilated 
infants who either had established BPD^ '^^ ^ or were at high risk of developing 
BPD were enrolled. Enrolment criteria were as follows : 
[1] postnatal age > 2 weeks： 
[2] need for assisted ventilation and supplemental oxygen during the first 
week of life, and oxygen or ventilator dependent at enrolment; 
[3] respiratory status expected to be stable over the 24-hour study period. 
For this reason, only infants with little change in ventilator parameters and 
Fi02 in the preceding three days were enrolled, and infants who had 
been started on or weaned off steroid within a week were excluded; 
[4] chest radiograph showing diffuse lung disease, but no localized lesions 
such as lobar collapse or consolidation; and 
[5] informed parental consent. 
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Infants with known anatomical abnormalities of the respiratory tract were 
not enrolled. 
8.5 Aerosol administration 
Each infant was given ®®"Tc-labelled salbutamol aerosol on two separate 
occasions, once from an MDI attached to a valved aerosol holding chamber 
device and on another occasion from a jet nebuliser. The two methods were 
used 24 hours apart at random order as determined by computer generated 
random numbers. Radiolabelling of the salbutamol MDI and respirator solution 
was carried out as described In Chapter 5. 
8.5.1 Non-ventilated infants 
With both methods of delivery, the aerosols were delivered to the infant 
via a face mask (Laerdal Resuscitation Mask, Laerdal, Stavanger, Norway) held 
over the infants' face. The skin around the mouth and nose was protected from 
the radioisotope with vaseline. 
Nebuliser: Nebulisation was carried out with a Sidestream jet nebuliser 
(MedicAid, UK), which was connected to the face mask with a T-piece so that 
running gas and exhaled gas and aerosol could escape through the 
exhalation tubing. Salbutamol respirator solution (Ventolin®. Glaxo, UK; 
100|jg/kg) was diluted to 3 ml with approxiamtely 4 miilicuries 的"Tc human 
serum albumin (HSA) in saline, and nebulised for 5 minutes at a gas flow rate 
of 6L/min. as recommended by the manufacturer. To prevent contamination 
of the environment by the radiolabelied aerosol, the exhalation tubing was 
connected to an absolute filter (Pall Biomedical, NY. USA). 
MDI : A radio-labelled MDI of salbutamol, containing approximately 30 
miilicuries 99mTc-Iabelled Ventolin®, was actuated Into a lead-lined 145-ml 
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valved holding chamber device (Aerochamber, Tmdell Medical. Canada) 
connected to the face mask. A total of two puffs (100|jg salbutamol/puff 
labelled with 189.5[31.4]pCj ®®"Tc04' mean[sem]) were given one minute 
apart. The canister was shaken vigorously for 10sec. prior to each puff. The 
infant was allowed to breathe into the facemask for 30 sec. after each puff, 
before the facemask and holding chamber were removed. Contamination of 
the environment was not a concern as any excess radiolabelled aerosol was 
retained In the Aerochamber. 
8.5.2 Ventilated infants 
All the infants were ventilated with a continuous flow, time-cycled, 
pressure-limit neonatal ventilator (Sechrist Ventilator, Model IV-100B, Sechrist 
Industries Inc., Anaheim, CA) during aerosol administration. The ventilator 
settings and humldlfication were similar to those used clinically on each 
individual infant, and kept identical during delivery by the MDI or nebuliser. An 
absolute filter was connected to the expiratory limb of the ventilator circuit to 
prevent any excape of radioactive aerosol into the environment. 
Nebuliser: The Sidestream nebuliser (MedicAid, UK) was connected 
through a side port to the inspiraotry limb of the ventilator tubings as 
described in Chapter 5. Nebulisation was carried out in the same way and 
with the same dose of saibutamol as for non-ventilated infants. During 
nebulisation the ventilator flow rate was reduced accordingly so that the total 
flow rate through the ventilator circuit and the ventilation pressure remained 
unchanged. 
MDI: A 145-ml valved holding chamber (MV15 Aerochamber, Trudell, 
Canada) was inserted between the Y-piece and the endotracheal tube as 
described in Chapter 5. Two puffs of saibutamol aerosol was actuated into 
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the holding chamber at end expiration at least one minute apart. The holding 
chamber was removed from the ventilator circuit two minutes after the 
second puff was administered. 
8.6 Particle characterization 
The particle size distribution of the delivered aerosols was measured for 
each delivery device in each of the ventilated and non-ventilated curcuits, using 
an 8-stage Non-Viable Anderson Cascade Impactor as described in Chapter 5. 
Aerosols were generated in the same way as described above. For the 
ventilated systems, aerosol characterisation was performewd on the aerosols 
exiting the endotracheal tube after passing through a humidified ventilator circuit 
with settings identical to those used on the infants. For the non-ventilated 
system aerosofs were characterised at the Laerdal Mask attached to the valved 
Aerochamber. 
8.7 Estimation of pulmonary deposition 
Pulmonary deposition of aerosol was estimated by gamma scintigraphy. 
Immediately after delivery of the radiolabelled salbutamol, the infant's lungs were 
imaged for 10 minutes with a gamma camera (GE Starcam 3200) interfaced to 
a computer. On each study day, the correction factor for tissue attenuation was 
obtained by scanning a plastic bag containing 250ml of water and a known 
amount of ^^"TcCV The mean (sem) value was 302.3(3,8) cpm/jjCi, and within 
4% of calibration factors for rabbits measured by perfusion scanning (M. 
Dolovich, personal communication). The airways and the lungs were delineated 
as the area of Interest on the computer screen, and the amount of radioactivity 
in each region was estimated from the camera count In non-ventilated infants, 
the amount of radioactivity on the face and in the stomach was also measured. 
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Aerosol deposition in the lungs from the jet nebuliser was expressed as 
a percentage of the amount of radioactivity delivered into the ventilator circuit. 
This was equivalent to the difference in radioactivity in the nebuliser before and 
after nebulisation. Secondarily, delivery was calculated as a percentage of the 
initial radioactivity placed into the nebuliser reservoir. Deposition from the MDI 
was expressed as a percentage of radioactivity actuated into the Aerochamber. 
The regional distribution of radioactivity in the lungs was determined by 
the method described by Sanchis et al.^^ Each lung was divided on the 
computer screen into three concentric zones of approximately similar area: a 
peri-hilar (central) zone, a middle zone, and an outer (peripheral) zone. Activity 
per unit area (cm勺 in these zones was expressed as a percentage of counts In 
the total lung. The ratio of inner (central) to outer (peripheral) zone radioactivity 
was calculated. 
8.8 
Demographic characteristics of Infants Enrolled: 
The characteristics of each group are shown in Table 8.1. Data from 11 
of the 13 non-ventilated babies and 7 of the 10 ventilated babies were available 
for regional deposition analyses. 
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The mass median aerodynamic diameters (MMADs) and geometric 
standard deviation (GSD) of the MDI aerosol, were 1.88±0.01pm and 1.45±0.03 
respectively after passing through the MV15 Aerochamber and endotracheal 
tube (for ventilated infants), and 1.83±0.03|jm and 1.52±0.02 respectively when 
exiting the Aerochamber with Laerdal mask (for non-ventilated infants). Aerosols 
delivered by the jet nebuliser to the infant had a MMAD of 0.83±0.01^jm and 
GSD of 1.69±0.02 in the ventilator system and MMAD of 1.01 ±0.04 and GSD of 
1.64±0.04 in the non-ventilated circuit. For both groups, aerosols delivered to 
the infants by nebulisation were significantly finer than those delivered by MDI 
(ventilated: p二0.005; non-ventilated: p<0.0001) 
Delivery Systems: 
The amount of activity delivered Into the circuit by the MDI and the jet 
nebuliser is given in Table 8.2 for each individual baby. 
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Amount of activity delivered into the ventilator circuit 
Name 
Amount of activity delivered (pCi) 






















































































Pulmonary Deposition In Non-Ventilated Group: 
Figure 8.1 is an example of a deposition image from one infant (H) in this 
group. Figure 8.2 illustrates the individual data for both modalities of delivery 
in each infant. Pulmonary deposition between infants was variable, ranging from 
0.12% to 2.26% of the actuated dose from the MDI and, for the jet nebuliser. 
from 0.87% to 3.43% of the amount delivered into the circuit and 0.12% to 
0.66% of the initial reservoir dose. The group data for lung deposition (Figure 
8.3) was 0.67±0.17% for the MDI and 1.74±0.21% of the amount delivered into 
the circuit by the nebuliser (p=0.0005). When lung deposition was calculated as 
a percentage of the initial activity in the nebuliser reservoir, the MDI (2 puffs) 
delivered more to the lung than did the jet nebuliser over the time period studied, 
ie 5 minutes of nebulisation (MDI 0.67±0.17% vs Jet nebuliser deposition 
0.28±0.04 %, p=0.025). 
Figure 8.1: Gamma scintigraphy image of the lungs following aerosol 
delivery: non-ventilated infants 
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Figure 8.2: Pulmonary deposition of ®®'"Tc-labened salbutamol to 
ventilated infants: incHvidua丨 data 
•MOi-as % of actuated dose 
a Neb-as % of amount nebulised 








Figure 8.3: Pulmonary deposition of 99fnTc-labelIed salbutamol: group 
mean (sem) 
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Pulmonary Deposition In Ventilated Group: 
Figure 8.4 is a sample image obtained from an infant (T) in this group. 
Figure 8. 5 illustrates the data for individual infants and Figure 8.6 the group 
means. As with the non-ventialted group, there was significant inter-subject 
variability in lung deposition from the two methods. Lung deposition from the 
MDI+ MV15 Aerochamber ranged from 0.35% to 2.12% with a mean±sem of 
0.98±0.19。/o. Lung deposition from the jet nebuliser, when expressed as a 
percentage of the amount of radioactivity delivered into the ventilator circuit, 
ranged from 0.4% to 2.62% with a nnean±sem of 0.95±0.23%. This was not 
significantly different from that of MDI delivery (p=0.894). When lung deposition 
was expressed as a percent of initial nebuliser dose, however, deposition was 
significantly lower than that from the MDI + MV15 Aerochamber mean (MDI 
0.98±0.19% vs nebuliser 0.22±0.08%, p=0.0009) 
Figure 8.4: Gamma scintigraphy image of the lungs following aerosol 
delivery: ventilated infants 
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Absolute Pulmonary Deposition of Saibutamol (Table 8.3): 
The calculated lung dose from the MDI was significantly greater than that 
from the nebuliser among the ventilated infants (1.96±0.41jjg vs 0.59±0.36(jg： 
p = 0.0025) but not in the non-ventilated ones (1.35±0.34^jg vs 0,77±0.20^jg; p 
=0.12). This however might not be a fair comparison since a uniform nominal 
dose of 200Mg of MDI saibutamol was used in all infants： while the initial 
nebuliser dose of saibutamol varied with body weight (100}jg/kg), being 
238.6±2.76pg for the non-ventilated infants, and 171.8±3.62Mg for the ventilated 
subjects. The results from the nebuiisers were therefore normalised to a 
reservoir dose of 200|jg using the nebuliser deposition percentages. This 
yielded a nebuliser lung dose of 0.57±0.08pig for the non-ventilated infants and 
0.43±0.16ijg for the ventilated infants. Both were significantly less than the lung 
dose delivered by the MDI (norM/entilated: p=0.025; ventilated: p=0.0009). 
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Table 8.3: Absolute amount of salbutamol deposited in lung 




































































































'Normalised to an initial reservoir dose of 200|jg 
Distribution of salbutamol in the lower respiratory tract: 
In both groups of infants, aerosol delivered by either the MDI or the jet 
nebuliser was evenly distributed between the right and left lungs. For the non-
ventilated infants, the mean±sem deposition in the right and left lungs, 
expressed as a percentage of total pulmonary deposition, was 52.15±2.17% and 
47.85±2.17% respectively (p=0.342) from the MDI, and 51.15士 1.67% and 
48.85±1.67% respectively (p=0.51) from the jet nebuliser. Similarly, there was 
no significant difference in deposition between the right and left lungs among the 
ventilated infants (MDI: 49.54±2.63% vs 50.46±2.63%, p=0.864; nebuliser: 
50.19±2.47% vs 49.81±2.47%, p=0.941) 
The central and peripheral distribution in each lung is expressed as the 
central to peripheral count ratio (Table 8.4). If a uniform distribution is achieved, 
a ratio of 1.0 would be expected. In both non-ventilated and ventilated infants, 
the ratio was consistently greater than one, suggesting that a larger amount of 
the aerosol was deposited in the central part of the lungs than in the periphery. 
Compared to the MDI, higher ratios, which signified more uneven distribution, 
were associated with the use of the nebuliser, with significant differences in the 
right lungs of both the non-ventilated and ventilated infants. 
Inner/outer lung zones ratio: Peripheral and central distribution 





















Aerosol Deposition at the other anatomical sites and delivery system: 
Table 8.5 shows the amount of radioactivity deposited on the face, trachea 
and stomach of the infants and the various parts of the delivery equipment. In 
both the non-ventilated and ventilated infants, most deposition was in the parts 
of the delivery system. Approximately 90% of the aerosol generated by the MDI 
was deposited in the Aerochamber, while over 20% of the aerosol delivered by 
the jet nebuliser was deposited at the tubings. In the non-ventilated infants, 











Aerosol deposition at the other anatomical sites of the infants and the 
delivery equipment (as a percentage of the amount delivered to the 
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8.9 Discussion 
Pulmonary deposition of aerosol: 
Most previous studies on ventilated in-vitro or animal models have 
demonstrated low pulmonary deposition ranging from 0.5% to 2% of the dose 
delivered. Similar results have been obtained from indirect estimates in 
ventilated infants using the urinary excretion of a dose of aerosoiised sodium 
cromoglycate?i.49 | am not aware of any aerosol deposition study in non-
ventilated human infants with BPD. Salmon et al has used the MDI and spacer 
to deliver cromoglycate aerosol to an older (3 to 9m) group of non-ventilated 
wheezy infants, and observed small and variable (0.3 to 1.5% of actuated dose) 
deposition in their l ungs .S l i gh t l y greater deposition (1.9±0.9。/o of actuated 
dose) was observed in rabbits breathing freely through a tracheostomy.知 The 
present study directly confirms that delivery of aerosol to the infant lungs is low, 
irrespective of method of delivery. Lung deposition in the subjects, especially 
the ventilated infants, were very similar to those obtained from previous in-vitro 
(filter), In-vivo (animal), and indirect human studies. 
With the dosing schedules and administration protocol used in this study 
(ie only 5 minutes of nebulisation and 2 puffs from the MDI), pulmonary 
deposition acheved by the MDI and jet nebuliser differed significantly. After 
normalising the initial nebuliser dose to that from the MDI (200pg), the absolute 
dose of the drug delivered to the lungs were significantly greater from the MDI 
than from the nebuiliser for both ventilated and non-ventilated infants. These 
differences however may not be of great clinical importance in paractice since 
for either method, it would be possible to increase the delivered dose readily by 
either an addrtional number of puffs from the MDI, or by increasing drug dose 
with the jet nebuliser. Another strategy to increase deposition from the nebuliser 
is to increase the time of nebulisation, although it has been shown that 
approximately 80% of the nebuliser solution is aerosoiised within the first 5-8 
minutes, and continuing aerosoiisation beyond this time may not increase lung 
107 
deposition significantly 123 
The therapeutic effects of an aerosolised medication may be governed 
not only by the total amount deposited but also by its distribution in the lungs. 
In this study, aerosol delivered by both devices, especially the nebuUser, was 
deposited mainly in the central lung region of the animals with relatively little 
deposition in the periphery. This is in contrast to the findings in the animal 
experiments (Chapter 5) and is likely related to the presence of pathological 
conditions in infants' lungs.^ ^^ As the small airways are the principal sites for 
medications such as beta-agonists, failure to reach the peripheral lung region 
may limit their therapeutic effects. 
An important finding of this study is the marked inter-subject variabllty in 
pulmonary deposition among both ventilated and non-ventilated infants. Similar 
observations have also been made by other workers on older infants and 
toddlers with obstructive airway d i s e a s e s . T h e variability is perhaps not 
surprising as aerosol delivery is affected by a number of factors including 
severity of the lung dsisease, ventilator s e t t i n g s , e s p e c i a l l y the peak 
inspiratory pressure and inspiratory in ventilated infants, and in non-
ventilated infants, the respiratory status, especially the tidal volume and minute 
ventilation. All these factors vary from subject to subject. Another possible 
explanation for the variable lung deposition is the different body weight of the 
infants. When the non-ventilated Infants are divided into two subgroups 
according to their weight using different cut-off levels, there was a significant 
difference In MDI (but not nebuliser) deposition between infants weighing 
<2500g and those >2500g (mean±sem: 0.43±0.04^jg vs 0.85±0.17pg; p = 
0.0068). Among the ventilated infants, similar analysis also showed a significant 
difference in the nebuliser (but not MDI) deposition between infants weighing 
below and above 1000g (0.23±0.02pg vs 0.96±0.46Mg； p = 0.041). It is however 
difficult to draw a definite conclusion from these observations because of the 
small sample size especially in the heavier subgroups (non-ventilated: n= 4; 
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ventilated: n = 3). Further studies are required to inventigate the relationship 
between body weight and lung deposition of aerosols. 
Irrespective of the reasons for the great variability in pulmonary 
deposition, the above findings suggest that a uniform dose of aerosollsed 
medications may not be applicable to all infants and dosing regimes may need 
to be individualised by titrating against clinical effects. 
Limitations of the present study: 
Like the animal studies (Chapter 5), the findings of the present study are 
specific to the delivery devices used in the experiments (MDI plus Aerochamber 
and Sidestream jet nebuliser) and may not necessarily be extrapolated to 
different types of devices. Furthermore, rapid absorption of the radiolabel from 
the lungs might result in underestimation of lung deposition. The 99mTc-HSA 
used in the jet nebuliser is a virtually non-absorbable tracer (half-life = 6 hours), 
but the MDI could technically only be labelled with Technetium pertechnetate 
which has a biological half-life of approximately 15 minutes in the normal lung. 
Systemic absorption of 99mTc04 from the lungs could have taken place during 
the 10-minute acquisition, resulting in increased tissue background and 
decreased radioactivity in the lung fields. This was however not obvious from 
the images, and uptake of radioactivity by the kidneys were not evident on the 
scans. 
8.10 Conclusions 
This study confirms that in both ventilated and non-ventilated infants with 
BPD, pulmonary deposition of salbutamol aerosol delivered by both MDI and jet 
nebuliser is small and varies from patient to patient. With both devices, only a 
small proportion of aerosol generated was available to the infants, the rest being 
either retained in the delivery system (MDI spacer) or lost to the ventilator circuit 
(nebuliser). Compared to healthy rabbit lungs, the distribution of aerosol in the 
lungs of BPD infants was less homogeneous with a significantly greater 
proportion being deposited at the central airway. This finding reiterates the 
limitations of animal studies discussed in Chapter 4. The study does not provide 
any data correlating lung deposition and the therapeutic effects of the aerosol. 
Since the ultrasonic nebuliser was not evaluated, it is not clear whether its high 
delivery efficiency shown on animals with healthy lungs is also present in infants 
with BPD. These issues will be addressed In the randomised controlled trial 
described in Chapter 9. 
Section 2: Part 3 Original studies: infants with BPD 
9.1 Introduction 
The animal study described in Chapter 5 demonstrated the superiority of 
the ultrasonic nebuliser used together with a small medication cup over the MDI 
and jet nebuliser in the delivery of aerosol to ventilated rabbits. The infant study 
(Chapter 8) showed that although there was marked individual variability. MDI 
plus a spacer device might be able to deliver more aerosol to the lungs of both 
ventilated and non-ventilated infants than the jet nebuliser None of the above 
studies however had assessed the therapeutic effect of the aerosol. Clinical or 
physiological data directly comparing the three devices are also not available In 
medical literature. In this randomised cross-over study, infants with established 
or early BPD were given a uniform dose of aerosoiised salbutamol by each of 
the devices in random sequence. The therapeutic effects of the aerosol was 
assessed clinically and also by measuring the pulmonary mechanics 
(compliance, airway resistance) and functional residual capacity of the infants 
before and after aerosol administration. 
As there are a number of models of jet nebulisers available in the market, 
two different makes of jet nebuliser were evaluated on on both the ventilated and 
non-ventilated infants in order to improve the generalisability of the findings. 
Characterization of aerosol particles had been carried out in the previous 
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experiments (ultrasonic nebuliser and Hudson jet nebulise: animal study in 
Chapter 5; MDI plus Aerochamber and Sidestream nebuliser: infant study in 
Chapter 8) and was not repeated in this study. 
9.2 Enrolment of infants 
The study was approved by the Ethics Committee of the Chinese 
University of Hong Kong. Preterm infants diagnosed consecutively in the 
Neonatal Unit. Prince of Wales Hospital to have BPD or to be at risk of 
developing BPD were enrolled if they satisfied the following enrolment criteria: 
[1] gestation < 32 weeks; 
[2] birth weight < 1.5 kg; 
[3] postnatal age > 2 weeks; 
[4] requiring mechanical ventilation for the treatment of respiratory distress 
syndrome for at least 3 days during the first weeks of life; 
[5] ventilator and/or oxygen dependent at time of enrolment; 
[6] chest radiograph consistent with changes of BPD; 
[7] ventilation and oxygen requirements being stable for at least 24 hours; 
and 
[8] parental consent. 
Infants with anatomical abnormalities of the airway were excluded. 
9.3 Study design 
This was a double-blind, randomised cross-over study. At 4-hour 
intervals and in random order, each infant was given one dose (200pg per dose 
irrespective of body weight) of saibutamoi aerosol each from the MDI plus an 
aerosol holding chamber, a jet nebuliser (Sidestream nebuliser, MedicAid, UK; 
or Hudson nebuliser, USA), and an ultrasonic nebuliser incorporated with a small 
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medication cup (Siemens Electronics Inc., Sweden). Randomisation was carried 
out using computer generated random numbers. The aerosol was delivered by 
one of my colleagues not involved in the clinical management of the infants. 
Another colleague, who was not present during aerosol delivery, was responsible 
for lung function measurement. The clinical team was also blinded to the 
randomisation. Throughout the experiment, the FiOj and ventilator settings (for 
ventilated infants) were kept unchanged. 
9.4 Delivery system 
9.4.1. Non-ventilated infants 
Study #1: Aerosol from both the MDI and the nebulisers were delivered 
through a face mask placed tightly over the Infant's face covering the nose 
and the mouth. Two MDI puffs (lOOpg per puff) of salbutamo丨 aerosol 
(Ventolin*. Glaxo, UK) was actuated 1 minute apart at end-expiration into a 
neonatal Aerochamber connected to the face mask. The Aerochamber used 
in this study had been modified from that used previously (Chapter 8) by 
removing the one-way valve and its wheel-spoke like supporting structure. 
The reason for this modification would be given under "Discussion". The 
face mask of the spacer was also replaced with a Laerdal Resuscitation 
Mask (Laerdal, Stavanger, Norway) which has a smaller dead space and fits 
more tightly to the infant's face. The MD! canister was shaken vigorously for 
at least 10 sec. before each actuation. The infant was allowed to breathe 
into the Aerochamber for 1 min. before the system was removed. 
Aerosol delivery by both the jet (Sidestream nebuliser, MedicAid. UK) 
and ultrasonic nebuliser (Siemens Electronics Inc., Sweden) were similar to 
that described in Chapter 8. The nebuliser was connected to a Laerdal face 
mask through a T-connector so that excess gas flow and aerosol could 
escape through the efferent limb of the connector. The jet nebuliser 
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operated at a flow rate of 6L/min. No additional gas flow was required when 
the ultrasonic nebuliser was being used. For each nebulisation, 200pg 
salbutamol respirator solution (Ventolin®, Glaxo, UK) diluted to 4 ml with 
isotonic saline was added to the standard nebuliser reservoir of the jet 
nebuliser, or the small 10-ml medication cup of the ultrasonic nebuliser. 
Nebulisation was continued until no more aerosol was visibly generated by 
the nebuliser (till "dry"). 
Study #2: Study #2 was identical to Study #1 except that a different make 
of jet nebuliser (Hudson, USA) was used instead of the Sidestream nebulise 厂 
9.4.2. Ventilated infants 
Study #1: The connection of the delivery devices to the ventilator circuit 
was similar to the animal study in Chapter 5. A MV15s Aerochamber was 
inserted between the Y-connector of the ventilator circuit and endotracheal 
tube immediately before aerosol delivery. The MV15s Aerochamber used in 
this study was a new device from the manufacturer (Trudell, Canada). It is 
identical to the MV15 Aerochamber used in the previous animal (Chapter 5 
and 6) and infant (Chapter 8) deposition studies except that it does not have 
a non-rebreathing valve at Its outlet. Two puffs of salbutamol MDI was 
actuated into the spacer 1 minute apart immediately at the end of the 
expiratory phase of the ventilator-generated breaths. The spacer was 
removed 1 minute after the second puff. 
The Sidestream jet nebuliser and the Siemens ultrasonic nebuliser 
were connected to the inspiratory tubings of the ventilator circuit 20 cm away 
from the endotracheal tube. Aerosol was generated in the same way and 
with the same dose of salbutamol and volume fill as for the non-ventilated 
infants. During jet nebulisation, the ventilator flow rate was decreased 
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accordingly so that the total flow rate through the ventilator tubings and the 
ventilator pressures remained unchanged. No adjustment of ventilator flow 
was required for the ultrasonic nebuliser which did not Involve any additional 
flow. At each delivery, nebullsation was continued till the reservoir became 
"dry". 
Study #2; Infants in study #2 were given the salbutamol aerosol in an 
identical manner as those in study 右 1 except that the Sidestream jet 
nebuliser was replaced by the Hudson jet nebuliser. 
9.5 Outcome 
9.5.1 Clinical parameters 
The infants were monitored for their heart rate, respiratory rate (for 
ventilated Infants, only spontaneous respirations were counted), transcutaneous 
oxygen saturation (SaO:), transcutaneous POj (tcPCy and PCO2 (tcPCOj) 
immediately before and for at least one hour after completion of aerosol delivery. 
Their values were recorded every minute except during lung function 
measurement. The areas under the curves plotting these values against time 
allowed comparison of the changes in each parameter following aerosol delivery 
by the three devices. 
9.5.2 Pulmonary function 
In both ventilated and non-ventilated infants, static respiratory system 
compliance (Crs) and resistance (Rrs) were measured with the SensorMedics 
Pulmonary Cart (SensorMedics Inc., Yorba Linda, CA, USA) immediately before, 
and at 15min., 30min., 1 hour, and 2 hours after completion of aerosol 
administration. The non-ventilated infants also had their functional residual 
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capacity (FRC) estimated using the same equipment immediately before 
measurement of lung mechanics. All the measurements were carried out during 
quiet breathings. According to our protocol, agitated and irritable infants would 
be sedated with chloral hydrate (60mg/kg) given through naso-gastric tube (it 
turned out that none of the infants required any sedation). Crs and Rrs were 
measured using the passive flow-volume technique^^® which involves the 
occlusion of the airway at end-inspiration to relax the respiratory muscles by 
evoking the Hering Breuer reflex. Release of the occlusion is followed by a 
passive exhalation required for the measurement of flow. For ventilated Infants, 
the measurement was carried out with a pneumotachograph (Hans Rudolph Inc., 
USA) (dead space 1.8ml) connected to the endotracheal tube. For non-ventilated 
infants, the pneumotachograph was connected to a Laerdal face mask covering 
the nose and mouth. The face mask was held tightly over the infant's face to 
minimise the dead space. The pneumotachograph was incorporated with a built-
in pneumatically driven sliding valve used for airway occlusion, and a side port 
which was connected to a pressure transducer for the measurement of airway 
pressure. Flow signals were integrated to volume with a microcomputer. The 
flow-voiume relationship allowed the determination of the total passive expiratory 
volume (VE) at zero flow; and also the flow at zero volume (Vo) appropriate for 
the occlusion pressure (Pa。). Crs and Rrs were calculated by the computer as 
follows: 
C r s = VE / Pao； 
Rrs = Pao / Vo 
A breath was accepted for analysis only when the occlusion pressure 
reached a stable plateau. In each measurement, Crs and Rrs were obtained 
from the mean values of at least 10 acceptable breaths with a coefficient of 
variation of less than 10%. 
FRC was measured in the non-ventilated infants using the nitrogen (Nj) 
washout technique. 1 游 In this technique, exhaled breaths through the face mask 
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is washed to a mixing chamber by a constant flow of 100% oxygen. The 
concentration of Nj leaving the mixing chamber is analysed continuously with a 
N2 analyser and displayed graphically as well as numerically on the computer 
screen. Washout is complete when N2 concentration fails to zero percent after 
the initial rise. From the total volume of N2 washed out (Vn》（-integral of flow 
rate x Nj concentration), the fraction of alveolar Nj before (FANj J and after 
(FAN2.p) washout, FRC is calculated by the computer from the following relations: 
Amount of Njin lung before washout (N jJ = FANja x FRC [1] 
Amount of Nj in lung after washout (N2.y)= FANj p x FRC [2] 
[1] - [2] gives: (N2.X - Nay〉= FRC(FAN2.3 - FAN^p); 
Since (N2,- Nj,) = VN, 
Hence FRC = Vn斯ANja - FAN:。） 
9.6 RESULTS 
9.6.1 Non-ventilated infants: 
Demography 
Ten infants were enrolled in each of Study #1 (7 males and 3 females) 
and Study #2 (6 males and 4 females). Their demographic characteristics are 
given in Table 9.1. 
With both jet nebulisers. the nebulisation time required for the reservoir 
to become "dry" was approximately 15 minutes. Nebulisation time of the 
ultrasonic nebuliser was slightly shorter, being approximately 13 minutes. 
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The baseline heart rate, respiratory rate, SaO�，tcPOj and tcPCOj of the 
infants immediately before treatment were shown in Table 9.2. Following 
aerosol delivery by ail the devices, significant tachycardia was observed in all 
infants. Maximum heart rate within the first 60 minutes after treatment ranged 
from 185 to 210 per minute. In contrast, no marked change in respiratory rate. 
SaOs, tcPOj or tcPCOs was observed from any single readings throughout the 
period of monitoring. The values of the above physiological parameters within 
the first 60 minutes after aerosol treatment were plotted against time. By 
comparing the areas under the curves (Table 9.3), it could be shown that in both 
8 
studies, significantly higher heart rate was associated with the use of MDI and 
ultrasonic nebuliser than with the jet nebullser. In contrast, there was no 
significant difference in respiratory rate or SaOg following aerosol delivery by any 
of the devices. In both studies, the ultrasonic nebuliser was apparently 
associated with the highest toPO: and lower tcPCOj, while the jet nebuliser had 
produced the opposite effect. As shown by multiple paitwise comparison, there 
were significant differences in both parameters following the use of the two 
devices. The differences between the ultrasonic nebuliser and MDI were less 
obvious, being statistically significant only in tcPOj in Study #1. When the MDI 
and jet nebuliser were compared, the former was associated with significantly 
higher tcPCOj in Study #2. 
Table 9.2: Heart rate, respiratory rate, SaOj, tcPOj and tcPCOz immediately before 
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One way repeated measures ANOVA 
Study #1: 
*p = 0.412 
•p = 0.296 
•p = 0.22 
•p = 0.702 
"p = 0.669 
Study #2: 
5p = 0.406 
卞=0.561 
^ = 0.293 
•p = 0.739 















2 (Jet Neb) 
3 (US Neb) 
Heart rate, respiratory rate, SaOj, tcPOj and tcPCOz within the first 60 
minutes after delivery of salbutamol aerosol, expressed as areas below 
the curves plotting the values of each parameter against time (minute): 
non-ventilated infants. Values are given in means (sem) except for 
tcP02 and tcPC02 which are given in medians. 
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One way repeated measures AN OVA or Friedman repeated measures ANOVA on ranks (significant 
difference by ANOVA was followed by Multiple pairwtse comparison by Student-Newman-Keul Method): 
Study #1： 
•p<0.0001 (MDI and US Neb > Jet Neb. p<0.05) 
'p = 0.52 
•p = 0.906 
•p 二 0.0136 (US Neb > MDI and Jet Neb. p<0.05) 
。p = 0.0033 (Us Neb > Jet Neb. p<0.05) 
$tudY#2: 
*p<Q.0001 (MDI and US Neb > Jet Neb, p<0.05) 
Tp = 0.0744 
节=0.625 
•p = 0.0082 (Us Neb > Jet Neb. p<0.05) 
> =0.007 (MDI and US Neb > Jet Neb, p<0.05) 




(i) Respiratory system compliance (Crs): Crs immediately before, and at 
the various time points after aerosol delivery by the three devices were tabulated 
in Table 9.4 and presented graphically in Figure 9.1. In both studies, and with 
all delivery devices, there was no significant difference in Crs measured at the 
four time points. In Study #1, both MDI and ultrasonic nebuliser groups showed 
an increasing trend in Crs for 30 minutes after treatment. This trend was 
however not observed in Study #2. 
Table 9.4: Respiratory system compliance IT leasured before and after salb •utamol 
aerosol: non-ventilated infants 
Respiratory system compliance (mi/cmH20/kg): mean (sem) 
Group Before 15min 30min 60min 120min 
Study m : 
1 (MDI) 1.71(0.17) 1.8(0.20) 1.85(0.18) 2.13(0.19) 191(02^  
2 (Jet Neb) 1.98(0.23) 1.53(0.21) 1.68(0.30) 1.73(0.18) 
3 (US Neb) 1.58(0.20) 1.67(0.21) 1.97(0.30) 1.80(0.20) 1.72fl17) 
Study #2: 
1 (MDI) 1.54(0.16) 1.71(0.18) 1.53(0.21) 1.50(0.23) 1 却 ; N 
2 (Jet Neb) 1.49(0.14) 1.54(0.27) 1.47(0.18) 1.62(0.18) 1.郷 17) 
3 (US Neb) 1.46(0.18) 1.46(0.18) 1.55(0.26) 1.69(0.21) 1.7DPI18) 
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B. Study #2 
0 60 1 20 0 60 120 0 60 ^20 
Duration after aerosol treatment (min) 
MDI —— Jet US 
Figure 9.1: Respiratory system compliance before and after salbutamol aerosol: non-ventilated 
infants: mean (sem) 
A. Study #1 
0 60 120 0 60 120 0 60 
Duration after aerosol treatment (min.) 
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(il) Respiratory system resistance (Rrs): Table 9.5 and Figure 9.2 show 
the Rrs at the 4 time points in relation to aerosol delivery. In both studies, and 
with all 3 devices, there was a significant drop in Rrs within 15 minutes after 
inhalation of salbutamoi aerosol. Maximum decline in Rrs was observed at the 
30-minute measurement, after which Rrs gradually returned to the baseline 
values. At 120 minutes. Rrs was significantly lower than the pre-treatment 
values only after aerosol delivery by the ultrasonic nebuliser. 





2 (Jet neb) 
3 (US neb) 
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1 (MDI) 
2 (Jet neb) 
3 (US neb) 
Before 




































One way repeated measures ANOVA (significant difference by ANOVA was followed by multiple pairwise 
comparison by Student-Newman-Keul Method): 
Study #1: 
• p < 0.0001 (30min<15min<60mm<120mln & before treatment: p<0.05) 
‘ P < 0.0001 (30min<15 min & 60mln<120min & before treatment: p<0.05) 
• p = < 0.0001 (30min<15 & 60mm<120min<before treatment: p<0.05) 
Study #2: 
* p < 0.0001 (30min<15min & 60min<120min & before treatment: p<0.05) 
T p < 0.0001 (30min<15min & 60min<120min & before treatment: p<0.05) 
• p < 0.0001 (30min<15mln & 60min<120min < before treatment: p<0.05) 
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Duration after aerosol treatment (mm) 
MOl Jet US 
B. Study #2 
0.00 
Duration after aerosol treatment (mm.) 
MDI Jet -0- US 
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Figure 9.2: Respiratory system resistance before and after salbutamol aerosol: non-ventilated 
infants: mean (sem) 
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Table 9.6 and Figure 9.3 show the post-treatment decrease in Rrs expressed 
as a percentage of the baseline Rrs. In Study #1，decrease in Rrs was significantly 
greater following MDI and ultrasonic delivery at 15 and 30 minutes than that following 
jet nebulisation. At 60 minutes, the ultrasonic nebuliser continued to perform best 
while the difference between the MDI and jet nebuliser did not reach statistical 
significance. At 120 minutes, no significant difference could be demonstrated among 
the three devices. 
In study #2，the use of both the MDI and ultrasonic nebuliser was associated 
with significantly greater decrease in Rrs when compared to the jet nebuliser 
throughout the entire study period. 
Table 9.6: 
Group 
Study m : 
1 (MDI) 
2 (Jet neb) 
3 (US neb) 
Study #2: 
1 (MDI) 
2 (Jet neb) 
3 (US neb) 
Percentage decrease in respiratory system resistance after delivery of 
saibutamot aerosol: non-ventilated infants 






























One way repeated measures ANOVA (sign币cant difference by ANOVA was followed by multiple pairwise 
comparison by Student-Newman-Keu丨 Method): 
SiydyJl： 
• p : 0.00025 (MDI & US > jet: p<0.05) 
‘ p : 0.0002 (MDf & US > jet: p<0.05) 
• p = 0.007 (US > jet: p<0.05) 
"p = 0.06 
gtgdY#2: 
»p = 0.0006 (MDI & US 
T p < 0.0001 (US > MDI 
^ p < 0.0001 (US & MDI 
‘ p = 0.0001 (US & MDI: 
•jet: p<0.05) 
‘jet: p < 0.05) 
‘jet: p < 0.05) 
.jet: p < 0.05) 
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Duration after aerosol treatment (min.) 
B. Study #2 
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H 
Duration after aerosol treatment (min.) . ^  
Figure 9.3: Percentage decrease in respiratory system resistance after salbutamol aerosol: non-
ventilated infants: mean (sem) 
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(iii) Functional residual capacity (FRC): FRC before and after aerosol 
treatment is given in Table 9.7 and Figure 9.4. In both studies, aerosol delivery with 
the MDI and ultrasonic nebuliser resulted in a significant albeit small increase in FRC. 
Peak values were observed at 30 minutes, after which FRC gradually returned to the 
baseline values. In contrast, FRC after jet nebulisation remained unchanged 
throughout the study period. 
Functional residual capacity before and after salbutamol 
ventilated infants 




2 (Jet neb) 
3 (US neb) 
Study #2; 
1 (MDI) 
2 (Jet neb) 




































One way repeated measures ANOVA (significant difference by AN OVA was followed by multiple pairwise 
comparison by Student-Newman-Keul Method): 
Stiidv#1: 
* P < 0.0001 (30min & 60min > before treatment & 120min: p<0.05) 
‘ p : 0.75 
' p = < 0.0001 (30mln > 60min & 120min > before treatment: p<0.05) 
SMY#2： 
*p < 0.0001 (30min & 60min >15min.&120min > before treatment: p<0.05) 
T p = 0.62 
- p < 0.0001 (15min. 30min & 60min >120min > before treatment: p<0.05) 
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B. Study #2 
22 
Figure 9.4: Functional residual capacity 
infants: mean (sem) 
A. Study #1 
after salbutamol aerosol: non-ventilated 
) 60 120 0 60 120 0 80 
Duration after aerosol treatment (min.) 
- • - MOI — J e t US 
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Improvement in FRC after aerosol treatment, expressed as percentage of 
baseline FRC (Table 9.8 and Figure 9.5), was significantly greater at 30 minutes 
following ultrasonic nebulisatlon than after jet nebulisation in Study #1. In Study #2， 
both MDI and ultrasonic nebuliser brought about significantly greater Improvement in 
FRC than the jet nebuliser at both 15 minutes and 30 minutes after aerosol delivery. 
In this experiment, the greatest improvement in FRC was observed in the MDI group. 
Percentage increase in functional residual capacity after delivery of 
salbutamol aerosol: non-ventilated infants 
Grpup 
1 (MDI) 
2 (Jet neb) 
3 (US neb) 
Study #2: 
1 (MDI) 
2 (Jet neb) 
3 (US neb) 



























0.61 (1.86) ‘ 
3.11(1.15)' 
One way repeated measures ANOVA (significant difference by ANOVA was followed by multiple pairwise 
comparison by Student-Newman-Keul Method) 
？tudY#1: 
• p = 0.043 (US > jet: p<0.05) 
‘ p = 0.0054 (US > jet: p<0.05) 
• p : 0.391 
"p = 0.095 
siudicsa： 
«p - 0.0018 (MDI & US > jet: p < 0.05) 
T p = 0.0001 (MDI > US > jet: p < 0.05) 
* p = 0.0039 (MDI > jet: p < 0.05) 
• p = 0.20 
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Figure 9.5: Percentage increase in functional residual capacity after saibutamol aerosol: non-
ventilated infants: mean (sem) 
A. Study #1 
B. Study #2 
15 30 60 120 
Duration after aerosol treatment (mm.) 
15 30 60 120 
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9.6.2 Ventilated infants 
Demography 
A total of 20 infants were enrolled, 10 for each of study #1 (6 males. 4 
females) and study #2 (8 males. 2 females) . Their demographic 
characteristics are given in Table 9.9. The nebulisation time of the nebuiisers 
was similar to that for the non-ventilated infants (jet: 15 minutes, ultrasonic: 13 
minutes) 
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Postnatal age (days) 
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Postnatal age (days) 













Table 9.10 shows the baseline heart rate, spontaneous respiratory rate, 
SaOj, tcP02 and tcPCOj. Similar to the non-ventilated infants, all infants in this 
group developed significant tachycardia following salbutamol treatment delivered 
by all three devices. Maximum heart rate reached 200 per minute. Table 9.11 
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gives the areas under the curves plotting the above parameters against time. 
Compared to the jet nebuliser, the use of the ultrasonic nebuliser and the MDI 
was associated with a faster heart rate in both studies and also a higher tcPOj 
in study #1. In study #2, while there was no statistically significant difference in 
tcPOj among the three devices, a significantly lower tcPCOj was observed after 
the use of the ultrasonic nebuliser than that following the use of the jet nebuliser. 
In both studies, the three types of delivery devices were not associated with any 





2 (Jet Neb) 
3 (US Neb) 
Heart rate, spontaneous respiratory rate, SaOj, tcPOj and tcPCO: 
immediately before salbutamol treatment: ventilated infants: mean(sem) 
Heart rate Respiratory rate 
























2 (Jet Neb) 
















One way repeated measures ANOVA 
Study #1 
Tp = 0.811 
:p = 0.655 
•p = 0.886 
"p = 0.887 
？ 
•p = 0.689 
'p = 0.497 








2 (Jet Neb) 
3 (US Neb) 
Heart rate, spontaneous respiratory rate, SaO，’ tcPOj and tcPCOj within 
the first 60 minutes after delivery of saibutamol aerosol (expressed as 
areas below the curves plotting the values of each parameter against 




Area under the curves; mean (sem) 
















2 (Jet Neb) 
















One way repeated measures ANOVA (significant difference by ANOVA was followed by multiple 
pairwise comparison by Student-Newman-Keu丨 Method): 
Study #1: 
»p 二 0.0054 (MDI and US Neb > Jet Neb. p<0.05) 
Tp =0.414 
•p = 0.619 
•p = 0.00043 (US Neb > MDI > Jet Neb, p<0.05) 
"p = 0.567 
US Neb > Jet Neb. p<0.05) 
Study #2: 
•p = 0.002 (MDI 
'p = 0.395 
•p = 0.350 
•p -0.193 
Op = 0.021 (US Neb > Jet Neb. p<0.05) 
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Pulmonary mechanics 
(i) Respiratory system compliance: In study #1, similar to the non-
ventilated infants, there was no significant change in Crs after aerosol 
treatment administered by any of the three delivery devices. In study #2，a 
significant increase in Crs was observed 30 min. and 60 min. after aerosol 
delivery by the ultrasonic nebuliser. The use of the MDI or jet nebuliser was 
not associated with any significant change in Crs within the first two hours of 





2 (Jet Neb) 
3 (US Neb) 
Respiratory system compliance before and after saibutamol aerosol: 
ventilated infants 
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One way repeated measures AN OVA (significant difference by ANOVA was followed by multiple 
pairwise comparison by Student-Newman-Keul Method): 
SiydxEL 
*p = 0.199 
•p = 0.527 
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Figure 9.6: Respiratory system compliance before and after salbutamol 
aerosol: ventilated infants: mean (sem) 
A. Study #1 
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(ii) Respiratory system resistance: In both studies, and with all 3 types of 
delivery devices, administration ofsalbutamol aerosol was followed by significant 
decrease in Rrs (Table 9.13 and Figure 9.7). The lowest Rrs was observed at 
30 minutes, after which it gradually returned to the baseline values. 
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3 (US Neb) 
Study #2; 
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Respiratory system resistance (cmHjO/ml/sec): 



























One way repeated measures ANOVA (significant difference by ANOVA was followed by 巾ultipte pairwise 
comparison by Student-Newman-Keul Method): 
Siudy #1: 
• p < 0.0001 (30min<15min<60mjn<120mm & before treatment: p<0.05) 
‘ p <0.0001 (30rnin<60min<120min & before treatment and 15min.<120min.<before treatment: p0.05) 
‘ p < 0.0001 (30min<15 & 60min<120min<before treatment: p<0.05) 
Study #2 
< 0.0001 (30min<15min $ 60min<120min < before treatment: p<0‘05) 
Tp < 0.0001 (30min<15 & 60min<120min and before treatment: p<0.05) 
^ < 0.0001 (30min<15 & 60min<120min and before treatment: p<0,05) 
6 3 n 
0 0 ； 
0 60 120 0 60 120 0 60 1 
Duration after aerosol treatment (min) 
MDt - a - Jet US 
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Figure 9.7: Respiratory system resistance before and after saibutamoi aerosol: ventilated 
infants: mean (sem) 
A. Study #1 
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The percentage drop in Rrs from the pre-treatment values were presented 
In Table 9.14 and Figure 9.8. In both studies, the greatest drop in Rrs following 
the use of all three types of delivery devices was observed 30 minutes after 
treatment and ranged from 17 to 56%. Throughout the entire study period, the 
greatest decrease in Rrs was observed following aerosol delivery by the 
ultrasonic nebuliser. The use of the jet nebulisers was in contrast associated 





2 (Jet neb) 
3 (US neb) 
Study #2; 
1 (MDI) 
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Percentage decrease in respiratory system resistance after delivery 
of salbutamo丨 aerosol: ventilated in^nts 






























One way repeated measures ANOVA (significant difference by ANOVA was followed by multiple 
pairwise comparison by Student-Newman-Keul Method): 
Study #1: 
• p = 0.0001 (US > MDI > Jet: p<0.05) 
‘ p < 0.0001 (US > MDI > Jet: p<0.05) 
• p = 0.0007 (US & MDI > Jet: p<0.05) 
" p = 0.103 
Study #2: 
«p = 0.0001 (US & MDI > Jet. p<0.05) 
T p < 0.0001 (US > MDI > Jet: p<0.05) 
: p < 0.0001 (US > MDI > Jet: p<0.05) 
‘ p < 0.0001 (US > MDI > Jet: p<0.05) 
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Figure 9.8: Percentage decrease in respiratory system resistance after salbutamol 
aerosol: ventilated infants: mean (sem) 
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9.7 Discussion 
In Chapters 3 and 4, the therapeutic effects of bronchodilators on infants 
with BPD were discussed . The findings of this study provide further evidence 
that salbutamol aerosol delivered by the MDI, jet nebuliser, or ultrasonic 
nebuliser can relieve airway obstruction in very young infants with established 
or early BPD. A maximum decrease in Rrs of up to 56% of the baseline value 
was recorded in both non-ventilated and ventilated infants. Since 40% of total 
airway resistance originates from the upper airway or endotracheal tube which 
does not respond to bronchodilators,祐 the actual improvement in lower 
respiratory tract resistance should be substantially greater than that observed. 
With the three types of delivery devices, maximum improvement in Rrs 
was documented 30 minutes after completion of aerosol delivery. Subsequently 
Rrs gradually increased, and by 2 hours, Rrs had returned to almost the baseline 
values in most infants. Thus the duration of action of inhaled salbutamol was 
around 2 hours in this population of infants. This is shorter than that observed 
by Denjean et al who performed serial lung function measurement on 7 infants 
with BPD after 200pg of salbutamol aerosol, and reported a duration of drug 
action of 3 hours.® 
Unlike Rrs, improvement in respiratory system compliance was observed 
only in some of the ventilated infants (study #2) following treatment with 
salbutamol delivered by the ultrasonic nebuliser, and none of the non-ventilated 
ones. Previous workers had also observed inconsistent response of Crs to 
bronchodilators. Improvement in Crs following relief of bronchial constriction is 
likely caused by recruitment of the atelectatic alveoli. Most of the infants in this 
study had only mild BPD requiring only minimal oxygen supplementation. It is 
possible that they did not have extensive lung atelectasis secondary to airway 
obstruction and therefore did not show any significant improvement in Crs after 
bronchodilator. 
In contrast, there was significant, albeit small improvement In functional 
residual capacity among the non-ventilated infants following aerosol treatment 
by the MDl or ultrasonic nebuliser. In infants with BPD, some lung 
compartments may fail to equilibrate with the inspired gas due to airway 
obstruction. In these infants, FRC may be underestimated by the nitrogen 
washout t e c h n i q u e - T h u s increase in FRC after bronchodilator treatment 
provides indirect evidence on the therapeutic effect of the medication. The 
degree of improvement should be directly related to the drug effect as well as 
the severity of pre-existing air trapping. The FRC in infants in Study #2 did not 
improve as much as that in Study #1，possibly because they had milder lung 
disease, being relatively older, heavier, and with lower oxygen requirement. The 
lack of effect of aerosol delivered by the jet nebulisers was likely related to the 
relatively low efficiency of the device. 
In Chapter 5, aerosol deposition from the MDI, the jet nebuliser, and the 
ultrasonic nebuliser was compared in ventilated rabbits. In this animal model, 
ultrasonic nebuliser, when used together with a small medication cup, was able 
to deposit the greatest amount of aerosol in the lungs. The present study 
provided clinical data that confirmed the superiority of the ultrasonic nebuliser 
not only in the ventilated infants, but also those who were breathing 
spontaneously without assisted ventilation. In both groups, the use of the 
ultrasonic nebuliser was associated with the greatest pharmacological effects of 
salbutamol including tachycardia and reduction in airway resistance. This could 
only be explained by the deposition of a larger quantity of the drug in the lungs 
by the device. In accordance with the lung function changes, the ultrasonic 
nebuliser was also associated with significantly greater though variable increase 
in tcPOz (but not SaOJ and reduction in tcPCOj in both the non-ventilated and 
ventilated Infants. The lack of difference in SaO: was not unexpected since 
most of the SaOj readings are around 90 to 95%, and the pulse oximeter is not 
sensitive in detecting small changes in oxygenation at this high range of SaOj. 
In the deposition studies on ventilated animals as well as ventilated and 
non-ventilated infants (Chapter 8), pulmonary deposition of aerosol delivered by 
the MDI was relatively small, being only 0.2-0.7% in the ventilated subjects and 
0.98% in the non-ventilated ones. In this present study, reduction in Rrs 
following MDI-aerosol was higher than expected, being comparable to that 
produced by the ultrasonic nebuliser (ventilated: MDI: 44.3%, ultrasonic: 56.1%; 
non-ventilated: MDI: 49%, ultrasonic: 55.9%). The spacer devices used 
together with the MDI in this study had been modified from the ones used in the 
animal and Infant deposition studies. The valveless MV15s Aerochamber used 
on ventilated infants was a new product from the same manufacturer as the 
valved MV15 Aerochamber (Trudell Inc., London, Canada). Experiments 
performed on filter lung models by the manufacturer have shown that using the 
valveless device was associated with an increase in aerosol deposition by 18%. 
and it appeared that impaction of aerosol particles on the valve might reduce 
aerosol delivery (Martin Foley. Director of Marketing, Trudell Medical Group, 
London, Canada: persona丨 communication). This finding prompted 
reconsideration of the suitability of using valved spacers on the non-ventilated 
infants. I have tried to observe the valve movement of the neonatal 
Aerochamber through its open rear end while the device was being used on an 
infant Some of the smaller infants failed to produce any visible movement of the 
valve during quiet breathing, presumably as a result of insufficient tidal flow. 
Since valveless spacers such as coffee cup has been used successfully before 
for aerosol delivery to small infants/ I decided to modify the Aerochamber as 
above described. The result was encouraging, and led to formulation of the 
hypothesis that In using the MDI to administer therapeutic aerosol to small 
infants with BPD, drug delivery and therefore Its therapeutic effects are impaired 
by the presence of a one-way valve in the spacer device The next study 




The findings of this study showed that the MDI, the jet nebuliser, and the 
ultrasonic nebuliser could effectively deliver salbutamol aerosol to both ventilated 
and non-ventilated small BPD infants, resulting in significant reduction in airway 
resistance. The greatest improvement was observed following the use of the 
ultrasonic nebuliser and the small medication cup. Aerosol delivery by the MDI 
and modified spacer devices, though less effective than that by the ultrasonic 
nebuliser, was superior to the jet nebuliser. These observations provide some 
guidance to paediatricians in their choice of aerosol device for the management 
of BPD patients. 
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Section 2: Prat 3 Original studies: infants with BPD 
10.1 introduction 
Spacer devices currently recommended for use in non-ventilated small 
infants include the neonatal Aerochamber (Trudell Inc., Canada) and the 
Babyhaler (Glaxo, U.K.). The neonatal Aerochamber contains a light-weight 
non-rebreathing valve at its outlet and the Babyhaler contains two one-way 
valves separating the inspiratory and expiratory line. In order to test the 
hypothesis that the one-way valves impede aerosol delivery to small infants, the 
following randomised cross-over study was carried out on 20 infants with BPD 
who were given a standard dose of saibutamol by MDI through either the 
Aerochamber or Babyhaler with or without the valve. Aerosol deposition in the 
lower respiratory tract was estimated indirectly from the clinical response of the 
infants to the aerosol. 
10.2 Subjects and methods 
The study was approved by the Ethics Committee, the Chinese University 
of Hong Kong. Twenty non-ventilated but oxygen dependent infants were 
enrolled in the study. For the evaluation of the neonatal Aerochamber (group 1, 
n = 10), the enrolment criteria were similar to those listed out in Chapter 9. 
Infants enrolled for the evaluation of the Babyhaler (group 2, n = 10) had 
relatively greater gestation (up to 36 weeks) and birth weight (up to 2000g). 
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Some of them did not have established BPD, but all had been mechanically 
ventilated for the treatment of respiratory distress for at 丨east 3 days during the 
first week of life, and were oxygen dependent at the time of enrolment. Each 
infant in group 1 was given two doses of salbutamol aerosol (2 puffs per dose, 
100|jg per puff) by the MDI 4 hours apart. One dose was delivered through an 
unmodified neonatal Aerochamber wrth the non-rebreathing valve in place, and 
the other dose through the Aerochamber without the valve as described in 
Chapter 9. The two Aerochambers were used in random sequence determined 
by the computer. FRC, Crs and Rrs were measured immediately before, and at 
15 minutes, 30 minutes, 60 minutes, and 120 minutes after drug delivery, and 
the infants were continuously monitored for their heart rate, respiratory rate, 
tcPOj, and tcPCOj for at least one hour following treatment. Details of drug 
administration and measurement of lung functions were as described in Chapter 
9. My co-worker responsible for lung function measurement was blinded to the 
type of spacer used for aerosol administration. Infants in group 2 were studied 
in a similar manner except that the aerosol was delivered through the Babyhaler 
instead of the Aerochamber. At random sequence, one dose was delivered 
through the unmodified device, and the other dose through a Babyhaler from 
which the one-way inspiratory valve had been removed. 
Particle sizing in this study was carried out using a 12-stage Micro-Orifice 
Uniform Deposit Impactor operated at a flow rate of 30 Ipm. The cut-off 
diameters of the stages are 18. 9.9, 6.2, 3.1, 1.8, 1.0, 0.54, 0.32, 0.177, 0.097, 
0.052pm. The substrates used in the impactor were Teflon membrane filters 
with 2pm pores (Gelman Sciences, model R2PJ047, USA). A total of 50 doses 
of MDI-salbutamoI was actuated into each of the spacer devices, with and 
without the one way non-rebreathing valve. The aerosols available at the exit of 
the spacer devices were collected on a Teflon membrane after-filter (Gelman 
Sciences, model R2PJ037, USA) and measured by an analytical balance 
(Ohaus, Model AP250D, USA). All the filters were kept in desiccator for more 





The demographic characteristics of the study infants are given in Table 
10.1. 
Table 10.1 Demographic characteristics of the study 
infants 
Mean(sern) Range 
Group 1 (n=10: male: female = 1:1) 
Gestation (weeks) 
Birth weight (g) 
Postnatal age (days) 












Group 2 (n=10: male: female = 1.5:1) 
Gestation (weeks) 
Birth weight (g) 
Postnatal age (days) 














The particle size (MMAD) of the aerosol at exit of the neonatal 
Aerochamber was 1.75±0.06^jm (GSD 2.20土0.05) with the valve and 
2.03±0.05|jm (GSD 1.93±0.03) without the valve. The MMAD of the aerosol 
leaving the Babyhaler was 1.88±0.05Mm (GSD 1.90士0.03) with the valve and 
2.31±0.01^Jm (GSD 2.05±0.04) without the valve. 
Clinical parameters 
In both groups, the heart rate, respiratory rate. SaOj, tcPOs and tcPCOj 
of the infants were similar immediately before aerosol delivery using the modified 
and unmodified spacers (Table 10.2). Following salbutamol treatment, all 
infants developed significant tachycardia (maximum heart rate 190 to 200 per 
minute) irrespective of the device used. In group 1, the areas under the curves 
(Table 10.3) plotting heart rate against time shows that within the first hour after 
treatment, a significantly greater degree of tachycardia was associated with the 
use of the Aerochamber without the one-way valve. Using the modified spacer 
also resulted in significantly lower tcPCO^ In contrast, respiratory rate, SaOj 
and tcPOj were not affected by the type of spacer used. In group 2, more 
significant tachycardia was associated with the use of the non-valved Babyhaler. 
There were however no differences in the other parameters following aerosol 









Heart rate, respiratory rate, SaOj, tcPOj and tcPCOj immediately before 
salbutamoi treatment: mean(sem) 
Heart rate 





2-taiied paired t test: 
Group 1 
0.649 
Tp = 0.792 
= 0.281 
•p = 0.429 
Respiratory rate 






'p = 0.884 
•p = 0.818 
•p = 0.367 
Op = 0.241 


























Heart rate, respiratory rate, and transcutaneous oxygen saturation 
within the first 60 minutes after delivery of salbutamoi aerosol 
(expressed as areas below the curves plotting the values of each 
parameter against time (minute). 
Area under the curves: mean (sem) 
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2 •tailed paired t test or Wilcoxon Signed Rank test: 
Group 1 Group 2 
*p = 0.0284 = 0.002 
'p = 0.770 •p = 0.807 
Op = 0.947 ®p = 0.275 
'p = 0.456 Op = 0.450 












(i) Respiratory system compliance: Similar to those in the previous study 
(Chapter 9), none of the infants in either group showed any significant 
change in Crs following aerosol delivery by the unmodified or modified 









Respiratory system compliance before and after salbutamoi aerosol 










1.99(0.16)' 2.17(0.12), 2.04(0.09)' 2.11(0.18)' 212(0.16)' 
1.91(0.12)' 2.18(0.15)' 2.09(0.56)' 2.13(0.23)' 2CB(0.15)' 
One way repeated measures ANOVA; 
Group 1 Group 2 
°p = 0.09 'p = 0.74 
•p = 0.52 'p = 0.6€ 
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Figure 10.1: Respiratory system compliance before and after salbutamol aerosol: mean 
(sem) 
A.. Group 1 (Aerochamber) 
I ？if^ 
(ii) Respiratory system resistance: Following aerosol delivery, all infants in 
both groups showed a significant fall in Rrs. Maximum decrease was noticed 30 
minutes after delivery. By 120 minutes, however, only infants receiving the 
aerosol from the non-va!ved Aerochamber had Rrs significantly lower than the 
baseline value (Table 10.5 and Figure 10.2). 
The magnitude of decrease in Rrs, expressed as percentage of the 
baseline Rrs, is given in Table 10.6 and Figure 10.3. In both groups, the use 
of the non-valved device was associated with a significantly larger decrease in 
Rrs from 15 minutes through 60 minutes following aerosol treatment. At 120 








Respiratory system resistance before and afte saibutamol aerosol 


























One way repeated measures ANOVA (significant difference from ANOVA is followed by multiple 
pairwise comparison by Student-Newman-Keul Method) 
Group 1 
• p < 0.0001 {30min<15min & 60min<120min & before treatment: p<0.05) 
' p < 0.0001 (30min<15min & 60min<120min< before treatment: p<0.05) 
Qroup 2 
• p < 0.0001 (30min<15mln<60min<120min & before treatment: p<0.05) 
° p < 0.0001 (30min<15min & 60min<120min & before treatment: p<0.05) 
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B. Group 2 (Babyhaler) 
Figure 10.2: Respiratory system resistance before and after salbutamol aerosol: 
(sem) 
A. Group 1 (Aerochamber) 
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Table 10.6: Percentage decrease in respiratory system resistance after 





























Paired t test: 
Group 1 
• p = 0.087 
‘p < 0.0001 
‘ p = 0.0023 
“p = 0.0001 
GroMP 2 
•p = 0.0258 
®p < 0.0001 
，p = 0.0283 
•p = 0.0533 
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Figure 10.3: Percentage decrease in respiratory system resistance after salbutamol 
aerosol: mean (sem) 
A. Group 1 (Aerochamber) 
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(iif) Functional residual capacity: In both groups, administration of 
salbutamol aerosol through either the modified or unmodified spacer devices 
was followed by a small but statistically significant improvement in FRC. 
Similar to Rrs, the most significant improvement was observed at 30 minutes 
after aerosol delivery. (Table 10.7 and Figure 10.4). 
When the percentage increase in FRC following aerosol treatment 
was compared between the valved and non-valved spacers, the latter was 
associated with a larger Improvement throughout the study period in both 
groups, although statistically significant differences were observed only at 









Functional residual capacity before and after salbutamol aerosol 
Functional residual capacity (ml/kg)： mean (sem) 






















One way repeated measures ANOVA or Friedman repeated measures ANOVA on Ranks (significant 
difference from ANOVA is followed by multiple pairwise comparison by Student-Newman-Keul Method): 
Group 1 
* p = 0.0042 (SOmin > 15min. 60min. 120min & before treatment: p<0.05) 
' p = < 0.0001 (30min > 15min, 60mtn & 120min > before treatment: p<0.05) 
Group 2 
= 0.002 {30min & 60 min > 15mln. 120min & before treatment: p <0.05) 
®P < 0.0001 (30min>15min. 60min. & 120min > before treatment: p <0.05) 
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B. Group 2 (Babyhaler) 
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Figure 10.4: Functional residual capacity before and after salbutamol aerosoi: mean 
(sem) 
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Paired t test: 
Group 1 
= 0.179 
' p = 0.115 
• p = 0.10 
• p = 0.019 
Percentage increase in functional residual capacity after 
delivery of salbutamol aerosol 












“ p = 0.237 
• p = 0.035 
®p = 0.221 












Figure 10.5: Percentage increase in functional residual capacity after salbutamol 
aerosol: mean (sem) 
A. Group 1 (Aerochamber) 
Duration after aerosol trratment (min.) 
159 
15 30 60 
Duration after aerosol treatment (mm ； 
B. Group 2 (Babyhaler) 
^m wrthvaM 




 B S B a J U U I 
: 1 s 
10.4 Discussion 
This study provides indirect evidence that in using the MDI and Neonatal 
Aerochamber or Babyhaler on non-ventilated small infants, the efficiency of 
aerosol delivery can be increased by removing the non-rebreathing valve from 
the spacers. In all infants, salbutamol delivered through the non-valved devices 
resulted in more significant tachycardia, 50% (Aerochamber) to 100% 
(Babyhaler) more reduction in Rrs, and greater improvement in FRC than when 
the aerosol was delivered through the unmodified spacers. In the group 1 
infants, using the non-valved Aerochamber was also associated with lower 
tcPCOz These observations strongly suggest that removing the non-
rebreathing valve has resulted In the deposition of a larger dose of the drug in 
the Infants' lungs. 
Among the currently available spacer devices, both the neonatal 
Aerochamber and Babyhaler are recommended for use in non-ventilated infants 
and small children. The light-weight valve of the neonatal Aerochamber has 
been shown to allow substantia丨 aerosol deposition on spontaneously breathing 
filter lung models at a tidal volume as low as 25 ml严 and the device has been 
used successfully on wheezy infants and children 6 to 36 months of age.®^ The 
Babyhaler has also been evaluated on wheezy infants/。.明畑 and is 
recommended for use on infants older than 3 months of age. Neither device has 
however been evaluated on neonates or smaller infants with smaller tidal 
volumes. The findings of this study demonstrate for the first time that when the 
devices are used on preterm infants with BPD, their non-rebreathing valves 
impair rather than enhance the therapeutic effects of the aerosol. 
The one-way non-rebreathing valves of spacer devices are used to 
prevent dilution of the aerosol inside the aerosol holding chamber by the exhaled 
breaths of the subjects. They also function as filters, removing the large 
particles and preventing their deposition in the oropharynx and upper airway. 
For newborns and small preterm infants, however, these theoretical advantages 
may be offset by the failure of the infants to open the valves effectively since the 
incompletely opened valve may act as a baffle, resulting in substantial aerosol 
loss due to impaction. Furthermore, since the tidal volumes of small preterm 
infants such as those in this study (7-10 ml) are only 5 - 7% of the internal 
volume of the Aerochamber, or 2- 3% of that of the Babyhaler, it is unlikely that 
they can cause significant aerosol dilution by rebreathing into the spacers. We 
have also shown that although particle size was Increased after removal of the 
valves, the aerosol available to the infants from both the valved and non-va!ved 
devices contain fine particles with MMAD well within the respirable range of 1 to 
5|jm. It thus appears unlikely that removing the valves would result in increased 
aerosol impaction at the upper airway. These findings also rule out systemic 
absorption of the Impacted salbutamol as the cause of the enhanced 
pharmacological effects of the medication observed in our infants following the 
use of the non-valved spacers. In light of these observations, it appears that 
until valves made of lighter material become available, both devices should have 
their non-rebreathing valves removed when used on newborns and small infants. 
10.5 Conclusions 
The findings of this study provide indirect evidence that in using the MDI 
and spacer device to deliver therapeutic aerosols to non-ventilated infants, 
aerosol deposition in the lower respiratory tract can be increased by removing 
the non-rebreathing valve from the spacers. Methods to enhance aerosol 
delivery by the MDI to ventilated and non-ventilated infants have been studied 
by previous workers. Manoeuvres that have been attempted include ventilating 
the infant manually through the spacer after actuation of the aerosol, 
delivering the aerosol through a catheter inserted into the infant's airway,^^ and 
the use of a spacer made of non-electrostatic materials/^® The present study 
provides a simple, non-invasive, and in-expensive way of improving the efficacy 
of MDI aerosols. 
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Section J： Delivery of aerosolised surfactant to ventilated animal models 
11.1 Introduction 
Intratracheal instillation of exogenous surfactant is now a standard 
treatment for preterm neonates with respiratory distress syndrome.^ ^^ 
Preliminary evidence suggests that it is also beneficial to full-term infants with a 
variety of lung conditions such as pneumonia and meconium aspiration 
s y n d r o m e . 1 3 2 1 3 5 |门 order to achieve uniform distribution in the lungs, the 
surfactant has to be given in relatively large volumes at a fast speed/^^^® 
Rapid administration of a large volume of the medication into the airways, 
however, has been shown to increase PaCOjand cerebral blood flow velocity in 
preterm infants.^ ^®^^ with intracranial haemorrhage as a potential consequence. 
The transient hypoxia commonly observed during surfactant instillation may also 
be detrimental to very unstable infants such as those suffering from persistent 
pulmonary hypertension. For these infants an alternative route of administration 
may be desirable. Over a decade ago Marks et al demonstrated that both jet 
and ultrasonic nebulisers were able to deliver phospholipids extracted from 
bovine lung lavage without altering the surface active properties of the lipids.'"'^  
In adult human lungs, it has been shown that aerosolised synthetic surfactant 
decreases endotoxin-induced cytokine (tumour necrosis factor, interleuki-1, 
interleukin-6, and lnterleukin-8) secretion by alveolar macrophages, suggesting 
that the aerosol can modulate inflammatory response in the lungs.^ ^^ In two 
clinical trials on adults with sepsis induced adult respiratory distress syndrome, 
continuous administration of surfactant aerosol was associated with a trend for 
improved survival, and no adverse side e f f e c t s . I n animal models of a 
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variety of induced lung injury, beneficial effects of nebulised surfactant have 
been observed even with a trivial amount of lung deposition.之下 2a. 145*147 八 review 
of these animal studies is given below. 
11.2 Review of deposition studies 
In a study reported by Lewis et al/^^ ventilated preterm lambs with RDS 
were given labelled natural surfactants (Survanta and a sheep surfactant) 
by either tracheal instillation or from a Vortran Intermittent Signal Actuated 
Nebuliser (VISAN, Vortran Medical Technology, USA). In the nebuliser group, 
the amount of surfactants deposited in the lungs after 3 hours of nebulisation 
was only 1.9% to 2.7% of the nebulised dose. Even with this small deposition, 
however, the animals had a more sustained improvement in oxygenation than 
those in the instillation group. Improvement in ventilation and dynamic lung 
compliance was similar In the two groups. 
In a similar study, Lewis et al compared the effects of nebulised and 
instilled Survanta on an animal (rabbit) model with acute lung injury induced by 
intravenous N-nitroso-N-methylurethane (NNNMU). Survanta but not saline or 
air placebo delivered by a jet nebuliser improved the ventilation efficiency and 
lung mechanics of the animals. In contrast, tracheally instilled Survanta resulted 
in deterioration In both parameters. The amount of nebulised Survanta detected 
in the lungs of the animals was 4.9±1 mg lipid /kg or 3.6±0.5% of the total 
amount nebulised. 
The therapeutic effects of nebulised and instilled surfactants was again 
compared by the same group of workers on adult sheep (weight 35±3 kg) 
whose lungs had been injured by saline wash out.^ ^ Animals given nebulised 
surfactant showed significantly greater improvement in oxygenation and required 
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lower ventilation pressure than those who were given the surfactant (100 mg 
lipid/kg) by instillation. Pulmonary deposition from nebulisation was only 1% of 
that in the instilled group {15.3±2.9 mg vs 1.732±70 mg), but distribution of the 
surfactant appeared to be more even in the nebulised group. 
Since patients with adult respiratory distress syndrome (ARDS) often have 
non-uniform lung pathology, their response to surfactant aerosol may be 
different from those with uniform lung diseases. The effects of nebulised 
surfactant on the two types of lung conditions have been investigated by Lewis 
et on a ventilated adult sheep model (weight 36±3 kg). The lungs of the 
animals were damaged by either total or partial bronchoalveolar lavage (BAL) 
with isotonic saline. The latter was achieved by occluding the right anterior lobe 
with a balloon-tipped catheter during BAL After 3 hours of nebulisation by a 
signal actuated nebuliser, total lung deposition of surfactant was similar in the 
two groups (total BAl_:12.2±1.2o/o, partial BAL: 10±1.2o/o of the amount 
nebulised). However, in the partial BAL group, 50% of lung deposition was 
recovered from the protected lobe. This was significantly more than the amount 
recovered from the same lobe of the total BAL group (20%), In association with 
this distribution pattern, improvement in PaOj, PaCOj, and ventilation 
requirement after aerosol treatment was observed only in the total BAL group 
and not in the partial BAL group. 
This study highlighted a potential limitation of nebulised surfactant: in 
patients with non-uniform lung injury, the surfactant might fail to exert its 
maximum therapeutic effects due to preferential deposition in the healthier and 
better ventilated parts of the lung that in fact do not need the medication. Since 
in real life, it is unlikely that part of the lung is completely disease free, the study 
was subsequently repeated by the same group of workers (Lewis et aP^ ®) on 
an improved model of non-uniform lung injury. In this model, the entire lungs of 
ventilated adult sheep (weight 41 ±2 kg) were firstly injured by total BAL, followed 
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by further damage of the right middle lobe and lingula by selective instillation of 
hydrochloric acid. The animal was then given radiolabelled Survanta either by 
nebullsation or tracheal instillation (dose =100mg or 4ml/kg). Total lung 
deposition in the nebulised group was 31 ±6% of the total amount aerosolised 
(approximately 15% of total reservoir dose), and about 8% of total lung 
deposition was recovered from the 2 most severely damaged lobes. In contrast, 
50% of total lung dose was recovered from these lobes in the instilled group. 
All animals showed improvement in oxygenation, PaCOj and ventilation 
requirement, which however was more gradual and more sustained in the 
nebulised group. 
In ail the above studies, jet nebulisers were used to generate the 
surfactant aerosol. The therapeutic effects of a natural surfactant generated by 
an ultrasonic nebuliser was demonstrated by Li et a广幼 on rats ventilated for 
respiratory failure after BAL. The animals were given either bolus of Instilled 
surfactant or nebulised surfactant for 60 minutes. Both modalities of treatment 
resulted in improvement in oxygenation and dynamic thoracic compliance. 
However, improvement following aerosol therapy was significantly slower and 
more gradual than that following instillation. 
A study on the protective effect of exogenous surfactant has been carried 
out by Zeiter et al.i^ in this study, either aerosolised Exosurf (group 1) or saline 
(group 2) was administered to intubated and ventilated adult sheep (weight 28 
to 38 kg), followed by an intravenous infusion of oleic acid. Subsequently, both 
groups of animals showed a similar decline in lung compliance and PaO: with 
a rise in airway resistance, suggesting that Exosurf had no acutely beneficial 
effect on oleic acid-induced lung injury. After 5-7 days, the experiments were 
repeated on the same animals but this time with group 1 being given nebulised 
saline and group 2 nebulised Exosurf. After oleic add Injection, animals in group 
2 (saline first and Exosurf second) had much more severe deterioration in 
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oxygenation and lung mechanics than those in group 1 (Exosurf first and saline 
second). This suggested that initial treatment with Exosurf might have 
accelerated healing or conferred protection to subsequent oleic acid-Induced 
lung injury. 
By nebulising a mixture of Exosurf combined with Sudan Black to 3 
additional sheep, the same group of workers demonstrated uniform distribution 
of the aerosol in the excised lung, including the small airways and air spaces. 
Quantitative data on pulmonary deposition and distribution of the surfactant were 
however not reported. 
Nebulised surfactant has also been demonstrated to have a protective 
effect on the lungs against hyperoxic damage. Fracica et aP^ ventilated 10 
baboons with 100% oxygen for 96 hours. Half of the animals were given an 
aerosol of a porcine surfactant intermittently during this period of hyperoxic 
challenge. Morphological examination at autopsy showed that the surfactant-
treated lungs had less neutrophil accumulation and better preservation of 
epithelial cellular integrity, suggesting that the surfactant aerosol had prevented 
destruction of the epithelial cells by the hyperoxic insults. In a similar 
experiment, Piantadosi et al^ ^^  observed that the aerosol of a synthetic 
surfactant (Exosurf) conferred the same degree of protection to baboons' lungs. 
11.3 Discussion 
From the above literature review, It can be concluded that natural 
surfactant can be nebulised into the lungs of ventilated animals to exert a 
therapeutic effect. Pulmonary deposition ranged from 1.9% to 31% of the 
amount nebulised, the greatest deposition being observed in large animals 
(sheep) weighing approximately 4 0 k g . I n small animals (rabbit), deposition 
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was relatively small, but even the smallest deposition was associated with 
improvement in lung mechanics and oxygenation status of the animals. None 
of the studies however provided any information directly applicable to the 
neonatal or infant population. The nebulisers (signal actuated) and ventilators 
(volume cycled) used were designed for adults and not generally used on small 
infants. The animals were ventilated with excessively high inflating pressures 
(30 to 40 cmHzO) and long inspiratory time (1 sec.). The extended nebuiisation 
time (3 hours) might be too long to fit into the neonatal intensive care unit 
routine. In one study,^ ® the nebuliser reservoir was immersed In ice to minimise 
evaporation of its content, and a 16-ml charging chamber was connected to the 
endotracheal tube. Both manoeuvres may not be safely used in small infants 
since cooling the nebuliser may further decrease the temperature of the inspired 
gas, and adding an additional dead space to the endotracheal tube may result 
in carbon dioxide retention. In most of the studies, the nebuliser was 
intermittently reloaded with fresh surfactant throughout nebuiisation. This 
resulted in a large consumption of surfactant and may not be an economical way 
to use this expensive medication. Given these considerations, it became evident 
that a study on a small animal model should be performed using ventilation 
parameters, nebuliser devices and dosing regime appropriate for the infant 
population. Since only natural surfactants have been tested in the previous 
deposition studies, a synthetic surfactant (Exosurf) was also investigated in this 
study. 
It has been shown in preterm lambs that when natural surfactant was 
delivered by tracheal instillation at birth, a minimum lung deposition of 19mg 
lipid/kg was required to improve the lung mechanics of the animals.^ ®^ From the 
above literature review, it appears that weight for weight, nebulised surfactant is 
therapeutically superior to surfactant given by tracheal instillation, and even a 
very small lung dose of nebulised surfactant could bring about clinical 
improvement comparable to that produced by a much larger dose of instilled 
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surfactant. The exact mechanism for this phenomenon is not known but may be 
related to the pattern of distribution of the exogenous surfactant in the lungs. The 
findings In animals with non-uniform lung injury suggest that in these animals, 
nebulised surfactant has a tendency to deposit at the healthier areas, depriving 
the more unhealthy parts of the lungs where the surfactant is needed m o s t . 
In contrast, tracheafly instilled surfactant tends to deposit preferentially in the 
most severely damaged parts of the 丨ungs.i妨 It thus appears that patients with 
heterogeneous lung diseases such as ARDS may benefit most from the 
combined therapeutic effects of instilled and nebulised surfactants. Future 
studies are required to address this interesting issue. 
An interesting observation made by the above investigators was the large 
amount of nebulised surfactant deposited in the T-piece and tubings of the 
ventilator circuit (up to 12.5士4.1% and 24.2土3.7o/o of the total amount nebulised 
respectively). I suspected that after condensation, the surfactant in the tubings 
might drain down the endotracheal tube into the lungs, resulting in over-
estimation of lung deposition. This has prompted an investigation on the effect 




As explained in Chapter 11, nebulised surfactant has a potential role in 
the management of infants with adult respiratory distress syndrome, persistent 
pulmonary hypertension, and other forms of lung injuries. In the literature 
review, there is evidence that although only a small amount of surfactant aerosol 
can be deposited in the lungs, its clinical effect may exceed that of surfactant 
delivered by tracheal instlllation.^ '^ -^ ® "'^ ^^ ^^  In a multicentre trial on adult patients 
with sepsis-induced adult respiratory distress syndrome, nebulised surfactant 
appears to be able to improve survival without causing any serious side 
e f f e c t s . I n all these previous studies, jet nebulisers had been used to 
generate the surfactant aerosol. 
In order to maximise the beneficial effects of the aerosol, the delivery 
system that can achieve the best pulmonary deposition should be used. Jet 
nebulisers have been shown to be relatively inefficienct In delivering aerosols 
through the ventilator circuital 兑町 especially in newborns.扣 ®® The experiments 
described in Chapter 5 and Chapter 9 have provided both in-vitro and in-vivo 
evidence that ultrasonic nebulisers are more efficient than the jet nebulisers in 
delivering saibutamol aerosol to small infants. Data on surfactant deposition 
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from ultrasonic nebulisers are however not available. The following study was 
conducted to characterise the jet and ultrasonic nebulisers with regard to their 
efficiency in delivering a synthetic and a natural surfactant to a neonatal lung 
model of surfactant deficiency under standardized experimental conditions. Also 
included in the evaluation were the evenness of distribution of the surfactants in 
the lungs, their fractional deposition in the airway and ventilator circuit, and their 
time-related pattern of accumulation in the lungs during nebulisation. 
12.2 Subjects and methods 
12.2.1 Labelling of the surfactants 
The surfactants used were Exosurf (Burroughs-Wellcome Laboratories. 
Canada), a synthetic surfactant, and Survanta (Abbott Laboratories. U.S.A.), a 
bovine surfactant. The method of labelling surfactant has previously been 
described by Davis et al."*" The suspension of Exosurf or Survanta was placed 
in a sterile capped multidose vial under nitrogen and 1 ml of a 2 mg/ml solution 
of stannous chloride in 0.45% sodium chloride solution was added. The 
suspension was diluted and the pH adjusted by adding 13.2 ml of 0.45% sodium 
chloride solution and 0.8 ml of 0.5 M phosphate buffer pH 7.6. The final pH was 
above 6.5. it is likely that the Technetium-99m (拥"Tc) labels the 
diapalmitoylphosphatidylcholine (DPPC) content of the surfactants after 
reduction of the to using stannous ion. Radiochemical purity 
was determined by spotting a small sample of the product on Tcm silica gel 
chromatography strips (ITLC-SG Gelman Instrument Company) and developing 
the chromatogram with acetone. The unbound travelled as the 
pertechnetate ion just behind the front while the labelled surfactant-的"Tc 
remained at the origin. The product contained less than 5% unbound 的"Tc 
before and after nebulisation. 
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12.2.2 Animal Model 
The study was approved by the Animal Ethics Committee, the McMaster 
University Medical Centre. The animal model consisted of an adult white New 
Zealand rabbit whose lungs were depleted of surfactant by bronchoalveolar 
lavage (BAL). The animal was anaesthetized and paralysed, and ventilated as 
described in Chapter 5. An intravenous line was established to allow infusion of 
10% dextrose (3 ml/kg/hour) throughout the study. An arterial line was inserted 
through the artery on the external ear to facilitate blood gas monitoring. BAL 
was performed with warm (37°C) normal saline 25ml/kg. The saline was run into 
the lungs at a hydrostatic pressure of 30 cm water taking about 10 seconds for 
the infusion, and then allowed to drain out of the lungs under gravity. This 
procedure was performed 4 times with the animal supine and a further 2 times 
after turning the animal prone. The whole procedure took approximately 30 
minutes. After BAL was commenced, ventilator settings were adjusted to give 
a PIP of 25 cmHjO. PEEP 4 cmHp, rate 30/minute, Ti 0.5 second, and 100% 
oxygen. A paper filter (Pall Biomedical. N.Y., USA) was connected to the 
expiratory limb of the ventilator circuit to prevent the contamination of the 
ventilator and the atmosphere by the radiolabelled aerosol. The same ventilator 
settings were used throughout the entire experiment and in all animals. 
12.2.3 Surfactant Nebulisation 
At about 1 hour after the completion of BAL, labelled (approximately 
280|jCi/ml) surfactant was nebulised into the inspiratory limb of the ventilator 
circuit. Fifteen ml of either Exosurf or Survanta was placed in the nebuliser and 
nebulised for one hour. A total of 19 rabbits were studied. Group A (n=11) was 
given radiolabeled Exosurf by either a jet nebuliser (Up-Mist Medication 
Nebuliser, Hospitak, USA) (group A1, n=5) or an ultrasonic nebuliser (Siemens 
Electronics Inc.. Sweden) (group A2, n=6). Group B (n=8) was given 
radiolabelled Survanta and was similarly divided into 2 subgroups according to 
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the type of nebuliser used (group B1 - jet nebuliser, n=4; group B2 - ultrasonic 
nebuliser. n=4). As described in Chapter 5, the jet nebuliser was connected to 
the inspiratory limb of the ventilator circuit 20cm away from the endotracheal 
tube, and operated with pure oxygen at a flow rate of 6L/min. During 
nebuiisation the gas flow rate from the ventilator was reduced accordingly so as 
to maintain the same PIP. The ultrasonic nebuliser was connected to the 
ventilator circuit in a similar manner. Since no additional flow was required, 
there was no need for any adjustment of the ventilator gas flow rate. Because 
of the large volume fill (15ml), the medication was nebulised directly from the 
standard 20-ml nebuliser reservoir without using the 10-ml medication cup. In 
all the groups the nebuliser and the ventilator tubings were positioned at a level 
below that of the animals so as to ensure that surfactant condensed inside the 
ventilator tubings did not drain into the lungs. 
Each animal received the nebulised medication for 60 minutes. Arterial 
blood gas status was determined before and after BAL. Measurements were 
repeated just prior to and 30 minutes after commencement of treatment, and 
also at the end of nebuiisation. As described in Chapter 5, accumulation of 
radioactivity in the lungs was monitored with a Large Field of View gamma 
camera (Model 410 LFOV, Ohio Nuclear) interfaced to a Digital PDP 11-23 
computer throughout nebuiisation. Consecutive 120-second frames were 
recorded for 60 minutes for a total of 60 frames. 
12.2.4 Effect of ventilator tubing position on pulmonary deposition 
In an earlier preliminary study, I had noticed that there was considerable 
condensation of surfactant in the ventilator tubings. I suspected that some of 
this condensed surfactant might drain Into the lungs, resulting in a falsely high 
recording of pulmonary deposition, in order to test this hypothesis I studied 4 
additional rabbits who were ventilated and given nebulised Exosurf with an 
ultrasonic nebuliser the same way and for the same duration as those in Group 
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A2 animals. However the ventilator tubings in these four rabbits were positioned 
in a more conventional clinical manner with the terminal part of the tubings at a 
level slightly higher than that of the animals. 
12.2.5 Estimation of Pulmonary Deposition and Distribution 
After completion of nebuiisation, the animals were sacrificed with IV 
pentobarbitone and the lungs excised. To ensure that surfactant condensed at 
the wall of the endotracheal tube did not drain into the lungs, the endotracheal 
tube was clamped dose to the tracheostomy upon discontinuation of mechanical 
ventilation. Lung dissection was carried out as described in Chapter 5. 
Radioactivity in each lung piece was estimated by a gamma well counter. 
Rdioactivity in different parts of the ventilator circuit, as well as the residual 
radioactivity in the nebuliser at the end of nebuiisation, was determined with a 
dose calibrator (Capintec Inc., Pittsburg. PA). Lung deposition and deposition 
in the airways and ventilator circuit were expressed as the percentage of the 
amount nebulised. The latter was estimated from the difference in radioactivity 
inside the nebuliser reservoir before and after aerosol delivery. Lung deposition 
was also expressed as the percentage of the total dose placed in the nebuliser 
reservoir, as well as the absolute amount of surfactant deposited. To 
demonstrate the distribution of surfactant in the various lung regions, deposition 
in each gram of lung tissue was expressed as the percentage of the total lung 
deposition. 
12.2.6 Estimation of particle size 
Particle size estimation was carried out as described for salbutamol 
(Chapter 5). The aerosols were sampled when they left the endotracheal tube 
after passing through the ventilator circuit. The ventilator settings were identical 
to those in the animal studies. Each experiment was repeated five times. 
174 
12.3 Results 
Description of Animals 
The body weight, pre- and post-BAL PaOj and PaCO: of the four groups 
of animals being compared were shown in Table 12.1. There was no 
statistically significant difference among the groups in any of the parameters. All 
the animals were rendered significantly hypoxic and hypercapnic after BAL. 
Table 12.1; 
Group 
The body weight, pre- and post-BAL P.Ojand P.COj of the animals: 
mean (sem) 
Body weight (g) 
P.02(mmHg) 
Pre~BAL Post-BAL 




2894(63) 297(44)t 39(4.8)， 39(4.4): 59(4.2): 
2933(59) 309(36)^  36(2.4)， 35(3.2): 54(5.6)' 
Bl{Jet-Survanta) 2957(51) 319(34” 40(3.5)^ 
B2(US-Survanta) 3020(78) 323(15 广 50(9.1)^ 
34(6.3)^  60(1.5)-
37(3.0” 55(6.7): 
Comparing pre- and post-BAL readings within each group: ^ p<0.01; : p<0.05： paired t test 
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Aerosol output (Table 12.2) 
a. Exosurf After 1 hour of nebulisation, the jet nebuliser was able to 
aerosolise 47.0±6.7% of the total dose of Exosurf into the ventilator circuit. This 
was significantly more efficient than the ultrasonic nebuliser which aerosolised 
only 27.5±2.3% of the total reservoir dose. 
b. Survanta Similar to Exosurf, nebulisation of Survanta was more efficient 
using the jet nebuliser than with the ultrasonic nebuliser. Aerosol output from 
either nebuliser was however rather small, being significantly less than that 
obtained from nebulisation of Exosurf. 
Table 12.2: Amount of surfactant nebulised into the ventilator 
circuit: Mean(sem) 
Group As % total reservoir dose 
A1 (Jet-Exosurf) 47.0(6.7 广 
A2(US-Exosurf) 27.5(2.3 广 
Bl(Jet-Survanta) 7.9(0.9)* 
B2(US-Survanta) 2.5(0.9)* 





• Kruskal-Wallis One way ANOVA: p=0002 
Multiple pairwise comparison by Student-Newman-Keul method: A1>A2>B1>B2 (p<0.05) 
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Particle size distribution 
The MMAD and GSD of the particles generated by the jet nebuliser were 
0.74(sd 0 . 0 5 _ and 1.37(sd 0.002) respectively for Exosurf, and 0.90(sd 
0.06)^jm and 1.42(sd 0.04) respectively for Survanta. The corresponding figures 
from the ultrasonic nebuliser were: Exosurf: 1.23(sd 0.16)pm and 1.52(sd 0.08); 
Survanta: 2.10(sd 1.75)|jm and 1.73(sd 0.65). The use of the jet nebuliser was 
associated with singlciantly smaller aerosol MMAD of Exosurf (p = 0.0002) but 
not that of Survanta (p = 0.16). 
Pulmonary deposition 
Pulmonary deposition of the surfactant aerosol is summarised in Table 
12.3. In the Exosurf groups, deposition was greater when delivered by the 
ultrasonic nebuliser (group A2) than by the jet nebuliser (group A1) both as the 
percentage of the amount nebulised (3.65±0.56o/o vs 0.61±0.17%; p = 0.001) 
and as the percentage of the total nebuliser dose (1.05±0.23% vs 0.28±0.10%. 
p = 0.021). The absolute amount of surfactant deposited by the two types of 
nebulisers was respectively 2.21±0.48mg and 0.59±0.21mg (p = 0.004). 
In the Survanta groups, the ultrasonic nebuliser (group B2) was also able 
to deposit a larger proportion of nebulised surfactant in the lungs than the jet 
nebuliser (group B1) {3.88±0.93% vs 0.94±0.16%, p=0.021). The superiority of 
the ultrasonic nebuliser was however no longer observed when pulmonary 
deposition was expressed as the percentage of the total initial nebuliser dose 
(0.09±0.02% vs 0.08±0.02%, p=0.687) or as the absolute amount of surfactant 
(0.34±0.08mg vs 0.30±0.08mg. p=0.83) due to the relatively low aerosol output 
from the ultrasonic nebuliser. 
When the two types of nebulisers were considered separately, 
comparable amount of Exosurf (group A1) and Survanta (group B1) was 
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deposited in the lungs by the jet nebuliser when lung deposition was expressed 
as the percentage of the amount nebulised (0.61 ±0.170/0 vs 0.94±0.16o/o， 
p=0.215). There was a trend favouring Exosurf if pulmonary deposition was 
expressed as the percentage of the total initial dose, but the difference did not 
reach statistical significance (0.28±0.1% vs 0.08±0.02%. p=0.11). The 
ultrasonic nebuliser also delivered a similar proportion of nebulised Exosurf and 
Survanta to the animal lungs (3.65 ± 0.56o/o vs 3.88±0.93o/o, p=0.824). When 
expressed as the percentage of the total initial dose, however, a significantly 
larger proportion of Exosurf was deposited in the lungs (1.05±0.23% vs 
0.09±0.02%, p=0.011). 
Table 12.3: Pulmonary deposition of surfactant 
Grpitp 
Pulmonary Deposition 


















As % of amount nebulised: A1 vsA2 
B1 vs B2 






As % of total initial nebuliser dose; A1 vs A2 
B1 vs B2 
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R lung: right lung, L lung:丨eft lung. Ant.azy.: anterior azygous lobe. R ant: right anterior lobe, R post: right 
posterior lobe. Postazy.; posterior azygous lobe, L ant.: left anterior lobe. L post.: left posterior lobe 
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Pulmonary Distribution of Surfactant 
The distribution of Exosurf and Survanta in the two lungs and each lung 
lobe are shown in Figure 12.1. In both groups, aerosol delivered by both jet and 
ultrasonic nebuiisers were evenly distributed between the right and left lungs, 
and also among the lung lobes. 
Figure 12.1: 
Exosurf: 
Distribution of 99mTc-labelled surfactant in the lungs and lung lobes: Y 
axis represents deposition per gram lung tissue expressed as percentage 
of total lung deposition 
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Lung Region 
Figure 12.2 shows the distribution of the surfactants between the 
peripheral and central regions of each lobe and also both lungs. In ail the 
groups, there was no significant difference between the two regions in any of the 
lobes. When the peripheral and central deposition of both lungs was compared, 
again no significant difference was demonstrated in any of the groups. 
Figure 12.2 Distribution of 99mTc-5urfiactant in peripheral and central lung regions: Y 
axis represents deposition per gram lung tissue expressed as percentage 
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Deposition in airway and ventilator circuit 
Table 12.4 shows the distribution of surfactant in different parts of the 
airways and ventilator circuit. In the Exosurf group, the ultrasonic nebuliser 
deposited significantly more surfactant at the trachea, the endotracheal tube, 
and the carina region. A similar trend was also seen in the Survanta group 
though a significant difference was observed only in deposition at the trachea. 
Table 12.4: Deposition of surfectant in the airway and ventilator circuit 
(as� / o f amount nebulised): mean (s.e.m.) 
Group Trachea Carina EI ETT connector Y： Insp. tubing 
A1 0.15(0.06)- med 0.16« 0.32(0.04)' 0.62(0.09) 





0.10(0.02)' 0.03(0.01) 0.80(0.19) 1.97(0.20) 








Dynamic Gamma Scintigraphy Study 
Figure 10.3 represents the dynamic scintigraphy taken during 
nebultsation, showing the accumulation of in the two lungs in relation to 
time. The Y-axis represents the radioactivity in the lungs, expressed as a 
percentage of the final total radioactivity accumulated, in the Exosurf groups, 
accumulation of radioactivity delivered by either the jet or ultrasonic nebuliser 
had an almost linear relationship with the duration of nebulisation up to the end 
of the 60-minute period. The pattern was however very-different in the group of 
animals receiving radiolabeiled Survanta from the ultrasonic nebuliser. There 
was an initial phase of rapid accumulation which lasted for about 20 minutes, 
after which the accumulation curve levelled off, suggesting that there was no 
further deposition in the lungs after the first 20 minutes. Nebulisation of 
Survanta from the jet nebuliser resulted in an accumulation curve with a similar 
but noticeably less prominent biphasic pattern. 
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* Exosurf - jet 
— E x o s u r f - ultrasonic 
• Survanta - jet 
^ Survanta - ultrasonic 
Figure 12.3: Dynamic scintigraphy showing accumulation of 99mTc-labelIed 
surfactants in the lungs 
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Blood Gases Changes 
Figure 12.4A and 12.4B show the PaOj and PaCOj measured before 
BAL, immediately after BAL, just prior to nebuiisation, 30 minutes after starting 
and at the end of nebuiisation. All groups of animals showed a significant drop 
in PaOj and rise In PaCOj after BAL. Repeated measures ANOVA of the post-
BAL blood gases showed that in the animals who were given Exosurf by the 
ultrasonic nebuliser (group 1B), the PaO? was significantly higher (p= 0.02) and 
the PaCOs significantly lower (p= 0.03) at the end of nebuiisation (time pomt 5) 
than at the beginning (time point 3). No statistically significant changes in the 
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Figure 12.4: Blood gas changes after nebuHsation of surfactant 
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Effect of Ventilator Tubing Position on Pulmonary Deposition 
Animals in group 3 (weight: 2782±76g) received nebulised Exosurf from 
an ultrasonic nebuliser with the terminal part of the ventilator tubings positioned 
at a slightly higher level than that of the animals. The amount of surfactant 
released into the ventilator circuit was 41.2±7.3% of the total amount in the 
nebuliser reservoir. This was greater than the aerosol output observed in group 
A2 though the difference did not reach statistical significance (p = 0.066). 
However pulmonary deposition in this group was significantly greater than that 
in group A2 (p=0.022). being 13.80±4.45% of the amount nebulised or 
8.87±2.82mg. 
Lobar distribution of surfactant was also different from that in group A2. 
A significant greater proportion (11.91 土 3.19o/o per g lung tissue) of the total 
pulmonary deposition was deposited in the right upper lobe while deposition in 
the other lobes ranged only from 2.28 土 0.73o/o to 5.77 土 3,12o/o of total lung 
deposition per g lung tissue (p = 0.026, one way AN OVA). When lobar 
deposition was compared with that of animals in group A2, deposition in the right 
anterior lobe (2.43 土 0.41o/o/g vs 5.26 土 0.86o/o/g，p = 0.024) right posterior 
azygous lobe (2.28 土 0.73o/o/g vs 4.92 土 0.73o/o/g, p = 0.041) and left anterior 
lobe (3.45 土 0.12o/o/g vs 6.37 ± 0.51 %/g, p=0.01) was significantly less than that 
in the corresponding lobes in group A2. 
12.4 Discussion 
Pulmonary deposition 
In the literature review in Chapter 11, I examined the evidence on the 
potential beneficial effects of aerosolised surfactant on animals with induced 
lung injury.27•功,145*151 ！门 the large animal models (adult sheep), up to 15% of the 
initial nebuliser dose was deposited in the lungs after three hours of 
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nebunsation.145Lung deposition in small animals (preterm lamb and adult 
rabbit) was significantly less, being only 1.9% and 3.6% of the nebulised 
amount.28147 ！门 these studies, aerosol delivery has been enhanced by a number 
of manoeuvures which may not be be applicable to the real clinical situations 
(please refer Chapter! 1, Discussion). 
In the present study, ventilator settings and nebulisers used were both 
aprropriate tor newborns and small infants. The findings showed that the 
ultrasonic nebuliser was able to deliver Exosurf at a comparable efficiency to that 
shown in Lewis' studies on small animals. Lung deposition was significantly 
smaller from the jet nebuliser despite its higher aerosol output The discrepancy 
was not due to difference in aerosol impaction at the ventilator tubings, as shown 
by the data on fractional deposition at the ventilator circuit. Neither was it related 
to any differences in pattern of aerosol accumulation in the lungs since with both 
nebilisers, lung deposition had a linear relationship with time, as shown in the 
dynamic scintigraphy study. It is possible that the aerosol generated by the 
ultrasonic nebuliser has more optimal particle size distribution. As shown in the 
particle sizing experiment, the jet nebuliser produced submlcronic particles which 
were significantly smaller than those generated by the ultrasonic nebuliser. It is 
posibie that some of these small particles were exhaled and failed to deposit in 
the lungs. 
Compared to Exosurf, nebulisatton of Survanta using either nebuliser 
resulted in only minimal aerosol output and hence lung deposition, it is likely 
that the low output was caused by the high viscosity of the surfactant. As 
discussed in Chapter 1, aerosol output is inversely proportional to the viscosity 
of the liquid. Survanta is a much more viscous solution in appearance than 
Exosurf. Evaporation of the aqueous components during nebulisation further 
increases its concentration and viscosity and eventually leads to cessation of 
aerosolisation，i This phenomenon can explain the shape of the dynamic 
scintigraphy curves obtained during nebulisation of Survanta by both the jet and 
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ultrasonic nebuliser (Figure 12.3). The curves showed that aerosol delivery by 
the ultrasonic nebuliser virtually ceased after the first 20 minutes. Compared 
to the ultrasonic nebuliser, the jet nebuliser appears to be less susceptible to the 
concentrating effect, but aerosol deposition in the lungs also slowed down after 
about 30 minutes of nebulisation. 
From the above observations, it appears that a greater and more steady 
aerosol output from both the jet and ultrasonic nebulisers can be achieved if one 
can prevent the progressive concentration of the surfactant solution. This might 
be accomplished by refilling the nebuliser reservoir intermittently with fresh 
surfactant during the course of nebulisation. This manoeuvre has been used by 
Lewis et ai in nebulising Survanta, resulting in lung deposition that was 
significantly greater than that observed in the present study. 
Pulmonary distribution 
In ail animals, both Survanta and Exosurf were fairly evenly distributed 
among the lung lobes and also between the peripheral and centra丨 lung regions. 
This concurred with the findings of Lewis et ai on animals with uniform lung 
injury^7.i34. 
Clinical effects of surfactant aerosol 
In this study, surfactants delivered by either jet or ultrasonic nebuliser 
failed to produce any significant therapeutic effect on the animals. Animals in 
group A2 received Exosurf delivered by the ultrasonic nebuliser and had the 
greatest amount of lung deposition. Only In this group was there a statistically 
significant improvement In PaO: and PaCOj after one hour of nebulisation. The 
improvement, however, was too small to be of any clinical importance. These 
findings were in contrast to those by Lewis et al who demonstrated clinically 
significant improvement in oxygenation and lung mechanics in animals following 
treatment with aerosolised surfactant.^ ®^^^^^^ There are a few possible 
explanations for this discrepancy. A natural surfactant was used in all of Lewis' 
studies that demonstrated treatment success. Since in the present study, a 
significant deposition with a natural surfactant (Survanta) could not be achieved, 
the only relevenat comparison would be with the group A2 animals who did 
receive a substantial lung dose of Exosurf. Exosurf, being a synthetic surfactant, 
might be less.potent and have a slower action than the natural surfactants. 
Another Important factor was the lung condition of the animals before surfactant 
treatment. Compared to those in Lewis' studies, animals in this study were 
rendered much more hypoxic and acidotic by BAL. The more severe lung Injury 
might have made the lungs less responsive to the surfactant. 
Effect of position of ventilator tubings on pulmonary deposition 
I had observed in a preliminary study that lung deposition of surfactant 
was increased when the terminal part of the ventilator tubings were at a higher 
position than that of the animals. I suspected that this was secondary to the 
intratracheal instillation of surfactant condensed inside the tubings. This was 
confirmed by the experiment on the group 3 animals which received Exosurf 
aerosol from the ultrasonic nebuliser at a lower position than the ventilator 
tubings. Compared to animals who were placed at a higher position than the 
ventilator tubings during nebuiisation (group A2), these animals had a more than 
4 fold greater deposition in the lungs. The excessive lung deposition could be 
accounted for only if some of the surfactant condensed in the ventilator tubings 
had drained into the lungs of the animals. This additional source of surfactant 
might also be responsible for the distribution pattern of surfactant in their lungs, 
which was different from that in all the other groups. 
The apparently higher nebuliser output in the low-position group (group 
3) could also be explained by the position of the tubings. As shown in Figure 
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12.5，when the animals were placed at a higher position than the tubings, 
surfactant condensing on the wall of the terminal part of the tubings might reflux 
back into the nebuliser due to 
gravity, resulting in 
underestimation of nebuliser 
output. Placing the animals 
at a low position brought the 
distal part of the ventilator 
tubings to a position lower 
than that of the nebuliser. 
Condensed surfactant could 
not reflux back to the 
nebuliser but would instead 
drain into the lungs of the 
animal. 
Figure 12.5: Position of nebuliser relative to ventilator tubing 
ETT 
12.5 Conclusions 
These findings showed that pulmonary deposition of nebulised surfactant 
varied considerably depending on the type of surfactant and nebuliser used. 
Both the jet and ultrasonic nebulisers were very inefficient in nebulising 
Survanta. presumably due to the high viscosity of the surfactant preparation. 
In the nebulisation of Exosurf, the ultrasonic nebuliser was superior to the jet 
nebuliser, being able to achieve substantial lung deposition comparable to that 
observed by previous workers.^ ®-^ ^®"^ ^^  The findings also provided indirect 
evidence that the therpeutic efficacy of aerosolised synthetic surfactant might be 
lower than that of aerosolised natural surfactants. The observations on the 
effect of ventilator tubing position on aerosol delivery should serve to remind 
future researchers that surfactant condensing inside the tubings might result in 
overestlmaton of lung deposition. 
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To the best of my knowledge, the present study is to date the only study 
that characterises a jet nebuliser and an ultrasonic nebuliser in the delivery of 
exogenous surfactants to a small animal model. The study provides the 
groundwork for future studies on the use of surfactant aerosol in newborns and 
young infants. 
191 
Section 4 Summary and Conclusions 
Chapter 13: Summary 
Chapter 14: Conclusions 
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S^Ctipn 1:_Background 
Chapter 1: An overview on aerosol delivery to young infants 
This thesis begins with an introduction on the use of therapeutic aerosols 
in newborns and young infants, and the factors that adversely affect the delivery 
of aerosol to patients in this age group. This is followed by an introduction on 
the design and characteristics of the currently available delivery devices - jet 
nebuliser, ultrasonic nebuliser, and MDI. 
Chapter 2: Objectives of the original studies in this thesis 
This chapter summarises the main objectives of the series of original 
studies described in this thesis. 
Seption 2: Delivery Qf brgnphgdil^tor 碎erogpls tp ipfgnfe 
Parti：_Literature reviews 
Chapter 3: Evidence on the therapeutic effects of aerosolised bronchodilators 
on small infants 
This Chapter first describes the controversies around the use of 
bronchodilators in small infants, followed by a review of previous studies that 
showed beneficial effects of aerosolised bronchodilator on infants with 日PD. 
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From this it is concluded that bronchodilator aerosols delivered by MDI or jet 
nebullser to both ventilated and non-ventilated BPD infants can reach the lower 
respiratory tract and produce pharmacological effects. 
Chapter 4: Deposition studies 
This Chapter reviews previous in-vitro and in-vivo studies that have 
estimated aerosol deposition in neonatal and infant lung models. The limitations 
of the various types of lung models were discussed. From this review, it is 
concluded that aerosol deposition from the MDI, jet nebuliser, or ultrasonic 
nebuliser is small, being 0.5-2% of the nominal dose delivered. This might 
already be an overestimation due to the inherent limitations of the lung models. 
Data comparing all three devices are not available and lack of uniformity in 
experimental condition makes between-study comparison impossible. 
Part 2: Original studies: animal models 
Chapter 5: Deposition of salbutamol aerosol in a ventilated rabbit model: 
comparison of MDI, Jet nebuliser, and ultrasonic nebuliser 
This Chapter presents an original study comparing the efficiency of the 
three devices in delivering radiolabeled salbutamol aerosol to a ventilated rabbit 
model. Pulmonary deposition, expressed as percentage of the initial nominal 
dose, was MDI: 0.22%, jet: 0.48%, ultrasonic (standard medication reservoir): 
0.9%, ultrasonic (small medication cup): 3.05%. Thus the ultrasonic nebuliser 
used together with a small cup was significantly more efficient than all other 
devices. Possible explanations for its superiority include greater aerosol output, 
and more complete aerosolisatlon of the medication as demonstrated by 
dynamic gamma scintigraphy recorded during nebulisation. With all the devices, 
the aerosol was evenly distributed in the lungs, and a substantial proportion 
could reach the peripheral lung regions. 
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Chapter 6: Effects of spontaneous breaths on aerosol delivery to ventilated 
rabbits. 
Many babies with BPD are on slow IMV with a significant proportion of 
their pulmonary ventilation being provided by their own spontaneous respiratory 
effort. This Chapter presents a study which evaluated the effect of spontaneous 
breaths on aerosol delivery to a ventilated animal model. A standard dose of 
saibutamol aerosol was delivered by the MDI to rabbits receiving slow IMV. 
These animals were not paralysed so that spontaneous breaths continued at a 
rate of 40 to 50 per minute. Aerosol deposition in the lungs of these rabbits was 
more than twice that in the totally ventilator-dependent animals described in 
Chapter 5, thus confirming the enhancing effect of spontaneous breaths on 
aerosol deposition. 
Part 3: Original studies: infants with BPD 
Chapter 7: Use of camera scintigraphy in estimation of aerosol deposition in 
small lungs: a validation study 
This study was carried out in preparation for the infant study described in 
Chapter 8. Gamma scintigraphy provides the only direct method for estimating 
pulmonary deposition in human subjects but its validity has never been 
evaluated. In this study, pulmonary deposition of radiolabeled aerosol in rabbits 
was firstly measured by gamma scintigraphy before the lungs were dissected out 
for a second measurement by a gamma well counter. The two measurements 
showed good correlation and agreement, confirming the accuracy of gamma 
scintigraphy in the estimation of aerosol deposition in small lungs. 
Chapter 8: Deposition study on infants with BPD: comparison between MDI 
and jet nebuliser 
In this randomised cross-over study, radiolabelied saibutamol was 
delivered by MDI and jet nebuliser to ventilated and non-ventilated infants with 
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BPD. In both groups and from both devices, pulmonary deposition was small 
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In all infants, more aerosol was deposited at the central lung regions than 
in the periphery, especially when the aerosol was delivered by the jet nebuliser. 
The discrepancy between central and peripheral distribution appears to be more 
marked than that observed in the animal study, presumably due the presence 
of BPD changes in the lungs of the infants. 
From the above observations, it can be concluded that aerosol delivery 
by both MDI and jet nebuliser to the lower respiratory tract of infants with BPD 
is small and variable. In order to Identify the most optimal dosing regime for 
any infant, titration against clinical response may be necessary. Since the 
ultrasonic nebuliser has achieved the greatest amount of lung deposition in 
animals (Chapter 5), its use in BPD infants deserves further studies. 
Chapter 9: Delivery ofsalbutamol aerosol to infants with BPD: a clinical study 
comparing MDI, jet nebuliser. and ultrasonic nebuliser 
In order to Identify the most efficient aerosol delivery device for infants 
with BPD, the MDI. jet nebuliser, and ultrasonic nebuliser (with small medication 
cup) was evaluated in this randomised cross-over study. In random sequence, 
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a uniform dose of saibutamol aerosol was delivered by each of the three devices 
to 20 non-ventilated and 10 ventilated infants with BPD. Following each delivery, 
there was a significant decrease in Rrs, which was maximum 30 minutes after 
treatment, and gradually returned to the baseline values after 120 minutes. FRC 
was also measured in the non-ventilated infants, and showed a similar pattern 
of improvement. In all the animals, the greatest improvement was associated 
with the use of the ultrasonic nebuliser, and the least improvement with the jet 
nebuiiser. Similarly, the use of the ultrasonic nebuliser was associated with a 
significantly greater degree of tachycardia and improvement in tcPOj and 
tcPC02. Thus the superiority of the ultrasonic nebuliser demonstrated in animals 
(Chapter 5) was confirmed in the BPD Infants. The therapeutic effect achieved 
by the MDI, though smaller than that by the ultrasonic nebuliser, was greater 
than what was expected from the observations in the animal and infant 
deposition studies. The spacer devices (MV15 Aerochamber and neonatal 
Aerochamber) used in this study differed from those used in the deposition 
studies by not having a one-valve at its outlet. This prompted us to carry out the 
next study presented in Chapter 10. 
Chapter 10: Aerosol delivery by MDI to BPD infants: should a valved spacer be 
used? 
By removing the one-way valve from the MV15 Aerochamber used on 
ventilator circuits, the manufacturer of the spacer device was able to increase 
aerosol output by 18%. In this randomised cross-over study on 10 non-
ventilated infants with BPD, administration of saibutamol aerosol through a 
neonatal Aerochamber without the one-way valve also resulted in significantly 
greater improvement in Rrs and FRC than when the valved spacer was used. 
This observation provides convincing evidence that in delivering aerosol to small 
infants, the MDI should be used together with a non-valved spacer device. It is 
likely that the one-way valve of even the "neonatal" spacers is too heavy to be 
opened effectively by the small tidal volumes of small infants with lung diseases. 
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Section 3: Delivery of aerosolised surfactant to ventilated animal model 
Chapter 11: Literature review 
This Chapter reviews the published articles on the use of nebulised 
surfactant in humans and animals. From the scanty human data available, it 
appears that nebulised surfactant may be of therapeutic value on adults with 
ARDS. The animal studies provide data on lung deposition which suggest that 
even a relatively small lung dose of aerosolised natural surfactant can improve 
the blood gas status of animals with either uniform or non-uniform lung injury. 
In all the published studies, however, only adults or animals ventilated with adult 
ventilators were examined. Data relevant to ventilated neonates or young infants 
are not available. 
Chapter 12: Original study: pulmonary deposition of aerosolised synthetic and 
natural surfactants by ultrasonic and jet nebulisers to an animal 
model of neonatal respiratory distress syndrome 
In this study, a synthetic surfactant (Exosurf) and a natural surfactant 
(Survanta) was nebulised to a ventilated rabbit model of RDS by a jet nebuliser 
or an ultrasonic nebuliser (standard medication reservoir). Pulmonary deposition 
was greatest when Exosurf was delivered by the ultrasonic nebuliser. Very little 
aerosol output was obtained from the nebulisation of Survanta by either delivery 
device, resulting in very scanty lung deposition. Aerosol output was particularly 
small when Survanta was nebulised by the ultrasonic nebuliser, presumably due 
to the high viscosity of the Survanta solution. No clinically significant 
improvement in either PaOj or PaCOg was observed after nebulisation for 1 
hour. From these observations, it could be concluded that the ordinary methods 
of nebulisation cannot effectively deliver either natural or synthetic surfactant 
preparations to ventilated infants with sick lungs. Further studies to improve the 
method of delivery are required before aerosolised surfactant can be considered 
for clinical use. 
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Bronchodilators given as aerosol are widely used in neonatal units for the 
treatment of infants with BPD. There is however confusion among paediatricians 
about the choice of the most appropriate delivery device, the dosing regime, and 
the therapeutic efficacy of the treatment. Many of these issues have already 
been addressed by previous workers. The information from the series of 
experiments described in this thesis provides further insight into this important 
area of neonatal/infant care: 
1- The studies confirm my hypothesis that commercially available aerosol 
delivery devices (the MDI, the jet nebuliser, and the ultrasonic nebuliser) can 
all deliver aerosolised salbutamol to reach the lower respiratory tract and 
improve the respiratory status of both ventilated and non-ventilated infants with 
BPD. The aerosol is evenly distributed in the healthy animal lungs but tends 
to stay in the central region in the diseased lungs of BPD infants. With ali three 
devices, the therapeutic effect of a single dose of salbutamol lasts for less than 
two hours, and therefore the medication should be given at least 2 hourly to 
ensure sustained bronchodilatation. Using the radiotracer technique, 1 also 
confirmed the findings of Salmon et al that pulmonary deposition of aerosol 
among these infants is very var iable.Thus a uniform dose of the medication 
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might not be applicable to ail infants, and titration against clinical effect to 
determine the most optimal dose might be necessary. 
Infants with BPD have very variable ventilation requirements. Some are 
totally ventilator-dependent, but many need only minimal ventilatory support. 
Studies comparing aerosol delivery in these two clinical scenarios have not 
been reported. In the animal studies, I have observed that aerosol deposition 
in the lungs of paralysed rabbits on full IPPV was significantly less that in those 
who continued to breathe spontaneously while receiving slow IMV. This 
suggests that spontaneous breaths have an enhancing effect on aerosol 
delivery, and infants who are totally ventilator-dependent may require higher 
doses of the medication. 
2. The studies also show that among the three types of delivery devices, the 
ultrasonic nebuliser. when used together with a small tapered-bottom 
medication cup, is able to deposit the greatest amount of aerosol in the lungs 
of ventilated rabbits, and achieve the most significant improvement In lung 
function in both ventilated and non-ventilated BPD infants. In contrast, the jet 
nebulisers appear to be the least efficient device in both the animal and infant 
studies. This observation, together with the other disadvantages of jet 
nebulisers, such as cooling of the airway and the need for external gas source, 
suggest that the device may not be suitable for aerosol treatment in small 
infants. In contrast, because of its convenience, the MDI and spacer would still 
be the preferred device by many paediatricians. Indirect evidence is provided 
for aerosol delivery by this method being enhanced by removing the non-
rebreathing valve from the spacer. When administered through a non-valved 
spacer, MDI saibutamoi has a therapeutic efficacy that is comparable, albeit 
statistically smaller than that delivered by the ultrasonic nebuliser with a small 
cup. 
3. My findings show that for the delivery of surfactant aerosol, neither the jet 
nor ultrasonic nebuliser can deliver a clinically useful amount of the medication 
to the lower respiratory tract of small animals. To my knowledge, the surfactant 
study is the only study on the delivery of surfactant aerosol to a lung model of 
ventilated infants. In this study, both jet and ultrasonic nebulisers were very 
inefficient in nebulising Survanta, a natural surfactant of bovine origin. Lung 
deposition remained unsatisfactory when the jet nebuliser was used to deliver 
a less viscous synthetic surfactant (Exosurf). When Exosurf was delivered by 
an ultrasonic nebuliser, a substantial amount of aerosol could reach the animal 
lungs but failed to produce any significant therapeutic effect. It thus appears 
that aerosolised surfactants are not yet ready for clinical use in small infants 
with lung injury, and further studies on this area are required. 
Future research 
In 1990, Silverman summarised the questions that need to be answered 
concerning the use of therapeutic aerosols in infants:^" 
1. Are lung disorders in newborns likely to be amenable to treatment 
with aerosols? 
2. Can adequate quantities of aerosol be delivered to the lungs of 
newborn babies, either during mechanical ventilation or during 
spontaneous breathing? 
3. Can specific sites in the airways and lungs be targeted? 
4. Are there any clinical or physiological data on long term therapeutic 
response to aerosol treatment in the newborns? 
These questions, which have provided the framework for aerosol 
research in infants, have only been partly answered even to-date , and many 
related issues have not been adequately addressed. In the treatment of 
infants with BPD, one important research area is to identify the most efficient 
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method for the delivery of potentially useful drugs. My studies have provided 
some relevant data concerning the delivery of a beta-agonist bronchodilator 
(salbutamol). In particular, the study on BPD infants has confirmed that 
salbutamol aerosol delivered by ail the currently available devices could reach 
the lower respiratory tract to exert pharmacological effects, with the ultrasonic 
nebuliser and small cup being the most efficient delivery device. However, 
since the infants had only relatively mild BPD, it would be useful to study a 
group of more severely affected infants to determine whether the findings could 
be generalised to the whole spectrum of BPD infants. Comparison of delivery 
efficiency should also be made with a wider range of jet nebulisers since there 
are considerable differences in aerosol output and particle size distribution 
among the large number of the devices currently available in market. Other 
potentially beneficial medications, such as sodium cromoglycate, frusemide 
and corticosteroid, also require individual evaluation. Sodium cromoglycate, 
with its effects of mast cell stabilising and inhibition of neutrophil activation and 
chemotaxis, may have a role in the treatment of BPD. The results of studies 
investigating the therapeutic effects of sodium cromoglycate aerosol on BPD 
infants have however been conflicting. It is possible that In studies that 
failed to demonstrate a beneficial effect, the amount of medication delivered 
to the lungs was too small.^ ®^ Frusemide given as an aerosol may reduce the 
amount of interstitial lung fluid, and has been shown to improve lung 
compliance and airway resistance of infants with BPD.^ ®® Corticosteroid given 
systemically improves the lung function of BPD infants and reduce their need 
for mechanical ventilation.^®'^  When given in the aerosol form, the medication 
may be equally beneficial but with fewer systemic side effects.^ -^ ®®"^ ®^  
Information on how best these aerosols should be delivered to ventilated and 
non-ventilated infants is however not available. Since both cromolyn sodium 
and frusemide are available in solution form, It is likely that they behave like 
salbutamol and can be most effectively delivered by the ultrasonic nebuliser 
with the small cup. Experimental data are however required to confirm this 
speculation. In contrast, topical steroids are formulated as suspended 
particles, and both jet and ultrasonic nebulisation may result in aerosolisation 
of the suspending fluid without the particles."'®^ Previous studies using jet or 
ultrasonic nebulisers have shown that only a small percentage of a nominal 
dose of steroid can be delivered to infant lung models.^ In light of my 
observation on the ultrasonic nebuliser with the small cup, the efficiency of this 
new device in delivering corticosteroid is worth testing. 
With regard to the use of surfactant aerosol, a more efficient method for 
the delivery of the viscous natural surfactant needs to be identified. Intermittent 
reloading of the nebuliser reservoir with fresh surfactant, or diluting the 
surfactant with an appropriate diluent, may both counteract the concentrating 
effect of nebulisation and deserve further investigation. During ultrasonic 
nebulisation of natural surfactants, the amount of heat generated may denature 
their protein content and reduce therapeutic efficacy?®^ It is possible to reduce 
the temperature of the surfactant solution by immersing the nebuliser reservoir 
in ice.28 Excessive cooling, however, has the disadvantage of lowering aerosol 
output, and further studies are required to determine the optimum temperature 
of the delivery system. 
Further studies are also required to evaluate new delivery devices and 
new propellants used in MDI. As discussed in Chapter 1, the continuous gas 
flow in neonatal ventilators removes the aerosol away from the infant, 
especially that generated during the expiratory phase. The use of a signal 
actuated nebuliser that generates aerosol only during inspiration may increase 
the amount of aerosol available for inhalation. A nebuliser with such design is 
now ready for adult use,^ ®* and It will be useful to apply this technology to 
improve the existing Infant nebulisers. Because of its ozone-depleting effect, 
chlorofluorocarbon is no longer recommended for use as propellant In 
pressurised dispensing devices. Although its use in MDIs for pharmaceuticals 
is still permitted, aerosol scientists are actively looking for an nonozone-




efficiency of this substitute In newborns and young infants require careful 
evaluation. 
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Appendix 1： Particle size 
a. Terminal settling velocity of aerosol particles^®^^ 
The terminal settling velocity of a falling particle is Its downward velocity at 
a point when the downward accelerating force is balanced by air resistance. 
At this point the velocity of the particle is steady (le no more acceleration) and 
can be calculated from the following equation: 
Kr = (Ppart - Pair)gd^ /I8/7 Where ppan = density of the particle 
Pa_r = air density 
g = gravitational acceleration 
d = diameter of the particle 
q = viscosity of air 
b. Particle size characterisation^^®^ 
For a given aerosol particle, the most important parameter determining 
deposition is the diameter. Aerosols are rarely composed of particles of 
uniform size and shape (monodisperse). Most aerosols contain particles 
having a wide range of size and shape distribution (heterodisperse). The 
diameters of heterodisperse particles cannot be measured by the usual 
method. Such particles can be characterised by the term "aerodynamic 
diameter" which is the diameter of a unit-density sphere having the same 
settling velocity as the particles in question. The aerodynamic diameter must 
be experimentally determined. Many heterodisperse aerosols fit a log-normal 
distribution, ie when the number of particles per given size interval were plotted 
against the logarithm of size, a normal distribution curve will be produced. The 




Count median diameter (CMD): The median of the physical diameters of 
the aerosol particles; 
Geometric standard deviation (GSD): The ratio of the diameter of the 
particle that is larger than 84.13% of all others to the count median diameter 
(in log-normal distribution, GSD = ratio of the 84.13% size to the 50% size 
[geometric mean or median]; in normal distribution, SD = difference in the 
84.13% size and the 50% size [mean])®° 
Mass median diameter (MMD): this is related to count median diameter 
by: In(MMD) = In(CMD)十 3(ln GSD尸 where In is the natural logarithm. This 
shows that the mass median diameter is larger than the count median 
diameter, because the larger particles contribute the predominant mass. 
The MMD is the diameter about which 50% of the total particle mass 
resides (a textbook with chapter on principles of inhaled therapy). 
Mass median aerodynamic diameter (MMAD): The mass median 
aerodynamic diameter is the aerodynamic diameter around which the mass 
is centred. It is equivalent to the product of MMD and the square root of 
particle density. MMAD is the single most important parameter governing 
the deposition of particles in the respiratory tract. 
Appendix 2: Equations governing aerosol 
deposition— 
a. Inertial impaction 
When a particle is being carried down the airway by an airstream, the 
probability of its being deposited by inertial impaction (I) in the airway is 
represented by the following relation: 
I « i/j (vsin^/gR where Vj = terminal settling velocity of the particle 
V = velocity of the airstream 
Q- angle of deflection of the airstream 
g = gravitational constant 
R = radius of airway 
b. Gravitational sedimentation 
The probability of deposition of the particle in the airway by gravitational 
sedimentation (S) is governed by the following relation: 
S « (t<j-.t.cos^)/R where Vj = terminal settling velocity of particle 
t = time of particle travelling in airway 
If/ = angle of airway with the horizontal 
R = radius of airway 
c. Diffusion 
The probability of deposition of the particle in the airway by diffusion (Diff) 
is governed by the following relation: 
Diff« / ( kTt/3TT/7dR) where k is a constant (Boltzman constant) 
T = absolute temperature 
t = time 
q = gas viscosity 
d = particle diameter 
R = radius of airway 
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Appendix 3: Formula for correction of radioactive 
decay of Technetium-99m 
Ao = AT.e<。_) 
where Aq = corrected radioactivity (ie activity at time of delivery of the 
radlolabelied aerosol) 
At = measured radioactivity 
e = natural logarithm (= 2.71828) 
T = time elapsed from delivery of radiolabelled aerosol to 
counting of radioactivity on the lung specimen 
t = half-life of Technetium-99m (=6.04 hours) 
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